{"questions": [{"id": "5a6f960fb750ff445500005c", "body": "Centor criteria are used for which disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23613571", "http://www.ncbi.nlm.nih.gov/pubmed/15231926", "http://www.ncbi.nlm.nih.gov/pubmed/22432746"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Centor criteria in children in a paediatric emergency department: for what it is worth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 0, "offsetInEndSection": 273, "text": "INTRODUCTION: Centor criteria (fever >38.5\u00b0C, swollen, tender anterior cervical lymph nodes, tonsillar exudate and absence of cough) are an algorithm to assess the probability of group A \u03b2 haemolytic Streptococcus (GABHS) as the origin of sore throat, developed for adults.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 274, "offsetInEndSection": 441, "text": "We wanted to evaluate the correlation between Centor criteria and presence of GABHS in children with sore throat admitted to our paediatric emergency department (PED).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1063, "text": "Only records with a full disease history were selected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1064, "offsetInEndSection": 1130, "text": "Out of a total 2118 visits for sore throats, 441 met our criteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1352, "offsetInEndSection": 1467, "text": "There was no significant difference in the prevalence of GABHS for all different Centor scores within an age group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1468, "offsetInEndSection": 1619, "text": "Likelihood ratios (LR) demonstrate that none of the individual symptoms or a Centor score of \u22653 seems to be effective in ruling in or ruling out GABHS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1747, "offsetInEndSection": 1897, "text": "CONCLUSIONS: Our results confirm the ineffectiveness of Centor criteria as a predicting factor for finding GABHS in a throat swab culture in children.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 1131, "offsetInEndSection": 1197, "text": "The children were divided into two age groups, 2-5 and 5-16 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23613571"}, {"offsetInBeginSection": 160, "offsetInEndSection": 259, "text": "Among adults, the sensitivity of this test varies on the basis of disease severity (spectrum bias).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15231926"}]}, {"id": "5a86ebf2faa1ab7d2e000038", "body": "Which are the main transcriptional activators of circadian oscillations?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11517254", "http://www.ncbi.nlm.nih.gov/pubmed/19917250", "http://www.ncbi.nlm.nih.gov/pubmed/20967239", "http://www.ncbi.nlm.nih.gov/pubmed/18177499", "http://www.ncbi.nlm.nih.gov/pubmed/22217096", "http://www.ncbi.nlm.nih.gov/pubmed/9115195"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Modeling circadian oscillations with interlocking positive and negative feedback loops.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 148, "offsetInEndSection": 340, "text": "To test the sufficiency of the proposed mechanisms, two differential equation-based models were constructed to describe the Neurospora crassa and Drosophila melanogaster circadian oscillators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 341, "offsetInEndSection": 522, "text": "In the model of the Neurospora oscillator, FRQ suppresses frq transcription by binding to a complex of the transcriptional activators WC-1 and WC-2, thus yielding negative feedback.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 979, "offsetInEndSection": 1128, "text": "Both models displayed circadian oscillations that were robust to parameter variations and to noise and that entrained to simulated light/dark cycles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 1129, "offsetInEndSection": 1283, "text": "Circadian oscillations were only obtained if time delays were included to represent processes not modeled in detail (e.g., transcription and translation).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 1284, "offsetInEndSection": 1363, "text": "In both models, oscillations were preserved when positive feedback was removed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 856, "offsetInEndSection": 978, "text": "PER also binds to dCLOCK to de-repress dclock, and dCLOCK in turn activates per transcription, yielding positive feedback.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11517254"}, {"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "Rhythmic PER abundance defines a critical nodal point for negative feedback within the circadian clock mechanism.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19917250"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1007, "text": "CLOCK:BMAL1 to drive the circadian negative feedback loop.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19917250"}, {"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "Emergence of noise-induced oscillations in the central circadian pacemaker.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20967239"}]}, {"id": "5a67c8c4b750ff4455000013", "body": "What is the link between TADs and GRBs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28874668", "http://www.ncbi.nlm.nih.gov/pubmed/26150425", "http://www.ncbi.nlm.nih.gov/pubmed/28060840", "http://www.ncbi.nlm.nih.gov/pubmed/24727717", "http://www.ncbi.nlm.nih.gov/pubmed/26518482", "http://www.ncbi.nlm.nih.gov/pubmed/27167421", "http://www.ncbi.nlm.nih.gov/pubmed/27919068", "http://www.ncbi.nlm.nih.gov/pubmed/1448082", "http://www.ncbi.nlm.nih.gov/pubmed/16943830"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Developmental genes in metazoan genomes are surrounded by dense clusters of conserved noncoding elements (CNEs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 235, "offsetInEndSection": 404, "text": "Clusters of CNEs define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks (GRBs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 405, "offsetInEndSection": 543, "text": "Their function and distribution around important regulatory genes raises the question of how they relate to 3D conformation of these loci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 544, "offsetInEndSection": 735, "text": "Here, we show that clusters of CNEs strongly coincide with topological organisation, predicting the boundaries of hundreds of topologically associating domains (TADs) in human and Drosophila.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 902, "offsetInEndSection": 1165, "text": "The close correspondence between extreme noncoding conservation and TADs suggests that these TADs are ancient, revealing a regulatory architecture conserved over hundreds of millions of years.Metazoan genomes contain many clusters of conserved noncoding elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 1166, "offsetInEndSection": 1358, "text": "Here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and Drosophila, revealing a conserved regulatory genomic architecture.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28874668"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Structural heterogeneity and functional diversity of topologically associating domains in mammalian genomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "Recent chromosome conformation capture (3C) derived techniques have revealed that topologically associating domain (TAD) is a pervasive element in chromatin three-dimensional (3D) organization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 391, "offsetInEndSection": 629, "text": "Based on our finding that there exist intrinsic chromatin interaction patterns in TADs, we define a theoretical parameter, called aggregation preference (AP), to characterize TAD structures by capturing the interaction aggregation degree.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}, {"offsetInBeginSection": 630, "offsetInEndSection": 942, "text": "Applying this defined parameter to 11 Hi-C data sets generated by both traditional and in situ Hi-C experimental pipelines, our analyses reveal that heterogeneous structures exist among TADs, and this structural heterogeneity is significantly correlated to DNA sequences, epigenomic signals and gene expressions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26150425"}]}, {"id": "5a7600b983b0d9ea6600000c", "body": "Which clinical trials for psoriasis involved tofacitinib? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28829236", "http://www.ncbi.nlm.nih.gov/pubmed/27267933", "http://www.ncbi.nlm.nih.gov/pubmed/26267722", "http://www.ncbi.nlm.nih.gov/pubmed/29134822", "http://www.ncbi.nlm.nih.gov/pubmed/28441904", "http://www.ncbi.nlm.nih.gov/pubmed/27692733", "http://www.ncbi.nlm.nih.gov/pubmed/24883332", "http://www.ncbi.nlm.nih.gov/pubmed/26889727", "http://www.ncbi.nlm.nih.gov/pubmed/27716172", "http://www.ncbi.nlm.nih.gov/pubmed/26889081"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 0, "offsetInEndSection": 350, "text": "INTRODUCTION: Tofacitinib is a pan JAK inhibitor with specificity for JAK3 over JAK1 over JAK2, which is approved in many countries for the treatment of rheumatoid arthritis (RA), including the United States and the European Union, either as monotherapy or in combination with conventional synthetic disease modifying anti-arthritis drugs (csDMARDs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 351, "offsetInEndSection": 501, "text": "Phase 2, 3 and 4 clinical trials have investigated the efficacy and safety of tofacitinib given either as monotherapy or in combination with csDMARDs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 502, "offsetInEndSection": 765, "text": "Areas covered: This review reports the safety, clinical, functional, and radiographic efficacy, of tofacitinib used as monotherapy in the treatment of adult patients with RA reported in the prospective, double-blind, controlled randomized trials reported to date.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 766, "offsetInEndSection": 950, "text": "One critical clinical question is whether tofacitinib monotherapy has similar efficacy as tofacitinib in combination with methotrexate (MTX); this question has recently been addressed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28829236"}, {"offsetInBeginSection": 0, "offsetInEndSection": 43, "text": "Tofacitinib for the treatment of psoriasis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 0, "offsetInEndSection": 327, "text": "INTRODUCTION: The identification of a number of psoriasis-susceptibility genes and a better understanding of the pathogenesis of the intracellular metabolic pathways, have generated new perspectives on psoriasis treatment, in particular new compounds that inhibit certain intracellular proteins involved in the immune response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 453, "offsetInEndSection": 773, "text": "COVERED: Tofacitinib is a small molecule that acts as a reversible, competitive inhibitor of ATP in the ATP binding site of JAK proteins, determining their inactivation, thus prevents the downstream activation of the STAT proteins, which are then unable to up-regulate the pro-inflammatory genes implicated in psoriasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 774, "offsetInEndSection": 909, "text": "The authors present an overview of Phases I - III clinical trials of tofacitinib for psoriasis based on peer-reviewed literature.EXPERT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}, {"offsetInBeginSection": 910, "offsetInEndSection": 1095, "text": "OPINION: In clinical practice, it is important to assess the response of psoriasis to tofacitinib and identify possible clinical, genetic, and immune biomarkers to predict the response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27267933"}]}, {"id": "5a551a8fb750ff4455000002", "body": "What is a potential side effect for Tymlos?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/17650055", "http://www.ncbi.nlm.nih.gov/pubmed/16370982", "http://www.ncbi.nlm.nih.gov/pubmed/27924737", "http://www.ncbi.nlm.nih.gov/pubmed/21385029", "http://www.ncbi.nlm.nih.gov/pubmed/25119580", "http://www.ncbi.nlm.nih.gov/pubmed/6131489", "http://www.ncbi.nlm.nih.gov/pubmed/2183167", "http://www.ncbi.nlm.nih.gov/pubmed/27836000", "http://www.ncbi.nlm.nih.gov/pubmed/24261314", "http://www.ncbi.nlm.nih.gov/pubmed/7021123"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "One of the great challenges of long-term treatment of schizophrenia and related disorders is minimizing the medical or psychological burden from persistent side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 170, "offsetInEndSection": 428, "text": "Because of the differences in side effect profiles between the newer and older antipsychotic medications, and distinct differences among the newer agents themselves, the spectrum of side effects associated with antipsychotic therapy has changed tremendously.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 429, "offsetInEndSection": 608, "text": "The authors review changing from one antipsychotic to another (\"switching\") as a potential treatment strategy for reducing the overall side effect burden of antipsychotic therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 609, "offsetInEndSection": 1441, "text": "This review identifies 6 steps to the evaluation of switching antipsychotics because of side effects: (1) Establish a causal attribution that the clinical problem is an adverse effect of the antipsychotic medication; (2) Understand the course of the side effect, especially regarding present and future risks for the individual patient receiving the antipsychotic treatment; (3) Understand the potential risks and benefits of other side effect interventions that do not require switching the antipsychotic; (4) Be aware of the side effect profiles of other possible antipsychotics, with an understanding of the potential effectiveness of changing (switching) to another antipsychotic for this side effect; (5) Calculate the side effect risks of switching antipsychotics; (6) Calculate the efficacy risks of switching antipsychotics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 1442, "offsetInEndSection": 1586, "text": "The authors explain how to evaluate the specific side effect in the context of the current medication and the overall management of the patient.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17650055"}, {"offsetInBeginSection": 0, "offsetInEndSection": 52, "text": "Interviews with elderly patients about side effects.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "Fifty older persons were interviewed about their medicines, side effects, and their responses to statements describing side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 244, "offsetInEndSection": 358, "text": "Participants knew much less about the potential side effects and almost nothing about potential drug interactions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 359, "offsetInEndSection": 525, "text": "They wanted to know all the side effects, and indicated that if their doctors told them about all the side effects, they would still follow the doctors' prescription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}, {"offsetInBeginSection": 740, "offsetInEndSection": 856, "text": "Responses to statements about side effects were more driven by the nature of the side effect than by its likelihood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16370982"}]}, {"id": "5a87f44061bb38fb2400000f", "body": "Which disorder has been approved for treatment with Alk inhibitors?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23201355", "http://www.ncbi.nlm.nih.gov/pubmed/28182271", "http://www.ncbi.nlm.nih.gov/pubmed/28979145", "http://www.ncbi.nlm.nih.gov/pubmed/26294238", "http://www.ncbi.nlm.nih.gov/pubmed/24166094", "http://www.ncbi.nlm.nih.gov/pubmed/27468827", "http://www.ncbi.nlm.nih.gov/pubmed/26992917", "http://www.ncbi.nlm.nih.gov/pubmed/28536155", "http://www.ncbi.nlm.nih.gov/pubmed/28065466", "http://www.ncbi.nlm.nih.gov/pubmed/27122312"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 0, "offsetInEndSection": 154, "text": "Anaplastic lymphoma kinase was first described in 1994 as the NPM-ALK fusion protein that is expressed in the majority of anaplastic large-cell lymphomas.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 155, "offsetInEndSection": 239, "text": "ALK is a receptor protein-tyrosine kinase that was more fully characterized in 1997.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 240, "offsetInEndSection": 353, "text": "Physiological ALK participates in embryonic nervous system development, but its expression decreases after birth.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 354, "offsetInEndSection": 514, "text": "ALK is a member of the insulin receptor superfamily and is most closely related to leukocyte tyrosine kinase (Ltk), which is a receptor protein-tyrosine kinase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 515, "offsetInEndSection": 808, "text": "Twenty different ALK-fusion proteins have been described that result from various chromosomal rearrangements, and they have been implicated in the pathogenesis of several diseases including anaplastic large-cell lymphoma, diffuse large B-cell lymphoma, and inflammatory myofibroblastic tumors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 809, "offsetInEndSection": 958, "text": "The EML4-ALK fusion protein and four other ALK-fusion proteins play a fundamental role in the development in about 5% of non-small cell lung cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1148, "text": "The formation of dimers by the amino-terminal portion of the ALK fusion proteins results in the activation of the ALK protein kinase domain that plays a key role in the tumorigenic process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 1149, "offsetInEndSection": 1292, "text": "Downstream signaling from ALK fusion proteins involves the Ras/Raf/MEK/ERK1/2 cell proliferation module and the JAK/STAT cell survival pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}, {"offsetInBeginSection": 1293, "offsetInEndSection": 1438, "text": "Furthermore, nearly two dozen ALK activating mutations participate in the pathogenesis of childhood neuroblastomas along with ALK overexpression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23201355"}]}, {"id": "5a723edd2dc08e987e00000c", "body": "Is Tofacitinib effective for Ulcerative Colitis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28467869", "http://www.ncbi.nlm.nih.gov/pubmed/22894574"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 174, "offsetInEndSection": 260, "text": "We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 260, "offsetInEndSection": 406, "text": "METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 407, "offsetInEndSection": 741, "text": "In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 790, "offsetInEndSection": 1011, "text": "In the OCTAVE Sustain trial, 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1300, "text": "RESULTS: In the OCTAVE Induction 1 trial, remission at 8 weeks occurred in 18.5% of the patients in the tofacitinib group versus 8.2% in the placebo group (P=0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% versus 3.6% (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 1300, "offsetInEndSection": 1462, "text": "PCONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "BACKGROUND: Ulcerative colitis is a chronic inflammatory disease of the colon for which current treatments are not universally effective.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22894574"}]}, {"id": "5a85a0f1faa1ab7d2e000032", "body": "What is the definition of General Regulatory Factors (GRFs)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12200417", "http://www.ncbi.nlm.nih.gov/pubmed/28448767", "http://www.ncbi.nlm.nih.gov/pubmed/28158860", "http://www.ncbi.nlm.nih.gov/pubmed/17158163", "http://www.ncbi.nlm.nih.gov/pubmed/27014338", "http://www.ncbi.nlm.nih.gov/pubmed/27540088", "http://www.ncbi.nlm.nih.gov/pubmed/25620770", "http://www.ncbi.nlm.nih.gov/pubmed/21914852", "http://www.ncbi.nlm.nih.gov/pubmed/25215414", "http://www.ncbi.nlm.nih.gov/pubmed/20371324"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "General regulatory factors (GRFs) as genome partitioners.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417"}, {"offsetInBeginSection": 658, "offsetInEndSection": 879, "text": "Together with Reb1p and Tbf1p, previously involved in the activity of Saccharomyces cerevisiae subtelomeric insulators, insulating potential emerges as a supplementary common property of General Regulatory Factors (GRFs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1088, "text": "Thus GRFs, which bind to sites scattered throughout the genome within promoters, would not only play a key role in regulating gene expression but also partition the genome in functionally independent domains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12200417"}, {"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Transcriptional control of yeast ribosome biogenesis: A multifaceted role for general regulatory factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767"}, {"offsetInBeginSection": 122, "offsetInEndSection": 419, "text": "This regulon has recently been shown to rely on a small set of transcriptional regulators (mainly Abf1, but also Reb1, Tbf1 and Rap1) previously referred to as general regulatory factors (GRFs) because of their widespread binding and action at many promoters and other specialized genomic regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767"}, {"offsetInBeginSection": 543, "offsetInEndSection": 786, "text": "Such a dynamic promoter association has the potential to orchestrate both activation and repression of Ribi genes in synergy with neighboring regulatory sites and through the functional interplay of histone acetyltransferases and deacetylases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28448767"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Abf1 and other general regulatory factors control ribosome biogenesis gene expression in budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860"}, {"offsetInBeginSection": 304, "offsetInEndSection": 519, "text": "Here, we show that most Ribi gene promoters also contain binding sites for one or more General Regulatory Factors (GRFs), most frequently Abf1 and Reb1, and that these factors are enriched in vivo at Ribi promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1305, "text": "Our observations point to GRFs as new multifaceted players in Ribi gene regulation both during exponential growth and under repressive conditions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28158860"}, {"offsetInBeginSection": 0, "offsetInEndSection": 195, "text": "Abf1 and Rap1 are general regulatory factors (GRFs) that contribute to transcriptional activation of a large number of genes, as well as to replication, silencing and telomere structure in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17158163"}]}, {"id": "5a68a463b750ff4455000014", "body": "Do chromatin features predict genes associated with eQTLs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23275551"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Transcription factor and chromatin features predict genes associated with eQTLs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Cell type-specific gene expression in humans involves complex interactions between regulatory factors and DNA at enhancers and promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 138, "offsetInEndSection": 381, "text": "Mapping studies for expression quantitative trait loci (eQTLs), transcription factors (TFs) and chromatin markers have become widely used tools for identifying gene regulatory elements, but prediction of target genes remains a major challenge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 382, "offsetInEndSection": 529, "text": "Here, we integrate genome-wide data on TF-binding sites, chromatin markers and functional annotations to predict genes associated with human eQTLs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 530, "offsetInEndSection": 702, "text": "Using the random forest classifier, we found that genomic proximity plus five TF and chromatin features are able to predict >90% of target genes within 1 megabase of eQTLs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}, {"offsetInBeginSection": 703, "offsetInEndSection": 956, "text": "Despite being regularly used to map target genes, proximity is not a good indicator of eQTL targets for genes   150 kilobases away, but insulators, TF co-occurrence, open chromatin and functional similarities between TFs and genes are better indicators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23275551"}]}, {"id": "5a760a4183b0d9ea66000016", "body": "What is filgotinib?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27988142", "http://www.ncbi.nlm.nih.gov/pubmed/25681059", "http://www.ncbi.nlm.nih.gov/pubmed/27993829", "http://www.ncbi.nlm.nih.gov/pubmed/27993828", "http://www.ncbi.nlm.nih.gov/pubmed/28838249", "http://www.ncbi.nlm.nih.gov/pubmed/26693854", "http://www.ncbi.nlm.nih.gov/pubmed/28645489", "http://www.ncbi.nlm.nih.gov/pubmed/24818516", "http://www.ncbi.nlm.nih.gov/pubmed/28622463", "http://www.ncbi.nlm.nih.gov/pubmed/28765121"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 191, "text": "Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "BACKGROUND: Filgotinib (GLPG0634, GS-6034) is a once-daily, orally administered, Janus kinase 1 (JAK1)-selective inhibitor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142"}, {"offsetInBeginSection": 1147, "offsetInEndSection": 1340, "text": "After week 10, patients were assigned based on responder status to filgotinib 100 mg once a day, filgotinib 200 mg once a day, or placebo for an observational period lasting a further 10 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142"}, {"offsetInBeginSection": 2375, "offsetInEndSection": 2548, "text": "INTERPRETATION: Filgotinib induced clinical remission in significantly more patients with active Crohn's disease compared with placebo, and had an acceptable safety profile.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27988142"}, {"offsetInBeginSection": 15, "offsetInEndSection": 186, "text": "OBJECTIVES: Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25681059"}, {"offsetInBeginSection": 0, "offsetInEndSection": 252, "text": "OBJECTIVES: To evaluate the efficacy and safety of different doses and regimens of filgotinib, an oral Janus kinase 1 inhibitor, as add-on treatment to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) and inadequate response to MTX.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829"}, {"offsetInBeginSection": 1452, "offsetInEndSection": 1537, "text": "Treatment-emergent adverse event rates were similar in placebo and filgotinib groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829"}, {"offsetInBeginSection": 1850, "offsetInEndSection": 1908, "text": "Filgotinib was generally well tolerated.TRIAL REGISTRATION", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993829"}, {"offsetInBeginSection": 0, "offsetInEndSection": 196, "text": "Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "OBJECTIVES: To evaluate the efficacy and safety of different doses of filgotinib, an oral Janus kinase 1 inhibitor, as monotherapy in patients with active rheumatoid arthritis (RA) and previous inadequate response to methotrexate (MTX).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27993828"}]}, {"id": "5a74d9980384be9551000008", "body": "What is LHON, also known as Lebers syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27843288", "http://www.ncbi.nlm.nih.gov/pubmed/9147893", "http://www.ncbi.nlm.nih.gov/pubmed/25566062", "http://www.ncbi.nlm.nih.gov/pubmed/9309689", "http://www.ncbi.nlm.nih.gov/pubmed/11329546", "http://www.ncbi.nlm.nih.gov/pubmed/16523300", "http://www.ncbi.nlm.nih.gov/pubmed/7916404", "http://www.ncbi.nlm.nih.gov/pubmed/10993496", "http://www.ncbi.nlm.nih.gov/pubmed/27756254", "http://www.ncbi.nlm.nih.gov/pubmed/8240101"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Leber's hereditary optic neuropathy is multiorgan not mono-organ.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 825, "offsetInEndSection": 980, "text": "Primary LHON mutations may rarely manifest without ocular compromise but with arterial hypertension, various neurodegenerative diseases, or Leigh syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27843288"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "High incidence of pre-excitation syndrome in Japanese families with Leber's hereditary optic neuropathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Cardiac conduction abnormalities have been reported in families with Leber's hereditary optic neuropathy (LHON).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 113, "offsetInEndSection": 331, "text": "The pre-excitation syndrome Wolff-Parkinson-White syndrome or Lown-Ganong-Levine syndrome, is reportedly common in Finns with LHON, being seen in 14 (9%) of the 163 individuals with mitochondrial DNA (mtDNA) mutations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 589, "offsetInEndSection": 834, "text": "It remains to be determined whether the high incidence of the pre-excitation syndrome in Finnish and Japanese LHON families is due to a particular genetic composition of ethnic groups such as in Finland and in Japan, or only to a reporting bias.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9147893"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "A Female Patient with Down Syndrome and Low-Penetrance Leber's Hereditary Optic Neuropathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566062"}, {"offsetInBeginSection": 0, "offsetInEndSection": 193, "text": "We present the case of a 19-year-old female with a history of Down syndrome (DS) who was referred to our neuro-ophthalmology clinic for evaluation of Leber's hereditary optic neuropathy (LHON).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566062"}, {"offsetInBeginSection": 194, "offsetInEndSection": 313, "text": "The patient's family history was significant for a known G11778A mutation in a maternal relative, consistent with LHON.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566062"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1213, "text": "Given the low penetrance of the mutation and the patient's sex, this case illustrates the possibility that the mitochondrial mutation demonstrated increased penetrance due to pre-existing mitochondrial dysfunction related to DS.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25566062"}]}, {"id": "5a8842a261bb38fb24000015", "body": "List proteins that are targeted by \"immune checkpoints inhibitors\".", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26282545", "http://www.ncbi.nlm.nih.gov/pubmed/27770382", "http://www.ncbi.nlm.nih.gov/pubmed/27683114", "http://www.ncbi.nlm.nih.gov/pubmed/26183909", "http://www.ncbi.nlm.nih.gov/pubmed/26765776", "http://www.ncbi.nlm.nih.gov/pubmed/27068940", "http://www.ncbi.nlm.nih.gov/pubmed/26680224", "http://www.ncbi.nlm.nih.gov/pubmed/23691926", "http://www.ncbi.nlm.nih.gov/pubmed/27664133", "http://www.ncbi.nlm.nih.gov/pubmed/26860624"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "A major breakthrough in cancer immunotherapy was the discovery of immune checkpoint proteins, which function to effectively inhibit the immune system through various mechanisms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 676, "offsetInEndSection": 786, "text": "Following the success of ipilimumab, other immune checkpoints were studied as possible targets for inhibition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 949, "offsetInEndSection": 1107, "text": "Unfortunately, the untoward effects of blocking the immune system's natural inhibitory mechanisms have manifested clinically as diarrhea, rash, and hepatitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 1108, "offsetInEndSection": 1276, "text": "Nevertheless, the exciting field of immune checkpoint inhibitors offers a potential curative option for many cancer patients who previously had a more dismal prognosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 467, "offsetInEndSection": 675, "text": "The first antibody directed against CTLA-4, ipilimumab, was quickly ushered into clinical trials and was approved by the US Food and Drug Administration (FDA) for the treatment of metastatic melanoma in 2011.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26282545"}, {"offsetInBeginSection": 0, "offsetInEndSection": 199, "text": "During immune responses antigen-specific T cells are regulated by several mechanisms, including through inhibitory receptors and regulatory T cells, to avoid excessive or persistent immune responses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 200, "offsetInEndSection": 460, "text": "These regulatory mechanisms, which are called 'immune checkpoints', suppress T cell responses, particularly in patients with chronic viral infections and cancer where viral antigens or tumor antigens persist for a long time and contribute to T cell exhaustion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 461, "offsetInEndSection": 667, "text": "Among these regulatory mechanisms, cytotoxic T lymphocyte associated protein-4 (CTLA-4) and programmed cell death 1 (PD-1) are the most well-known receptors and both have been targeted for drug development.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 820, "offsetInEndSection": 956, "text": "In this review we describe several receptors that function as immunological checkpoints as well as the pharmaceuticals that target them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27770382"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "Methylation of RAD51B, XRCC3 and other homologous recombination genes is associated with expression of immune checkpoints and an inflammatory signature in squamous cell carcinoma of the head and neck, lung and cervix.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27683114"}]}, {"id": "5a736efc3b9d13c708000006", "body": "Which chromosomes are implicated in the Emanuel syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19606488", "http://www.ncbi.nlm.nih.gov/pubmed/22434056", "http://www.ncbi.nlm.nih.gov/pubmed/22876593", "http://www.ncbi.nlm.nih.gov/pubmed/27973931", "http://www.ncbi.nlm.nih.gov/pubmed/18286821", "http://www.ncbi.nlm.nih.gov/pubmed/24171835", "http://www.ncbi.nlm.nih.gov/pubmed/28981939", "http://www.ncbi.nlm.nih.gov/pubmed/27785401", "http://www.ncbi.nlm.nih.gov/pubmed/27617132"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Phenotypic delineation of Emanuel syndrome (supernumerary derivative 22 syndrome): Clinical features of 63 individuals.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 96, "text": "Emanuel syndrome is characterized by multiple congenital anomalies and developmental disability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 97, "offsetInEndSection": 217, "text": "It is caused by the presence of a supernumerary derivative chromosome that contains material from chromosomes 11 and 22.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 218, "offsetInEndSection": 407, "text": "The origin of this imbalance is 3:1 malsegregation of a parental balanced translocation between chromosomes 11 and 22, which is the most common recurrent reciprocal translocation in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 539, "offsetInEndSection": 683, "text": "We designed a questionnaire to collect information from families recruited through an international online support group, Chromosome 22 Central.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 833, "offsetInEndSection": 939, "text": "We received information on 63 individuals with Emanuel syndrome, ranging in age from newborn to adulthood.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 1477, "offsetInEndSection": 1635, "text": "This study provides new information on the clinical spectrum and natural history of Emanuel syndrome for families and physicians caring for these individuals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19606488"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "Prenatal screening characteristics in Emanuel syndrome: a case series and review of the literature.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "PURPOSE: Emanuel syndrome is a rare chromosomal disorder characterized by severe mental retardation and multiple anomalies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}, {"offsetInBeginSection": 348, "offsetInEndSection": 433, "text": "We aimed to identify a prenatal screening pattern characteristic of Emanuel Syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22434056"}]}, {"id": "5a86c938faa1ab7d2e000034", "body": "Which genes belong to the AUX/IAA family of transcription repressors in plants?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28111153", "http://www.ncbi.nlm.nih.gov/pubmed/27247276", "http://www.ncbi.nlm.nih.gov/pubmed/17077182", "http://www.ncbi.nlm.nih.gov/pubmed/17919906", "http://www.ncbi.nlm.nih.gov/pubmed/22368074", "http://www.ncbi.nlm.nih.gov/pubmed/27049520", "http://www.ncbi.nlm.nih.gov/pubmed/16478940", "http://www.ncbi.nlm.nih.gov/pubmed/22409484", "http://www.ncbi.nlm.nih.gov/pubmed/16284307", "http://www.ncbi.nlm.nih.gov/pubmed/17430601"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Plant Stress Tolerance Requires Auxin-Sensitive Aux/IAA Transcriptional Repressors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "The Aux/IAA proteins are auxin-sensitive repressors that mediate diverse physiological and developmental processes in plants [1, 2].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 133, "offsetInEndSection": 248, "text": "There are 29 Aux/IAA genes in Arabidopsis that exhibit unique but partially overlapping patterns of expression [3].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 249, "offsetInEndSection": 443, "text": "Although some studies have suggested that individual Aux/IAA genes have specialized function, genetic analyses of the family\u00a0have been limited by the scarcity of loss-of-function phenotypes [4].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 444, "offsetInEndSection": 560, "text": "Furthermore, with a few exceptions, our knowledge of the factors that regulate Aux/IAA expression is limited [1, 5].", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 561, "offsetInEndSection": 760, "text": "We\u00a0hypothesize that transcriptional control of Aux/IAA genes plays a central role in the establishment of the auxin-signaling pathways that regulate organogenesis, growth, and environmental response.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 761, "offsetInEndSection": 852, "text": "Here, we describe a screen for\u00a0transcription factors (TFs) that regulate the Aux/IAA genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1042, "text": "Several DREB/CBF TFs directly promote transcription of the IAA5 and IAA19 genes in response to abiotic stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 1043, "offsetInEndSection": 1183, "text": "Recessive mutations in these IAA\u00a0genes result in decreased tolerance to stress conditions, demonstrating a role for auxin in abiotic stress.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}, {"offsetInBeginSection": 1184, "offsetInEndSection": 1326, "text": "Our results demonstrate that stress\u00a0pathways interact with the auxin gene regulatory network (GRN) through transcription of\u00a0the Aux/IAA genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28111153"}]}, {"id": "5a6a2bbcb750ff4455000022", "body": "What is Cellbase?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22693220", "http://www.ncbi.nlm.nih.gov/pubmed/28535294"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 135, "text": "CellBase, a comprehensive collection of RESTful web services for retrieving relevant biological information from heterogeneous sources.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 888, "offsetInEndSection": 997, "text": "CellBase provides a solution to the growing necessity of integration by easing the access to biological data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 998, "offsetInEndSection": 1135, "text": "CellBase implements a set of RESTful web services that query a centralized database containing the most relevant biological data sources.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 1200, "offsetInEndSection": 1285, "text": "CellBase documentation can be found at http://docs.bioinfo.cipf.es/projects/cellbase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22693220"}, {"offsetInBeginSection": 771, "offsetInEndSection": 935, "text": "HGVA calculates population frequencies for these projects and enriches their data with variant annotation provided by CellBase, a rich and fast annotation solution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28535294"}]}, {"id": "5a76155c83b0d9ea6600001e", "body": "Which phase III clinical trials for rheumatoid arthritis involve baricitinib? (November 2017)", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27910962", "http://www.ncbi.nlm.nih.gov/pubmed/28255337", "http://www.ncbi.nlm.nih.gov/pubmed/27799159", "http://www.ncbi.nlm.nih.gov/pubmed/28923098", "http://www.ncbi.nlm.nih.gov/pubmed/27689735", "http://www.ncbi.nlm.nih.gov/pubmed/28290136", "http://www.ncbi.nlm.nih.gov/pubmed/28405473", "http://www.ncbi.nlm.nih.gov/pubmed/27577235"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Baricitinib: JAK inhibition for rheumatoid arthritis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 0, "offsetInEndSection": 210, "text": "Rheumatoid arthritis (RA), a chronic autoimmune inflammatory disease characterized by inflammation and joint destruction, is associated with pain, progressive disability, systemic comorbidities and early death.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 535, "offsetInEndSection": 827, "text": "Baricitinib (LY-3009104, INCB-028050), a new potent and selective tyrosine-protein kinase JAK1/JAK2 inhibitor, has shown clinical efficacy in patients with RA refractory to aggressive standard-of-care treatment (with both conventional DMARDs and bDMARDs) when administered orally at 4 mg q.d.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 828, "offsetInEndSection": 865, "text": "in pivotal phase III clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 1040, "offsetInEndSection": 1143, "text": "A phase III study aimed at assessing long-term (4 years) safety and efficacy of baricitinib is ongoing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27910962"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Baricitinib in rheumatoid arthritis: evidence-to-date and clinical potential.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Biologics have changed expectation and outcomes for rheumatoid arthritis (RA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 470, "offsetInEndSection": 568, "text": "They are available as oral agents, which is also different from the currently available biologics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 569, "offsetInEndSection": 935, "text": "Baricitinib has now been evaluated in four phase III clinical trials, and although safety concerns cannot fully be answered until the drug is studied over longer periods of time, the data to date suggest that this drug with its once daily dosing, rapid onset of action and efficacy as monotherapy represents an important addition to the RA therapeutic armamentarium.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1035, "text": "Further study and experience will better define how baricitinib will be used and by which patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28255337"}]}, {"id": "5a87124561bb38fb24000001", "body": "What is cebocephaly", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23072180", "http://www.ncbi.nlm.nih.gov/pubmed/19673365", "http://www.ncbi.nlm.nih.gov/pubmed/16061113", "http://www.ncbi.nlm.nih.gov/pubmed/957381", "http://www.ncbi.nlm.nih.gov/pubmed/9132501", "http://www.ncbi.nlm.nih.gov/pubmed/2255999", "http://www.ncbi.nlm.nih.gov/pubmed/828460", "http://www.ncbi.nlm.nih.gov/pubmed/411936", "http://www.ncbi.nlm.nih.gov/pubmed/23599105", "http://www.ncbi.nlm.nih.gov/pubmed/115387"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Severe semilobar holoprosencephaly and lissencephaly associated with cebocephaly in a newborn.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Holoprosencephaly is frequently accompanied by midline facial abnormalities such as hypotelorism, cyclopia, etmocephaly and cebocephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 137, "offsetInEndSection": 226, "text": "Cebocephaly is a very rare congenital anomaly combining with semilobar holoprosencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23072180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Alobar holoprosencephaly associated with cebocephaly and craniosynostosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Cebocephaly is a very rare congenital midline facial anomaly characterized by a blind-ended single nostril and ocular hypotelorism, and is usually combined with alobar holoprosencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 187, "offsetInEndSection": 275, "text": "We report here a case of alobar holoprosencephaly with cebocephaly and craniosynostosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19673365"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "A case of holoprosencephaly and cebocephaly associated to torch infection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113"}, {"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Cebocephaly is a very rare congenital anomaly combining a severe midline facial malformation and holoprosencephaly.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113"}, {"offsetInBeginSection": 116, "offsetInEndSection": 423, "text": "Here we report on first case of cebocephaly with semilobar holoprosencephaly, hypotelorism, and a single nostril due to intrauterine TORCH infection (Toxoplasmosis, other [syphilis, varicella-zoster, parvovirus B19], Rubella, Cytomegalovirus [CMV], and Herpes infections) in the English language literature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16061113"}, {"offsetInBeginSection": 0, "offsetInEndSection": 60, "text": "Further studies on the genetic heterogeneity of cebocephaly.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/957381"}]}, {"id": "5a8881118cb19eca6b000006", "body": "Has the proteome of mice hippocampus been analysed?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/18283665", "http://www.ncbi.nlm.nih.gov/pubmed/15863242", "http://www.ncbi.nlm.nih.gov/pubmed/27062398", "http://www.ncbi.nlm.nih.gov/pubmed/17663576", "http://www.ncbi.nlm.nih.gov/pubmed/28449397"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 117, "text": "Interlocking transcriptomics, proteomics and toponomics technologies for brain tissue analysis in murine hippocampus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 218, "offsetInEndSection": 469, "text": "We find that transcriptome and proteome levels of function as well as the topological organization of synaptic protein clusters, detected by toponomics at physiological sites of hippocampus CA3 region, are all largely conserved between different mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 470, "offsetInEndSection": 718, "text": "While the number of different synaptic states, characterized by distinct synaptic protein clusters, is enormous (>155,000), these states together form synaptic networks defining distinct and mutually exclusive territories in the hippocampus tissue.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 719, "offsetInEndSection": 877, "text": "The findings provide insight in the systems biology of gene expression on transcriptome, proteome and toponome levels of function in the same brain subregion.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 217, "text": "We have correlated transcriptomics, proteomics and toponomics analyses of hippocampus tissue of inbred C57BL/6 mice to analyse the interrelationship of expressed genes and proteins at different levels of organization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18283665"}, {"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Proteome analysis in hippocampus of mice overexpressing human Cu/Zn-superoxide dismutase 1.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863242"}, {"offsetInBeginSection": 815, "offsetInEndSection": 948, "text": "In total 1056 spots were analysed, resulting in the identification of 445 polypeptides that were the products of 157 different genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15863242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Proteome rearrangements after auditory learning: high-resolution profiling of synapse-enriched protein fractions from mouse brain.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062398"}, {"offsetInBeginSection": 480, "offsetInEndSection": 831, "text": "Aiming at the identification of biological processes and signaling pathways involved in auditory memory formation, here, a label-free quantification approach was utilized to identify regulated synaptic junctional proteins and phosphoproteins in the auditory cortex, frontal cortex,\u00a0hippocampus, and striatum of mice 24\u00a0h after the learning experiment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062398"}, {"offsetInBeginSection": 1132, "offsetInEndSection": 1341, "text": "For example, several members of the Septin family of cytoskeletal proteins were up-regulated only in the hippocampus, while Septin-9 was down-regulated in the hippocampus, the frontal cortex, and the striatum.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27062398"}]}, {"id": "5a742d620384be9551000002", "body": "Which disease risk can be estimated with the Stop-Bang questionnaire?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27610133", "http://www.ncbi.nlm.nih.gov/pubmed/27898430", "http://www.ncbi.nlm.nih.gov/pubmed/25837173", "http://www.ncbi.nlm.nih.gov/pubmed/22270686", "http://www.ncbi.nlm.nih.gov/pubmed/25758298", "http://www.ncbi.nlm.nih.gov/pubmed/25010615", "http://www.ncbi.nlm.nih.gov/pubmed/26961117", "http://www.ncbi.nlm.nih.gov/pubmed/26378880", "http://www.ncbi.nlm.nih.gov/pubmed/27938922", "http://www.ncbi.nlm.nih.gov/pubmed/26557740"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Length of Stay in Ambulatory Surgical Oncology Patients at High Risk for Sleep Apnea as Predicted by STOP-BANG Questionnaire.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27610133"}, {"offsetInBeginSection": 12, "offsetInEndSection": 197, "text": "The STOP-BANG questionnaire has been used to identify surgical patients at risk for undiagnosed obstructive sleep apnea (OSA) by classifying patients as low risk (LR) if STOP-BANG score", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27610133"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "An update on the various practical applications of the STOP-Bang questionnaire in anesthesia, surgery, and perioperative medicine.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 11, "offsetInEndSection": 190, "text": "REVIEW: The present review aims to provide an update on the various practical applications of the STOP-Bang questionnaire in anesthesia, surgery, and perioperative medicine.RECENT", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 191, "offsetInEndSection": 358, "text": "FINDINGS: The STOP-Bang questionnaire was originally validated as a screening tool to identify surgical patients who are at high-risk of obstructive sleep apnea (OSA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 359, "offsetInEndSection": 482, "text": "A recent meta-analysis confirmed that STOP-Bang is validated for use in the sleep clinic, surgical, and general population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 483, "offsetInEndSection": 580, "text": "Patients with a STOP-Bang score of 0--2 can be classified as low-risk for moderate-to-severe OSA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 581, "offsetInEndSection": 666, "text": "Those with a score of 5--8 can be classified as high-risk for moderate-to-severe OSA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 667, "offsetInEndSection": 920, "text": "In patients with a score of 3 or 4, a specific combination of a STOP score at least 2 + BMI more than 35\u200akg/m or STOP score at least 2 + male or STOP score at least 2 + neck circumference more than 40\u200acm indicates higher risk for moderate-to-severe OSA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1068, "text": "Further, patients with a STOP-Bang score at least 3 can be classified as high risk for moderate-to-severe OSA if the serum HCO3 at least 28\u200ammol/l.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27898430"}]}, {"id": "5a86ea05faa1ab7d2e000037", "body": "How is CTCF activated post-translationally?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21465478", "http://www.ncbi.nlm.nih.gov/pubmed/19170077", "http://www.ncbi.nlm.nih.gov/pubmed/21912613", "http://www.ncbi.nlm.nih.gov/pubmed/15361875", "http://www.ncbi.nlm.nih.gov/pubmed/24362533", "http://www.ncbi.nlm.nih.gov/pubmed/25183525", "http://www.ncbi.nlm.nih.gov/pubmed/20110362", "http://www.ncbi.nlm.nih.gov/pubmed/23843455", "http://www.ncbi.nlm.nih.gov/pubmed/29077515", "http://www.ncbi.nlm.nih.gov/pubmed/26657029"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "CTCF is an evolutionary conserved and ubiquitously expressed protein that binds thousands of sites in the human genome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 120, "offsetInEndSection": 310, "text": "Ectopic expression of CTCF in various normal and tumoral human cell lines inhibits cell division and clonogenicity, with the consequence to consider CTCF a potential tumor-suppressor factor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 929, "offsetInEndSection": 1105, "text": "Indeed, the ability of CTCF to bind their promoters strictly depends by cell-type features as DNA methylation, BORIS-binding and post-translational modifications as PARYlation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21465478"}, {"offsetInBeginSection": 0, "offsetInEndSection": 238, "text": "CCCTC-binding factor (CTCF) is a ubiquitous Zn-finger-containing protein with numerous recognized functions, including, but not limited to, gene activation and repression, enhancer-blocking, X-chromosome inactivation, and gene imprinting.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077"}, {"offsetInBeginSection": 363, "offsetInEndSection": 466, "text": "In addition, CTCF undergoes several post-translational modifications, including poly(ADP-ribosyl)ation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077"}, {"offsetInBeginSection": 612, "offsetInEndSection": 753, "text": "Here, we summarize and critically discuss the available data on the interplay between CTCF and poly(ADP-ribosyl)ation in these two processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19170077"}, {"offsetInBeginSection": 349, "offsetInEndSection": 436, "text": "However, it is still unknown how UV stress down-regulates CTCF affecting the cell fate.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613"}, {"offsetInBeginSection": 603, "offsetInEndSection": 705, "text": "We found that activated Bcl-3 was able to bind to the \u03baB sites identified in the CTCF promoter region.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613"}, {"offsetInBeginSection": 815, "offsetInEndSection": 907, "text": "The Bcl-3/p50 complex suppressed CTCF promoter activity to down-regulate CTCF transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613"}, {"offsetInBeginSection": 908, "offsetInEndSection": 1037, "text": "Unlike the effect of EGF, UV stress-induced Bcl-3 activation suppressed CTCF activity without involving the I\u03baB\u03b1 and p65 pathway.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21912613"}]}, {"id": "5a6a2f88b750ff4455000024", "body": "What is Target Explorer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12824372"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Target Explorer: An automated tool for the identification of new target genes for a specified set of transcription factors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 417, "offsetInEndSection": 664, "text": "Target Explorer automates the entire process from the creation of a customized library of binding sites for known transcription factors through the prediction and annotation of putative target genes that are potentially regulated by these factors.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}, {"offsetInBeginSection": 820, "offsetInEndSection": 901, "text": "Target Explorer is available at http://trantor.bioc.columbia.edu/Target_Explorer/", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12824372"}]}, {"id": "5a772e9dfaa1ab7d2e000001", "body": "Was saracatinib being considered as a treatment for Alzheimer's disease in November 2017?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26062928", "http://www.ncbi.nlm.nih.gov/pubmed/25874001", "http://www.ncbi.nlm.nih.gov/pubmed/29112196", "http://www.ncbi.nlm.nih.gov/pubmed/11802333", "http://www.ncbi.nlm.nih.gov/pubmed/26271177", "http://www.ncbi.nlm.nih.gov/pubmed/28828744", "http://www.ncbi.nlm.nih.gov/pubmed/11763163", "http://www.ncbi.nlm.nih.gov/pubmed/28817221", "http://www.ncbi.nlm.nih.gov/pubmed/22299278", "http://www.ncbi.nlm.nih.gov/pubmed/21977379"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 244, "offsetInEndSection": 313, "text": "Saracatinib (AZD0530) is a novel selective oral Src kinase inhibitor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 1386, "offsetInEndSection": 1641, "text": "CONCLUSION: Saracatinib is a novel oral Src kinase inhibitor that was well tolerated but failed to meet its primary endpoint of improvement in 4 month progression-free survival as a single agent in previously treated metastatic colorectal cancer patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 74, "offsetInEndSection": 243, "text": "Increased Src activity has been shown to correlate with disease progression and poor prognosis, suggesting Src could serve as a therapeutic target for kinase inhibition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 461, "offsetInEndSection": 617, "text": "Saracatinib was administered at 175 mg by mouth daily for 28 day cycles until dose-limiting toxicity or progression as determined by staging every 2 cycles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26062928"}, {"offsetInBeginSection": 0, "offsetInEndSection": 158, "text": "A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "INTRODUCTION: Despite significant progress, a disease-modifying therapy for Alzheimer's disease (AD) has not yet been developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 129, "offsetInEndSection": 248, "text": "Recent findings implicate soluble oligomeric amyloid beta as the most relevant protein conformation in AD pathogenesis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 599, "offsetInEndSection": 801, "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 1224, "offsetInEndSection": 1322, "text": "Primary endpoints were safety, tolerability, and cerebrospinal fluid (CSF) penetration of AZD0530.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}]}, {"id": "5a897729fcd1d6a10c000009", "body": "What is the asosciation between the  eustachian tube and the uvula?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6586052", "http://www.ncbi.nlm.nih.gov/pubmed/18695625", "http://www.ncbi.nlm.nih.gov/pubmed/17049625", "http://www.ncbi.nlm.nih.gov/pubmed/19644792", "http://www.ncbi.nlm.nih.gov/pubmed/21112097", "http://www.ncbi.nlm.nih.gov/pubmed/7401840"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Otitis media and eustachian tube caliber.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "Clinical data supported the hypothesis that most otitis media requiring surgery is part of a life-long bilateral process that correlates with small mastoid air system, and with a bougie-assessable large eustachian tube.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 220, "offsetInEndSection": 334, "text": "Cleft palate, even in the microform of cleft uvula, was an indicator of large eustachian tube (p less than 0.001).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 335, "offsetInEndSection": 486, "text": "The 1.48 mm mean eustachian tube caliber of the otitis patients was larger (p less than 0.001) than the 0.73 mm mean of the reference eustachian tubes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 487, "offsetInEndSection": 545, "text": "Eustachian tube caliber was not a correlate of age or sex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 756, "offsetInEndSection": 872, "text": "Large eustachian tube caliber seemed a reliable correlate of the spectrum of manifestations of chronic otitis media.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6586052"}, {"offsetInBeginSection": 0, "offsetInEndSection": 104, "text": "The patulous eustachian tube complicated with amyotrophic lateral sclerosis: a video clip demonstration.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18695625"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "We report a 60-year-old case diagnosed as the amyotrophic lateral sclerosis with patulous eustachian tube (ET).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18695625"}, {"offsetInBeginSection": 112, "offsetInEndSection": 411, "text": "To our knowledge, this is the first case report of the amyotrophic lateral sclerosis complicating patulous ET in the literature, demonstrating the movement of the tympanic membrane, the pharyngeal orifice of the ET and abnormal movement of the uvula because of paralysis of the soft palate on video.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18695625"}, {"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Floating the uvula: an intraoperative method for detecting bifidity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17049625"}]}, {"id": "5a888b56d543831129000002", "body": "What induces Arabidopsis ROF1 expression?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19366428", "http://www.ncbi.nlm.nih.gov/pubmed/17080288"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Arabidopsis ROF1 (FKBP62) modulates thermotolerance by interacting with HSP90.1 and affecting the accumulation of HsfA2-regulated sHSPs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Arabidopsis ROF1 (AtFKBP62) is a peptidyl prolyl cis/trans isomerase and a member of the FKBP (FK506 binding protein) family.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 363, "offsetInEndSection": 564, "text": "Exposure to heat stress induces nuclear localization of the ROF1-HSP90.1 complex, which is dependent upon the presence of the transcription factor HsfA2, which interacts with HSP90.1 but not with ROF1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19366428"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Arabidopsis immunophilins ROF1 (AtFKBP62) and ROF2 (AtFKBP65) exhibit tissue specificity, are heat-stress induced, and bind HSP90.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288"}, {"offsetInBeginSection": 174, "offsetInEndSection": 317, "text": "We report the characterization of the Arabidopsis large FKBPs ROF1 (AtFKBP62) and ROF2 (AtFKBP65) expression and protein accumulation patterns.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17080288"}]}, {"id": "5a67a207b750ff4455000008", "body": "List indications for palivizumab for treatment of RSV-induced bronchiolitis. ", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21077358", "http://www.ncbi.nlm.nih.gov/pubmed/12171262", "http://www.ncbi.nlm.nih.gov/pubmed/28807039", "http://www.ncbi.nlm.nih.gov/pubmed/20705882", "http://www.ncbi.nlm.nih.gov/pubmed/20695756", "http://www.ncbi.nlm.nih.gov/pubmed/28987219", "http://www.ncbi.nlm.nih.gov/pubmed/26636747", "http://www.ncbi.nlm.nih.gov/pubmed/19811111", "http://www.ncbi.nlm.nih.gov/pubmed/20457017", "http://www.ncbi.nlm.nih.gov/pubmed/16236360"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 113, "text": "[Two cases of symptomatic West syndrome suffering from severe respiratory syncytial virus-induced bronchiolitis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 0, "offsetInEndSection": 236, "text": "We report two cases of symptomatic West syndrome with severe respiratory syncytial virus (RSV)-induced bronchiolitis: one was a 9-month-old boy who was hospitalized for shock, and the other was a 15-month-old boy in pre-shock condition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 532, "offsetInEndSection": 722, "text": "According to a one-year epidemiological survey of RSV infection conducted in 2004-2005 in Nagano prefecture, 7 of 238 hospitalized RSV cases were found to have basic neuromuscular disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 899, "offsetInEndSection": 994, "text": "Neuromuscular disorders may thus be an important risk factor for severe forms of RSV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 995, "offsetInEndSection": 1187, "text": "Although children with such disorders should be protected from RSV, they are currently excluded from the indication for palivizumab administration as passive immunization against RSV in Japan.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21077358"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Management of bronchiolitis: current practices in Ireland.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "To establish current practice for hospital-based treatment of uncomplicated respiratory syncytial virus (RSV) infection in the Republic of Ireland.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 347, "offsetInEndSection": 469, "text": "The scenario was of a 3-month-old infant with uncomplicated but moderately severe RSV infection requiring hospitalization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 1049, "offsetInEndSection": 1172, "text": "The routine use of RSV monoclonal antibody, palivizumab, for RSV prophylaxis was reported by 49% (31/63) of paediatricians.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}, {"offsetInBeginSection": 1348, "offsetInEndSection": 1455, "text": "The management of infants with RSV bronchiolitis varies greatly among consultant paediatricians in Ireland.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12171262"}]}, {"id": "5a86f074faa1ab7d2e00003a", "body": "With which cancers has the loss of SMARCB1 been associated?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26941181", "http://www.ncbi.nlm.nih.gov/pubmed/23432645", "http://www.ncbi.nlm.nih.gov/pubmed/24853101", "http://www.ncbi.nlm.nih.gov/pubmed/28974397", "http://www.ncbi.nlm.nih.gov/pubmed/22797305", "http://www.ncbi.nlm.nih.gov/pubmed/23060122", "http://www.ncbi.nlm.nih.gov/pubmed/26743474", "http://www.ncbi.nlm.nih.gov/pubmed/23851500", "http://www.ncbi.nlm.nih.gov/pubmed/25490678", "http://www.ncbi.nlm.nih.gov/pubmed/23174932"], "snippets": [{"offsetInBeginSection": 158, "offsetInEndSection": 335, "text": "Since discovering genetic alterations of the SMARCB1 gene in malignant rhabdoid tumours, the family of tumours harbouring loss of SMARCB1 expression has been steadily expanding.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26941181"}, {"offsetInBeginSection": 656, "offsetInEndSection": 796, "text": "Indeed, the mutation rate in RTs is among the lowest of all cancers sequenced, with loss of SMARCB1 as essentially the sole recurrent event.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23432645"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101"}, {"offsetInBeginSection": 669, "offsetInEndSection": 867, "text": "Consequently, investigation of the mechanisms by which SMARCB1 mutation causes cancer has relevance not only for rhabdoid tumors, but also potentially for the wide variety of SWI/SNF mutant cancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24853101"}, {"offsetInBeginSection": 94, "offsetInEndSection": 405, "text": "In the course of clinical care, we encountered a patient with a complete loss of SMARCB1 (switch/sucrose nonfermentable-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1), which encodes INI-1 (integrase interactor 1), as the sole detected driver of their urinary tract tumor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28974397"}, {"offsetInBeginSection": 940, "offsetInEndSection": 1001, "text": "RESULTS: CGP identified 10 patients with SMARCB1 alterations.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28974397"}, {"offsetInBeginSection": 1002, "offsetInEndSection": 1215, "text": "Of the 10 patients, 4 (1 each with renal pelvis, ureter, bladder, and unknown primary cancer) had complete loss of SMARCB1, and 6 had loss of heterozygosity with an unknown effect on function or heterozygous loss.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28974397"}, {"offsetInBeginSection": 1439, "offsetInEndSection": 1575, "text": "CONCLUSION: The genomic profiles of the tumors from patients with UC revealed a population of tumors driven by complete loss of SMARCB1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28974397"}, {"offsetInBeginSection": 374, "offsetInEndSection": 569, "text": "Here we sequenced the exomes of 35 rhabdoid tumors, highly aggressive cancers of early childhood characterized by biallelic loss of SMARCB1, a subunit of the SWI/SNF chromatin remodeling complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22797305"}, {"offsetInBeginSection": 754, "offsetInEndSection": 899, "text": "Our results demonstrate that high mutation rates are dispensable for the genesis of cancers driven by mutation of a chromatin remodeling complex.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22797305"}]}, {"id": "5a6d022ab750ff445500002a", "body": "Is there any linear-time and linear-space algorithm for the computation of avoided words in biological sequences?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28293277"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 86, "text": "On avoided words, absent words, and their application to biological sequence analysis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}, {"offsetInBeginSection": 62, "offsetInEndSection": 225, "text": "RESULTS: In this article, we propose an [Formula: see text]-time and [Formula: see text]-space algorithm to compute all [Formula: see text]-avoided words of length", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}, {"offsetInBeginSection": 336, "offsetInEndSection": 434, "text": "We present a linear-time and linear-space algorithm for the computation of avoided words of length", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293277"}]}, {"id": "5a735b383b9d13c708000002", "body": "What is the name of the RNAi investigational drug being developed against hereditary amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28893208", "http://www.ncbi.nlm.nih.gov/pubmed/27033334", "http://www.ncbi.nlm.nih.gov/pubmed/25003808", "http://www.ncbi.nlm.nih.gov/pubmed/23432579", "http://www.ncbi.nlm.nih.gov/pubmed/10137064", "http://www.ncbi.nlm.nih.gov/pubmed/10137850", "http://www.ncbi.nlm.nih.gov/pubmed/28389707"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "BACKGROUND: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 240, "offsetInEndSection": 485, "text": "METHODS: Here we describe the rationale and design of the Phase 3 APOLLO study, a randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of patisiran in patients with hATTR amyloidosis with polyneuropathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 115, "offsetInEndSection": 246, "text": "RNA interference (RNAi) is a clinically validated technology that may be a promising approach to the treatment of ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 247, "offsetInEndSection": 353, "text": "The vast majority of TTR, the soluble precursor of TTR amyloid, is expressed and synthesized in the liver.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 354, "offsetInEndSection": 565, "text": "RNAi technology enables robust hepatic gene silencing, the goal of which would be to reduce systemic levels of TTR and mitigate many of the clinical manifestations of ATTR that arise from hepatic TTR expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 566, "offsetInEndSection": 676, "text": "To test this hypothesis, TTR-targeting siRNAs were evaluated in a murine model of hereditary ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 677, "offsetInEndSection": 839, "text": "RNAi-mediated silencing of hepatic TTR expression inhibited TTR deposition and facilitated regression of existing TTR deposits in pathologically relevant tissues.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 840, "offsetInEndSection": 935, "text": "Further, the extent of deposit regression correlated with the level of RNAi-mediated knockdown.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1097, "text": "In comparison to the TTR stabilizer, tafamidis, RNAi-mediated TTR knockdown led to greater regression of TTR deposits across a broader range of affected tissues.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1286, "text": "Together, the data presented herein support the therapeutic hypothesis behind TTR lowering and highlight the potential of RNAi in the treatment of patients afflicted with ATTR amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27033334"}]}, {"id": "5a67b48cb750ff4455000010", "body": "SGOT is an abbreviation for an enzyme other wise known as alanine amino transferase, yes or no?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21375200", "http://www.ncbi.nlm.nih.gov/pubmed/1678364", "http://www.ncbi.nlm.nih.gov/pubmed/589307", "http://www.ncbi.nlm.nih.gov/pubmed/1681419", "http://www.ncbi.nlm.nih.gov/pubmed/17880731", "http://www.ncbi.nlm.nih.gov/pubmed/5349302", "http://www.ncbi.nlm.nih.gov/pubmed/17904308", "http://www.ncbi.nlm.nih.gov/pubmed/1355593", "http://www.ncbi.nlm.nih.gov/pubmed/5470040", "http://www.ncbi.nlm.nih.gov/pubmed/16877991"], "snippets": [{"offsetInBeginSection": 378, "offsetInEndSection": 626, "text": "The study excluded by screening for AntiHCV, HBsAg and patients with aspartate amino transferase (SGOT), alanine amino transferase (SGPT), GGT levels more than three times the normal and subject with a total leukocyte count more than 10,000/microl.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21375200"}, {"offsetInBeginSection": 157, "offsetInEndSection": 280, "text": "When the worms were incubated in DEC, substances known to have neurotransmitter effect were found increased except glycine.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1678364"}, {"offsetInBeginSection": 419, "offsetInEndSection": 584, "text": "DEC inhibited activities of monoamine oxidase, aspartate amino transferase and alanine amino transferase and enhanced those of cathepsin and glutamate dehydrogenase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1678364"}, {"offsetInBeginSection": 156, "offsetInEndSection": 550, "text": "Mean values of glutamate dehydrogenase (GDH), serum aspartate and alanine transferase (SGOT and SGPT), ornithine carbamoyltransferase (OCT), and gamma-glutamyltranspeptidase (gamma-GTP) tended to rise with increasing liver cell necrosis, though values of SGOT, SGPT, OCT, and gamma-GTP showed considerable overlap between the 32 patients with histologically proved hepatitis and the 68 without.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/589307"}, {"offsetInBeginSection": 0, "offsetInEndSection": 136, "text": "Effect of glucagon and some other alpha and beta adrenergic agonists and antagonists on alanine amino transferase of perfused rat liver.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "Glucagon increased alanine amino transferase (AAT) activity in perfused rat liver by about 90% over control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 109, "offsetInEndSection": 200, "text": "Propranolol, the beta receptor antagonist, abolished the effect of glucagon on this enzyme.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 201, "offsetInEndSection": 406, "text": "Well known beta receptor agonists like isoproterenol, norepinephrine and epinephrine also increased the enzyme activity under identical condition and the enhancement was similarly abolished by propranolol.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 407, "offsetInEndSection": 514, "text": "These experiments suggest that the effect of glucagon on AAT was mediated through beta adrenergic receptor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}, {"offsetInBeginSection": 887, "offsetInEndSection": 1036, "text": "From all these results we are proposing that in our system phenoxybenzamine is acting as beta agonist although it is known to be an alpha antagonist.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1681419"}]}, {"id": "5a893da7bc7bade53a000001", "body": "Is CREB a key memory protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16266283", "http://www.ncbi.nlm.nih.gov/pubmed/9530494", "http://www.ncbi.nlm.nih.gov/pubmed/22267118", "http://www.ncbi.nlm.nih.gov/pubmed/21712073", "http://www.ncbi.nlm.nih.gov/pubmed/23504989", "http://www.ncbi.nlm.nih.gov/pubmed/12006982", "http://www.ncbi.nlm.nih.gov/pubmed/15988467", "http://www.ncbi.nlm.nih.gov/pubmed/28017136", "http://www.ncbi.nlm.nih.gov/pubmed/19110430", "http://www.ncbi.nlm.nih.gov/pubmed/21734652"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 73, "text": "CREB, synapses and memory disorders: past progress and future challenges.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 233, "offsetInEndSection": 423, "text": "The cAMP responsive element binding protein (CREB) is a nuclear transcription factor that modulates transcription of genes containing cAMP responsive elements (CRE sites) in their promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 424, "offsetInEndSection": 529, "text": "CREB is a key part of many intracellular signaling events that critically regulate many neural functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 530, "offsetInEndSection": 635, "text": "Numerous studies on invertebrates and vertebrates demonstrate that CREB is critical for long-term memory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 636, "offsetInEndSection": 834, "text": "Here, we review the key features of CREB-dependent transcription and critically evaluate the data examining the roles of CREB in different forms of plasticity, including long-term memory in mammals.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 1070, "offsetInEndSection": 1170, "text": "Several human cognitive disorders have been linked to alterations of CREB-regulated gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 1171, "offsetInEndSection": 1277, "text": "Therefore, we explore the possibility of targeting CREB function in developing novel treatment strategies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 1278, "offsetInEndSection": 1364, "text": "Finally, we highlight areas of research on CREB that are ripe for further advancement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16266283"}, {"offsetInBeginSection": 0, "offsetInEndSection": 163, "text": "The cAMP responsive element binding protein (CREB) is a nuclear protein that modulates the transcription of genes with cAMP responsive elements in their promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}, {"offsetInBeginSection": 164, "offsetInEndSection": 276, "text": "Increases in the concentration of either calcium or cAMP can trigger the phosphorylation and activation of CREB.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9530494"}]}, {"id": "5a67ade5b750ff445500000c", "body": "Does erythromycin increase risk of hypertrophic pyloric stenosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12693559", "http://www.ncbi.nlm.nih.gov/pubmed/12090829", "http://www.ncbi.nlm.nih.gov/pubmed/10609814", "http://www.ncbi.nlm.nih.gov/pubmed/11562617", "http://www.ncbi.nlm.nih.gov/pubmed/27655365", "http://www.ncbi.nlm.nih.gov/pubmed/12100810", "http://www.ncbi.nlm.nih.gov/pubmed/25687145", "http://www.ncbi.nlm.nih.gov/pubmed/18358279", "http://www.ncbi.nlm.nih.gov/pubmed/12381214"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Risk of infantile hypertrophic pyloric stenosis after maternal postnatal use of macrolides.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "A case report has suggested that exposure to erythromycin through breast milk might cause infantile hypertrophic pyloric stenosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 131, "offsetInEndSection": 283, "text": "This study therefore examined whether macrolides, transmitted via breast milk, increase the risk of infantile hypertrophic pyloric stenosis in neonates.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 614, "offsetInEndSection": 894, "text": "The odds ratios for infantile hypertrophic pyloric stenosis varied between 2.3 and 3.0 according to different periods of postnatal exposure, and after stratification for gender they were 10.3 [95% confidence interval (95% CI) 1.2-92.3] for girls and 2.0 (95% CI 0.5-8.4) for boys.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 895, "offsetInEndSection": 1001, "text": "The use of macrolides during breast-feeding increases the risk of infantile hypertrophic pyloric stenosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12693559"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Very early exposure to erythromycin and infantile hypertrophic pyloric stenosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "OBJECTIVE: To assess the link between very early erythromycin exposure and pyloric stenosis in young infants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 301, "offsetInEndSection": 426, "text": "Cases of infants with a hospital discharge diagnosis of pyloric stenosis and an associated surgical procedure code were used.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 427, "offsetInEndSection": 561, "text": "Erythromycin exposure and other antibiotic exposure between 3 and 90 days of life were identified from prescription files.MAIN OUTCOME", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}, {"offsetInBeginSection": 562, "offsetInEndSection": 664, "text": "MEASURES: Hospital discharge diagnosis of pyloric stenosis, and an associated surgical procedure code.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12090829"}]}, {"id": "5a870b7bfaa1ab7d2e00003d", "body": "What is the function of STAR elements in yeast telomeres?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/10228166", "http://www.ncbi.nlm.nih.gov/pubmed/21351687", "http://www.ncbi.nlm.nih.gov/pubmed/21949764", "http://www.ncbi.nlm.nih.gov/pubmed/8720065", "http://www.ncbi.nlm.nih.gov/pubmed/16228207", "http://www.ncbi.nlm.nih.gov/pubmed/16132818", "http://www.ncbi.nlm.nih.gov/pubmed/10517334", "http://www.ncbi.nlm.nih.gov/pubmed/12498682", "http://www.ncbi.nlm.nih.gov/pubmed/7991584", "http://www.ncbi.nlm.nih.gov/pubmed/9188726"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Cohabitation of insulators and silencing elements in yeast subtelomeric regions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "In budding yeast, the telomeric DNA is flanked by a combination of two subtelomeric repetitive sequences, the X and Y' elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 331, "offsetInEndSection": 404, "text": "These elements were named STARs, for subtelomeric anti-silencing regions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 661, "offsetInEndSection": 739, "text": "In addition, an intervening STAR uncouples the silencing of neighboring genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 928, "offsetInEndSection": 1025, "text": "In contrast, sequences located more centromere proximal in X and Y' elements reinforce silencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 1098, "offsetInEndSection": 1259, "text": "Overall, our results suggest that the silencing emanating from telomeres can be propagated in a discontinuous manner via a series of subtelomeric relay elements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 488, "offsetInEndSection": 660, "text": "When two STARs bracket a reporter gene, its expression is no longer influenced by surrounding silencing elements, although these are still active on a second reporter gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10228166"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "DNA fragments isolated from the left end of chromosome III in yeast are repaired to generate functional telomeres.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 0, "offsetInEndSection": 226, "text": "DNA fragments isolated from the left end of chromosome III in the yeast Saccharomyces cerevisiae are recognized as telomeres in yeast, since plasmids constructed with such fragments are replicated as linear molecules in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}, {"offsetInBeginSection": 227, "offsetInEndSection": 402, "text": "The fragments have a 1.18-kb region homologous with the type X regions at yeast telomeres that contain ARS elements that allow the autonomous replication of plasmids in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21351687"}]}, {"id": "5a6d13fbb750ff445500002f", "body": "What is MINDY (motif interacting with Ub-containing novel DUB family)?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27292798"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "MINDY-1 Is a Member of an Evolutionarily Conserved and Structurally Distinct New Family of Deubiquitinating Enzymes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Deubiquitinating enzymes (DUBs) remove ubiquitin (Ub) from Ub-conjugated substrates to regulate the\u00a0functional outcome of ubiquitylation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 138, "offsetInEndSection": 274, "text": "Here we report the discovery of a new family of DUBs, which we have named MINDY (motif interacting with Ub-containing novel DUB family).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 275, "offsetInEndSection": 417, "text": "Found in all eukaryotes, MINDY-family DUBs are highly selective at cleaving K48-linked polyUb, a signal that targets proteins for degradation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 613, "offsetInEndSection": 776, "text": "The crystal structure of MINDY-1 (also known as FAM63A) in complex with propargylated Ub reveals conformational changes that realign the active site for catalysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 777, "offsetInEndSection": 870, "text": "MINDY-1 prefers cleaving long polyUb chains and\u00a0works by trimming chains from the distal end.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}, {"offsetInBeginSection": 871, "offsetInEndSection": 984, "text": "Collectively, our results reveal a new family of DUBs that may have specialized roles in regulating proteostasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27292798"}]}, {"id": "5a735c143b9d13c708000003", "body": "Is patisiran currently (November 2017) in clinical phase II trials?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26338094", "http://www.ncbi.nlm.nih.gov/pubmed/28893208"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "BACKGROUND: Transthyretin-mediated amyloidosis is an inherited, progressively debilitating disease caused by mutations in the transthyretin gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 146, "offsetInEndSection": 419, "text": "This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of patisiran (ALN-TTR02), a small interfering RNA encapsulated within lipid nanoparticles, in patients with transthyretin-mediated familial amyloid polyneuropathy (FAP).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 419, "offsetInEndSection": 682, "text": "METHODS: In this phase II study, patients with FAP were administered 2 intravenous infusions of patisiran at one of the following doses: 0.01 (n\u2009=\u20094), 0.05 (n\u2009=\u20093), 0.15 (n\u2009=\u20093), or 0.3 (n\u2009=\u20097) mg/kg every 4\u00a0weeks (Q4W), or 0.3\u00a0mg/kg (n\u2009=\u200912) every 3\u00a0weeks (Q3W).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 682, "offsetInEndSection": 764, "text": "RESULTS: Of 29 patients in the intent-to-treat population, 26 completed the study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 765, "offsetInEndSection": 1017, "text": "Administration of patisiran led to rapid, dose-dependent, and durable knockdown of transthyretin, with the maximum effect seen with patisiran 0.3\u00a0mg/kg; levels of mutant and wild-type transthyretin were reduced to a similar extent in Val30Met patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 1486, "offsetInEndSection": 1637, "text": "CONCLUSIONS: Patisiran was generally well tolerated and resulted in significant dose-dependent knockdown of transthyretin protein in patients with FAP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 1638, "offsetInEndSection": 1718, "text": "Patisiran 0.3\u00a0mg/kg Q3W is currently in phase III development.TRIAL REGISTRATION", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26338094"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}, {"offsetInBeginSection": 0, "offsetInEndSection": 240, "text": "BACKGROUND: Patisiran is an investigational RNA interference (RNAi) therapeutic in development for the treatment of hereditary ATTR (hATTR) amyloidosis, a progressive disease associated with significant disability, morbidity, and mortality.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28893208"}]}, {"id": "5a787544faa1ab7d2e00000b", "body": "Is Kummell\u2019s disease an avascular necrosis of the vertebral body?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9280031", "http://www.ncbi.nlm.nih.gov/pubmed/27446290", "http://www.ncbi.nlm.nih.gov/pubmed/19321060", "http://www.ncbi.nlm.nih.gov/pubmed/12865850", "http://www.ncbi.nlm.nih.gov/pubmed/19214087", "http://www.ncbi.nlm.nih.gov/pubmed/19124637", "http://www.ncbi.nlm.nih.gov/pubmed/22220246", "http://www.ncbi.nlm.nih.gov/pubmed/23814399"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 50, "text": "Idiopathic avascular necrosis of a vertebral body.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 48, "offsetInEndSection": 157, "text": "OBJECTIVES: To review the English literature pertaining to idiopathic avascular necrosis of a vertebral body.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 158, "offsetInEndSection": 293, "text": "As an illustrative example, the case of a 60-year-old woman with idiopathic avascular necrosis of L4 is presented.SUMMARY OF BACKGROUND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 294, "offsetInEndSection": 361, "text": "DATA: Avascular necrosis of a vertebral body is an uncommon entity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 362, "offsetInEndSection": 530, "text": "Avascular necrosis has been described in the context of other underlying lesions, such as with malignancy, infection, radiation therapy, and systemic steroid treatment.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 531, "offsetInEndSection": 662, "text": "The intravertebral vacuum cleft phenomenon seen on plain films has been strongly associated with vertebral body avascular necrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 716, "offsetInEndSection": 822, "text": "Vertebral body avascular necrosis was initially identified with imaging studies and confirmed with biopsy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 823, "offsetInEndSection": 919, "text": "A comprehensive preoperative evaluation did not identify a specific cause of avascular necrosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 920, "offsetInEndSection": 996, "text": "The patient underwent vertebral body resection with fibula allograft struts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}, {"offsetInBeginSection": 996, "offsetInEndSection": 1225, "text": "CONCLUSIONS: Although vertebral body collapse in an osteoporotic individual is relatively common, a case is reported of vertebral body collapse and subsequent necrosis without evidence of underlying disease at 48-month follow-up.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9280031"}]}, {"id": "5a895a96fcd1d6a10c000003", "body": "Can a circRNA be translated into protein?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28344080", "http://www.ncbi.nlm.nih.gov/pubmed/28344082", "http://www.ncbi.nlm.nih.gov/pubmed/25449546", "http://www.ncbi.nlm.nih.gov/pubmed/28634583", "http://www.ncbi.nlm.nih.gov/pubmed/28223408", "http://www.ncbi.nlm.nih.gov/pubmed/29116363", "http://www.ncbi.nlm.nih.gov/pubmed/28705773", "http://www.ncbi.nlm.nih.gov/pubmed/29028266", "http://www.ncbi.nlm.nih.gov/pubmed/27612318", "http://www.ncbi.nlm.nih.gov/pubmed/29036403"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 100, "text": "Circular RNAs (circRNAs) are abundant and evolutionarily conserved RNAs of largely unknown function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344080"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Circ-ZNF609 Is a Circular RNA that Can Be Translated and Functions in Myogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082"}, {"offsetInBeginSection": 306, "offsetInEndSection": 523, "text": "Here we\u00a0performed expression profiling of circRNAs during in\u00a0vitro differentiation of murine and human myoblasts, and we identified conserved species regulated in myogenesis and altered in Duchenne muscular dystrophy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082"}, {"offsetInBeginSection": 907, "offsetInEndSection": 1106, "text": "Circ-ZNF609 is associated with heavy polysomes, and it is translated into a protein in a splicing-dependent and cap-independent manner, providing an example of a protein-coding circRNA in eukaryotes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28344082"}, {"offsetInBeginSection": 792, "offsetInEndSection": 864, "text": "The resulting circRNA can be translated to generate functional proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25449546"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "Circular RNAs: Biogenesis, Function and Role in Human Diseases.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 607, "offsetInEndSection": 722, "text": "Interestingly, they have been found to be abundant, evolutionally conserved and relatively stable in the cytoplasm.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 723, "offsetInEndSection": 921, "text": "These features confer numerous potential functions to circRNAs, such as acting as miRNA sponges, or binding to RNA-associated proteins to form RNA-protein complexes that regulate gene transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 922, "offsetInEndSection": 1161, "text": "It has been proposed that circRNA regulate gene expression at the transcriptional or post-transcriptional level by interacting with miRNAs and that circRNAs may have a role in regulating miRNA function in cancer initiation and progression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}, {"offsetInBeginSection": 1162, "offsetInEndSection": 1478, "text": "circRNAs appear to be more often downregulated in tumor tissue compared to normal tissue and this may be due to (i) errors in the back-splice machinery in malignant tissues, (ii) degradation of circRNAs by deregulated miRNAs in tumor tissue, or (iii) increasing cell proliferation leading to a reduction of circRNAs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28634583"}]}, {"id": "5a67afb7b750ff445500000d", "body": "List main clinical features of the POEMS syndrome.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2227242", "http://www.ncbi.nlm.nih.gov/pubmed/10378364", "http://www.ncbi.nlm.nih.gov/pubmed/27208909", "http://www.ncbi.nlm.nih.gov/pubmed/25984208", "http://www.ncbi.nlm.nih.gov/pubmed/8699962", "http://www.ncbi.nlm.nih.gov/pubmed/22453306"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 47, "text": "[Unusual cause of ascites: the POEMS syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 211, "text": "A 39-year-old woman presented with polyneuropathy, hepatomegaly, splenomegaly, endocrinopathy, monoclonal protein and skin changes, several of the many clinical features of the recently described POEMS syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 297, "offsetInEndSection": 348, "text": "In this case ascites was a main presenting feature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 349, "offsetInEndSection": 426, "text": "Thus, the POEMS syndrome must be added to the list of rare causes of ascites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2227242"}, {"offsetInBeginSection": 0, "offsetInEndSection": 166, "text": "[46-year-old patient with polyneuropathy, hepatosplenomegaly, endocrinopathy, M-gradient, skin manifestations, sclerotic bone changes and therapy refractory ascites].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "The POEMS syndrome is a rare multisystemic disorder with polyneuropathy, organomegaly, endocrinopathy of various forms, production of monoclonal (M) component, and skin changes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 340, "offsetInEndSection": 471, "text": "Extensive evaluation revealed that the patient had no underlying liver disease, malignancy, infection, or cardiac or renal disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 541, "offsetInEndSection": 701, "text": "The patient had many clinical features of the described POEMS syndrome including sclerotic bone lesions, a persistent lambda-paraprotein and refractory ascites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 702, "offsetInEndSection": 753, "text": "In this case ascites was a main presenting feature.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}, {"offsetInBeginSection": 754, "offsetInEndSection": 842, "text": "Thus, the POEMS syndrome must be added to the list of rare causes of refractory ascites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10378364"}]}, {"id": "5a89528dfcd1d6a10c000001", "body": "Where do centromeres locate according to the Rabl orientation of eukaryotic nuclei?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/9886774", "http://www.ncbi.nlm.nih.gov/pubmed/21674259", "http://www.ncbi.nlm.nih.gov/pubmed/11559751", "http://www.ncbi.nlm.nih.gov/pubmed/20501974", "http://www.ncbi.nlm.nih.gov/pubmed/26208647", "http://www.ncbi.nlm.nih.gov/pubmed/15102067"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Non-Rabl patterns of centromere and telomere distribution in the interphase nuclei of plant cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 136, "offsetInEndSection": 267, "text": "Such a polarized orientation of centromeres and telomeres is believed to be preserved in the interphase and is known as Rabl model.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 268, "offsetInEndSection": 375, "text": "We analyzed the distributions of centromeres and telomeres in interphase nuclei from several plant species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 376, "offsetInEndSection": 505, "text": "Although Rabl polarity was observed in wheat, rye, barley and oats, non-Rabl patterns were discovered in sorghum, rice and maize.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 506, "offsetInEndSection": 658, "text": "In the non-Rabl patterns, both centromeres and telomeres were dispersed throughout the interphase nucleus, except in the area occupied by the nucleolus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 659, "offsetInEndSection": 866, "text": "Both Rabl and non-Rabl distribution patterns of centromeres and telomeres were consistent in interphase nuclei derived from meristematic root tip cells, microspore mother cells and differentiated leaf cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 867, "offsetInEndSection": 1021, "text": "Our study demonstrated that there is a diversity of interphase chromatin organization and that the classical Rabl model is not universal in plant species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9886774"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Similar rye A and B chromosome organization in meristematic and differentiated interphase nuclei.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259"}, {"offsetInBeginSection": 122, "offsetInEndSection": 258, "text": "These special features inspired us to analyse whether there are differences between A and B chromatin organization in interphase nuclei.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259"}, {"offsetInBeginSection": 259, "offsetInEndSection": 451, "text": "Applying fluorescence in situ hybridization, we found that both rye A and B chromosomes added to hexaploid wheat showed in meristematic nuclei a string-like shape and a clear Rabl orientation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21674259"}]}, {"id": "5a6e18d8b750ff4455000038", "body": "Are Conserved Nonexonic Elements (CNEEs) important in phylogenomics research?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28637293"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Conserved Nonexonic Elements: A Novel Class of Marker for Phylogenomics.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 0, "offsetInEndSection": 186, "text": "Noncoding markers have a particular appeal as tools for phylogenomic analysis because, at least in vertebrates, they appear less subject to strong variation in GC content among lineages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 187, "offsetInEndSection": 289, "text": "Thus far, ultraconserved elements (UCEs) and introns have been the most widely used noncoding markers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 290, "offsetInEndSection": 536, "text": "Here we analyze and study the evolutionary properties of a new type of noncoding marker, conserved nonexonic elements (CNEEs), which consists of noncoding elements that are estimated to evolve slower than the neutral rate across a set of species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 747, "offsetInEndSection": 1158, "text": "Using a data set of 16 birds plus an alligator outgroup, and \u223c3600-\u223c3800 loci per marker type, we found that although CNEEs were less variable than bioinformatically derived UCEs or introns and in some cases exhibited a slower approach to branch resolution as determined by phylogenomic subsampling, the quality of CNEE alignments was superior to those of the other markers, with fewer gaps and missing species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 1159, "offsetInEndSection": 1309, "text": "Phylogenetic resolution using coalescent approaches was comparable among the three marker types, with most nodes being fully and congruently resolved.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 1310, "offsetInEndSection": 1554, "text": "Comparison of phylogenetic results across the three marker types indicated that one branch, the sister group to the passerine + falcon clade, was resolved differently and with moderate (>70%) bootstrap support between CNEEs and UCEs or introns.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}, {"offsetInBeginSection": 1555, "offsetInEndSection": 1865, "text": "Overall, CNEEs appear to be promising as phylogenomic markers, yielding phylogenetic resolution as high as for UCEs and introns but with fewer gaps, less ambiguity in alignments and with patterns of nucleotide substitution more consistent with the assumptions of commonly used methods of phylogenetic analysis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28637293"}]}, {"id": "5a7361d83b9d13c708000005", "body": "What is miravirsen?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25385103", "http://www.ncbi.nlm.nih.gov/pubmed/24068553", "http://www.ncbi.nlm.nih.gov/pubmed/24354366", "http://www.ncbi.nlm.nih.gov/pubmed/27805315", "http://www.ncbi.nlm.nih.gov/pubmed/23534542", "http://www.ncbi.nlm.nih.gov/pubmed/26503793", "http://www.ncbi.nlm.nih.gov/pubmed/25218783", "http://www.ncbi.nlm.nih.gov/pubmed/23109665", "http://www.ncbi.nlm.nih.gov/pubmed/22545703", "http://www.ncbi.nlm.nih.gov/pubmed/24385319"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "In vitro antiviral activity and preclinical and clinical resistance profile of miravirsen, a novel anti-hepatitis C virus therapeutic targeting the human factor miR-122.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Miravirsen is a \u03b2-D-oxy-locked nucleic acid-modified phosphorothioate antisense oligonucleotide targeting the liver-specific microRNA-122 (miR-122).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 149, "offsetInEndSection": 304, "text": "Miravirsen demonstrated antiviral activity against hepatitis C virus (HCV) genotype 1b replicons with a mean 50% effective concentration (EC50) of 0.67 \u03bcM.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 676, "offsetInEndSection": 854, "text": "Miravirsen demonstrated broad antiviral activity when tested against HCV replicons resistant to NS3, NS5A, and NS5B inhibitors with less than 2-fold reductions in susceptibility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 855, "offsetInEndSection": 1134, "text": "In serial passage studies, an A4C nucleotide change was observed in the HCV 5' untranslated region (UTR) from cells passaged in the presence of up to 20 \u03bcM (40-fold the miravirsen EC50 concentration) at day 72 of passage but not at earlier time points (up to 39 days of passage).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 1394, "offsetInEndSection": 1538, "text": "A C3U HCV variant demonstrated overall reductions in susceptibility to miravirsen but was fully susceptible to all other anti-HCV agents tested.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25385103"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Miravirsen (SPC3649) can inhibit the biogenesis of miR-122.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}, {"offsetInBeginSection": 288, "offsetInEndSection": 390, "text": "MiR-122 is a liver-specific miRNA with an important role in the life cycle of hepatitis C virus (HCV).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}, {"offsetInBeginSection": 522, "offsetInEndSection": 678, "text": "Miravirsen is composed of locked nucleic acid (LNAs) ribonucleotides interspaced throughout a DNA phosphorothioate sequence complementary to mature miR-122.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}, {"offsetInBeginSection": 798, "offsetInEndSection": 977, "text": "While miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA, its target sequence is also present in pri- and pre-miR-122.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24068553"}]}, {"id": "5a7a44b4faa1ab7d2e000010", "body": "Is Loss of function one of the cardinal signs of inflammation?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29135930", "http://www.ncbi.nlm.nih.gov/pubmed/28282278", "http://www.ncbi.nlm.nih.gov/pubmed/23583354"], "snippets": [{"offsetInBeginSection": 60, "offsetInEndSection": 255, "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Inflammation is the body's response to injury or infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Functio Laesa: Cancer Inflammation and Therapeutic Resistance.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "Tumor, calor, rubor, and dolor describe four cardinal signs of inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 77, "offsetInEndSection": 244, "text": "The fifth-functio laesa, or loss of function-was promulgated by Rudolf Virchow, who, in the 19th century, also noted an intricate link between inflammation and cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 245, "offsetInEndSection": 522, "text": "However, the role of cancer inflammation in driving loss of therapeutic efficacy has only recently been fully appreciated, as a result of molecular and immunohistochemical approaches applied in clinical medicine and the availability of novel agents for modulating inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28282278"}, {"offsetInBeginSection": 0, "offsetInEndSection": 130, "text": "Inflammation is a beneficial host reaction to tissue damage and has the essential primary purpose of restoring tissue homeostasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 246, "offsetInEndSection": 440, "text": "The cardinal signs of inflammation dolor, calor, tumor and rubor are intrinsically associated with events including vasodilatation, edema and leukocyte trafficking into the site of inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 441, "offsetInEndSection": 627, "text": "If uncontrolled or unresolved, inflammation itself can lead to further tissue damage and give rise to chronic inflammatory diseases and autoimmunity with eventual loss of organ function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}, {"offsetInBeginSection": 1362, "offsetInEndSection": 1602, "text": "Such strategies have proved beneficial in several pre-clinical models of inflammatory diseases, suggesting that pharmacological modulation of the resolution process may be useful for the treatment of chronic inflammatory diseases in humans.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23583354"}]}, {"id": "5a89a20ffcd1d6a10c00000e", "body": "List factors that promote lymphangiogenesis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16557570", "http://www.ncbi.nlm.nih.gov/pubmed/28804221", "http://www.ncbi.nlm.nih.gov/pubmed/25142796", "http://www.ncbi.nlm.nih.gov/pubmed/26968383", "http://www.ncbi.nlm.nih.gov/pubmed/22967508", "http://www.ncbi.nlm.nih.gov/pubmed/18519975", "http://www.ncbi.nlm.nih.gov/pubmed/19958632", "http://www.ncbi.nlm.nih.gov/pubmed/16611067", "http://www.ncbi.nlm.nih.gov/pubmed/26706909", "http://www.ncbi.nlm.nih.gov/pubmed/16793912"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "Tumor lymphangiogenesis and metastatic spread-new players begin to emerge.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 144, "offsetInEndSection": 347, "text": "Studies of tumor models in animals and clinicopathological data have indicated that growth of lymphatic vessels (lymphangiogenesis) in the vicinity of solid tumors may contribute to lymphatic metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 348, "offsetInEndSection": 533, "text": "Research over the past 5 years has identified a range of lymphangiogenic growth factors that could conceivably play a role in promoting tumor lymphangiogenesis and lymphatic metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 534, "offsetInEndSection": 805, "text": "The most extensively studied signaling system that promotes lymphangiogenesis in tumors involves the secreted lymphangiogenic proteins vascular endothelial growth factor-C (VEGF-C) and VEGF-D, and their cognate receptor on lymphatic endothelium VEGF receptor-3 (VEGFR-3).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 806, "offsetInEndSection": 1103, "text": "More recent studies have identified other signaling molecules that can also promote lymphangiogenesis in vivo, including hepatocyte growth factor and members of the fibroblast growth factor, angiopoietin, platelet-derived growth factor and insulin-like growth factor families of secreted proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16557570"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "S1P Provokes Tumor Lymphangiogenesis via Macrophage-Derived Mediators Such as IL-1", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28804221"}, {"offsetInBeginSection": 776, "offsetInEndSection": 912, "text": "Recent findings highlight a rather underappreciated role of S1P in tumor lymphangiogenesis, referring to the production of interleukin-1", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28804221"}, {"offsetInBeginSection": 493, "offsetInEndSection": 775, "text": "However, mechanistically, the role of TAM-induced lymphangiogenesis has only been poorly described, mostly linked to the production of lymphangiogenic factors such as vascular endothelial growth factor C (VEGF-C) and VEGF-D, or transdifferentiation into lymphatic endothelial cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28804221"}, {"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "SIX1 promotes tumor lymphangiogenesis by coordinating TGF\u03b2 signals that increase expression of VEGF-C.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}, {"offsetInBeginSection": 85, "offsetInEndSection": 209, "text": "Malignant tumors release growth factors such as VEGF-C to induce lymphangiogenesis, thereby promoting lymph node metastasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25142796"}]}, {"id": "5a68f448b750ff4455000018", "body": "Which bacteria causes erythrasma?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21393451", "http://www.ncbi.nlm.nih.gov/pubmed/7969634", "http://www.ncbi.nlm.nih.gov/pubmed/25477907", "http://www.ncbi.nlm.nih.gov/pubmed/6859802", "http://www.ncbi.nlm.nih.gov/pubmed/12010076", "http://www.ncbi.nlm.nih.gov/pubmed/27294050", "http://www.ncbi.nlm.nih.gov/pubmed/3965026", "http://www.ncbi.nlm.nih.gov/pubmed/9614412", "http://www.ncbi.nlm.nih.gov/pubmed/8469500", "http://www.ncbi.nlm.nih.gov/pubmed/15189194"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Exogenous coproporphyrin III production by Corynebacterium aurimucosum and Microbacterium oxydans in erythrasma lesions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Erythrasma is a superficial skin disease caused by Gram-positive Corynebacterium species.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 90, "offsetInEndSection": 216, "text": "Coral-red fluorescence under Wood's light, strongly suggestive of erythrasma, can be attributed to the presence of porphyrins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21393451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "OBJECTIVE: To determine the proportional contributions of tinea pedis, intertrigo, erythrasma and Candida to 'swimmer's eczema.'", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 511, "offsetInEndSection": 644, "text": "In 56% of the patients with swimmer's eczema dermatophytes were recognised, 10% showed erythrasma and in 30% no cause could be found.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 789, "offsetInEndSection": 885, "text": "CONCLUSION: Swimmer's eczema has several causes, which can be determined with mycological tests.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7969634"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Interdigital foot infections: Corynebacterium minutissimum and agents of superficial mycoses.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907"}, {"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Interdigital foot infections are mostly caused initially by dermatophytes, yeasts and less frequently by bacteria.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907"}, {"offsetInBeginSection": 115, "offsetInEndSection": 206, "text": "Erythrasma caused by Corynebacterium minutissimum can be confused with superficial mycoses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25477907"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Bacterial skin infections are important to recognize because we have the means to eradicate almost all of them.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6859802"}]}, {"id": "5a89537cfcd1d6a10c000002", "body": "Are mouse chromosomes acrocentric?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/6538846", "http://www.ncbi.nlm.nih.gov/pubmed/7606923", "http://www.ncbi.nlm.nih.gov/pubmed/8528584", "http://www.ncbi.nlm.nih.gov/pubmed/23030344", "http://www.ncbi.nlm.nih.gov/pubmed/2767161", "http://www.ncbi.nlm.nih.gov/pubmed/11387219", "http://www.ncbi.nlm.nih.gov/pubmed/6177004", "http://www.ncbi.nlm.nih.gov/pubmed/2832136", "http://www.ncbi.nlm.nih.gov/pubmed/100785", "http://www.ncbi.nlm.nih.gov/pubmed/1733676"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "Flow cytometry isolation and improved visualization of sorted mouse chromosomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 0, "offsetInEndSection": 205, "text": "While analysis and sorting of human chromosomes by flow cytometry has been widely used, isolation of a pure mouse chromosome remains very difficult, since most murine chromosomes are quite similar in size.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 206, "offsetInEndSection": 326, "text": "To overcome this problem, we have analysed mouse cell lines having either Robertsonian translocations or isochromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 327, "offsetInEndSection": 452, "text": "The resulting metacentric chromosomes are very different in size and in morphology from normal mouse acrocentric chromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 754, "offsetInEndSection": 904, "text": "These chromosomes have been sorted and can be easily recognized by fluorescence microscopy when collected onto serum-albumin-coated microscope slides.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 905, "offsetInEndSection": 1131, "text": "The technical modifications made, coupled with the existence of a great diversity of metacentric chromosomes resulting from Robertsonian translocations, should allow the purification of a number of different mouse chromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 81, "offsetInEndSection": 170, "text": "Purification of chromosomes X and ISO-1 from cell lines with Robertsonian translocations.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/6538846"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "Establishment of permanent wild-mouse cell lines with readily identifiable marker chromosomes.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Physical gene mapping by in situ hybridization is a difficult task in an all-acrocentric mouse karyotype, because all of the chromosomes are morphologically very similar.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}, {"offsetInBeginSection": 574, "offsetInEndSection": 649, "text": "Chromosome 19 and the sex chromosomes are the only acrocentric chromosomes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7606923"}]}, {"id": "5a6e1db0b750ff4455000039", "body": "What is Q-nexus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27814676"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Q-nexus: a comprehensive and efficient analysis pipeline designed for ChIP-nexus.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 0, "offsetInEndSection": 241, "text": "BACKGROUND: ChIP-nexus, an extension of the ChIP-exo protocol, can be used to map the borders of protein-bound DNA sequences at nucleotide resolution, requires less input DNA and enables selective PCR duplicate removal using random barcodes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 379, "offsetInEndSection": 563, "text": "To date, only a very limited number of software packages are available for the analysis of ChIP-exo data, which have not yet been systematically tested and compared on ChIP-nexus data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 1042, "offsetInEndSection": 1105, "text": "CONCLUSIONS: The Q-nexus software is efficient and easy to use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}, {"offsetInBeginSection": 1547, "offsetInEndSection": 1621, "text": "An implementation of Q-nexus is available at http://charite.github.io/Q/ .", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27814676"}]}, {"id": "5a74a8a70384be9551000005", "body": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27147553", "http://www.ncbi.nlm.nih.gov/pubmed/24432033", "http://www.ncbi.nlm.nih.gov/pubmed/19853645", "http://www.ncbi.nlm.nih.gov/pubmed/26930249", "http://www.ncbi.nlm.nih.gov/pubmed/26000366", "http://www.ncbi.nlm.nih.gov/pubmed/27316377", "http://www.ncbi.nlm.nih.gov/pubmed/28423924", "http://www.ncbi.nlm.nih.gov/pubmed/21744502", "http://www.ncbi.nlm.nih.gov/pubmed/28085753", "http://www.ncbi.nlm.nih.gov/pubmed/21330062"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Conventional chemotherapy treatments for pancreatic cancer are mainly palliative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 370, "offsetInEndSection": 435, "text": "siG12D-LODER has successfully passed a phase 1/2a clinical trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27147553"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "Novel therapeutic modalities and drug delivery in pancreatic cancer - an ongoing search for improved efficacy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 137, "offsetInEndSection": 308, "text": "There has been little improvement in the prognosis of pancreatic cancer cases in the past decades, highlighting the crucial need for more effective therapeutic approaches.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 582, "offsetInEndSection": 790, "text": "In addition to standard chemotherapeutic drugs, these delivery systems can be utilized to deliver therapeutic agents such as siRNA, oncolytic viruses, small molecule inhibitors, antibodies, and suicide genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 1019, "offsetInEndSection": 1153, "text": "Despite significant preclinical data, there are currently very few clinical trials involving pancreatic cancer targeted drug delivery.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 1154, "offsetInEndSection": 1306, "text": "This article summarizes current developments in targeted pancreatic cancer drug delivery, focusing on delivery systems, targets, and therapeutic agents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24432033"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "Targeted drug delivery in pancreatic cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853645"}, {"offsetInBeginSection": 0, "offsetInEndSection": 81, "text": "Effective drug delivery in pancreatic cancer treatment remains a major challenge.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853645"}, {"offsetInBeginSection": 211, "offsetInEndSection": 300, "text": "Recent advances in drug delivery systems hold great promise for improving cancer therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19853645"}]}, {"id": "5a678d63b750ff4455000003", "body": "What are the 4 cardinal signs of inflammation according to Celsus?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12799851", "http://www.ncbi.nlm.nih.gov/pubmed/29135930", "http://www.ncbi.nlm.nih.gov/pubmed/15041917", "http://www.ncbi.nlm.nih.gov/pubmed/7734328"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 331, "text": "According to semiotics, which may be defined as the doctrine of the essential nature and fundamental varieties of signs, objects, and interpretants, pain is considered to be a sign (significant) with very different meanings (significance) either as a naturalistic symptom (of disease) or as a symbol used in a metaphorical context.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851"}, {"offsetInBeginSection": 1008, "offsetInEndSection": 1195, "text": "It was Galen who added the disturbance of function (functio laesa) as the fifth cardinal sign of inflammation to the four well-known cardinal signs of Celsus (rubor, calor, tumor, dolor).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12799851"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "Inflammation is the body's response to injury or infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930"}, {"offsetInBeginSection": 60, "offsetInEndSection": 255, "text": "As early as 2000 years ago, the Roman encyclopaedist Aulus Cornelius Celsus recognised four cardinal signs of this response-redness, heat, swelling and pain; a fifth sign is loss of function.[...", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29135930"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "[The role of neuromodulators (substance P and calcitonin gene-related peptide) in the development of neurogenic inflammation in the oral mucosa].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917"}, {"offsetInBeginSection": 936, "offsetInEndSection": 1482, "text": "In fact it has been understood that behind the typical signs of inflammation (the famous four cardinal signs of Celsus: pain, redness, swelling, heat) no abstract entities or strange alchemies are concealed, but a series of well-known, classified substance, the so-called \"inflammation mediators\", namely a variety of substances of cellular or plasmatic origin united by the fact that exist, in stationary state conditions, in the form of inactive precursors, or sequestered in intracellular sites where they are unable to carry out their action.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15041917"}, {"offsetInBeginSection": 0, "offsetInEndSection": 88, "text": "Inflammation: John Hunter's \"A treatise on the blood, inflammation and gun-shot wounds\".", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}, {"offsetInBeginSection": 94, "offsetInEndSection": 222, "text": "Throughout the nineteenth century this was considered the most important study of inflammation and has been widely quoted since.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}, {"offsetInBeginSection": 223, "offsetInEndSection": 395, "text": "After a section on the nature of blood and the circulatory system, in which he describes the vascular supply in detail, he passes on to an extensive survey of inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}, {"offsetInBeginSection": 575, "offsetInEndSection": 673, "text": "He bases his observations on the four cardinal signs of Celsus (redness, heat, swelling and pain).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7734328"}]}, {"id": "5a8a9abdfcd1d6a10c000019", "body": "List polyubiquitin binding proteins involved in NF-kappaB signaling.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19285159"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 102, "text": "Identification of polyubiquitin binding proteins involved in NF-kappaB signaling using protein arrays.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "Attachment of ubiquitin to proteins represents a central mechanism for the regulation of protein metabolism and function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 122, "offsetInEndSection": 250, "text": "In the NF-kappaB pathway, binding of NEMO to polyubiquitinated substrates initiates the pathway in response to cellular stimuli.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 251, "offsetInEndSection": 357, "text": "Other polyubiquitin binding proteins can antagonize this pathway by competing with NEMO for polyubiquitin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 358, "offsetInEndSection": 462, "text": "We have used protein arrays to identify polyubiquitin binding proteins that regulate NF-kappaB activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 463, "offsetInEndSection": 558, "text": "Using polyubiquitin as bait, protein arrays were screened and polyubiquitin binders identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 559, "offsetInEndSection": 793, "text": "Novel polyubiquitin binders AWP1, CALCOCO2, N4BP1, RIO3, TEX27, TTC3, UBFD1 and ZNF313 were identified using this approach, while known NF-kappaB regulators including NEMO, A20, ABIN-1, ABIN-2, optineurin and p62 were also identified.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 794, "offsetInEndSection": 962, "text": "Overexpressed AWP1 and RIO3 repressed NF-kappaB activity in a manner similar to optineurin, while siRNAs directed against AWP1 and RIO3 also reduced NF-kappaB activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 963, "offsetInEndSection": 1135, "text": "TNFalpha-dependent degradation of IkappaBalpha was also suppressed by overexpression of AWP1 and RIO3, possibly due to the polyubiquitin binding activity of these proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}, {"offsetInBeginSection": 1136, "offsetInEndSection": 1317, "text": "Protein array screening using polyubiquitin enabled rapid identification of many known and novel polyubiquitin binding proteins and the identification of novel NF-kappaB regulators.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19285159"}]}, {"id": "5a690487b750ff445500001f", "body": "Which virus can be diagnosed with the monospot test?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26275628", "http://www.ncbi.nlm.nih.gov/pubmed/28130396", "http://www.ncbi.nlm.nih.gov/pubmed/20086647", "http://www.ncbi.nlm.nih.gov/pubmed/24650116", "http://www.ncbi.nlm.nih.gov/pubmed/19772007", "http://www.ncbi.nlm.nih.gov/pubmed/23918629", "http://www.ncbi.nlm.nih.gov/pubmed/17217023", "http://www.ncbi.nlm.nih.gov/pubmed/11369969", "http://www.ncbi.nlm.nih.gov/pubmed/21108750", "http://www.ncbi.nlm.nih.gov/pubmed/11298158"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 107, "text": "False positivity of monospot test in an immunocompetent elderly woman with acute cytomegalovirus infection.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 103, "offsetInEndSection": 237, "text": "Initial investigations revealed atypical lymphocytosis, thrombocytopenia, elevated liver enzymes, and a positive monospot test result.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 238, "offsetInEndSection": 547, "text": "Further investigation showed the Epstein-Barr virus viral capsid antibody IgM/IgG and Epstein-Barr virus DNA by polymerase chain reaction to be negative; however, interestingly her cytomegalovirus (CMV) IgM and IgG were positive, suggesting that her mononucleosis-like syndrome was due to acute CMV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 548, "offsetInEndSection": 696, "text": "Herein, we report the first case of a heterophile-positive mononucleosis syndrome caused by acute CMV infection in an elderly immunocompetent woman.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 697, "offsetInEndSection": 804, "text": "This case conveys that monospot test can yield false-positive result in the setting of acute CMV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26275628"}, {"offsetInBeginSection": 0, "offsetInEndSection": 63, "text": "How to use \u2026 the Monospot and other heterophile antibody tests.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Epstein-Barr virus (EBV) is a highly prevalent virus, transmitted via saliva, which often causes asymptomatic infection in children but frequently results in infectious mononucleosis in adolescents.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 199, "offsetInEndSection": 419, "text": "Heterophile antibody tests, including the Monospot test, are red cell or latex agglutination assays, which detect antired cell antibodies produced as part of a polyclonal antibody response occurring during EBV infection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 420, "offsetInEndSection": 560, "text": "Heterophile antibody tests are rapid, cheap and specific tests that can be performed from the onset of symptoms of infectious mononucleosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}, {"offsetInBeginSection": 1000, "offsetInEndSection": 1112, "text": "Virus-specific serology is required in children under the age of 4 or if an older child is heterophile negative.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28130396"}]}, {"id": "5a896a06fcd1d6a10c000006", "body": "What is the phenomenon of gene kissing?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23099887", "http://www.ncbi.nlm.nih.gov/pubmed/17933509", "http://www.ncbi.nlm.nih.gov/pubmed/27785578", "http://www.ncbi.nlm.nih.gov/pubmed/26063576", "http://www.ncbi.nlm.nih.gov/pubmed/21059491", "http://www.ncbi.nlm.nih.gov/pubmed/25918627", "http://www.ncbi.nlm.nih.gov/pubmed/27403349", "http://www.ncbi.nlm.nih.gov/pubmed/26370077", "http://www.ncbi.nlm.nih.gov/pubmed/27721082", "http://www.ncbi.nlm.nih.gov/pubmed/9534425"], "snippets": [{"offsetInBeginSection": 135, "offsetInEndSection": 274, "text": "This positioning can also result in the clustering of genes with similar expression patterns, a phenomenon sometimes called \"gene kissing.\"", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887"}, {"offsetInBeginSection": 884, "offsetInEndSection": 1049, "text": "We speculate that our findings might provide insight into other types of gene kissing, some of which also require cis-acting DNA sequences and trans-acting proteins.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887"}, {"offsetInBeginSection": 275, "offsetInEndSection": 450, "text": "We have found that yeast genes are targeted to the nuclear periphery through interaction of the nuclear pore complex with small, cis-acting \"DNA zip codes\" in their promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23099887"}, {"offsetInBeginSection": 0, "offsetInEndSection": 19, "text": "Chromosome kissing.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 133, "offsetInEndSection": 260, "text": "Nevertheless, several contacts between different chromosomal loci have been documented, a phenomenon called chromosome kissing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 456, "offsetInEndSection": 742, "text": "Recent approaches that allow to detect chromosome kissing events in an unbiased manner suggest that chromatin folding is such that cis contacts with neighboring elements are most frequent, but contacts with remote parts of the same chromosome or with different chromosomes are possible.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 743, "offsetInEndSection": 889, "text": "These contacts are modulated by specific chromatin features of each locus, and they may play important roles in the regulation of gene expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 890, "offsetInEndSection": 972, "text": "Chromosome kissing events may also be at the origin of chromosomal rearrangements.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17933509"}, {"offsetInBeginSection": 0, "offsetInEndSection": 39, "text": "Ictal kissing: occurrence and etiology.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Ictal kissing is a rare semiological manifestation in patients with epilepsy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27785578"}]}, {"id": "5a6e24a5b750ff445500003c", "body": "Which workflow in Bioconductor has been developed for accessing human RNA-seq samples?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29043067"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "recount workflow: Accessing over 70,000 human RNA-seq samples with Bioconductor.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067"}, {"offsetInBeginSection": 0, "offsetInEndSection": 129, "text": "The recount2 resource is composed of over 70,000 uniformly processed human RNA-seq samples spanning TCGA and SRA, including GTEx.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29043067"}]}, {"id": "5a74b1730384be9551000007", "body": "Which retinal dystrophy related gene is targeted by the AAV2-hRPE65v2 drug?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27375040", "http://www.ncbi.nlm.nih.gov/pubmed/29097191", "http://www.ncbi.nlm.nih.gov/pubmed/22323828"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 185, "text": "Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 917, "offsetInEndSection": 1102, "text": "We assessed safety, immune response, retinal and visual function, functional vision, and activation of the visual cortex from baseline until 3 year follow-up, with observations ongoing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 1811, "offsetInEndSection": 1934, "text": "INTERPRETATION: To our knowledge, AAV2-hRPE65v2 is the first successful gene therapy administered to the contralateral eye.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 1172, "offsetInEndSection": 1344, "text": "FINDINGS: No adverse events related to the AAV were reported, and those related to the procedure were mostly mild (dellen formation in three patients and cataracts in two).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27375040"}, {"offsetInBeginSection": 738, "offsetInEndSection": 862, "text": "Current therapies for RP in ongoing or completed clinical trials include gene therapy, cell therapy, and retinal prostheses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191"}, {"offsetInBeginSection": 1047, "offsetInEndSection": 1327, "text": "Among many clinical trials of gene therapy for hereditary retinal diseases, a phase 3 clinical trial of voretigene neparvovec (AAV2-hRPE65v2, Luxturna) recently showed significant efficacy for RPE65-mediated inherited retinal dystrophy including Leber congenital amaurosis and RP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191"}, {"offsetInBeginSection": 1328, "offsetInEndSection": 1405, "text": "It is about to be approved as the first ocular gene therapy biologic product.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29097191"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "AAV2 gene therapy readministration in three adults with congenital blindness.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22323828"}]}, {"id": "5a679875b750ff4455000004", "body": "Do bacteria from the genus Morexella cause respiratory infections?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/8007629", "http://www.ncbi.nlm.nih.gov/pubmed/28063019", "http://www.ncbi.nlm.nih.gov/pubmed/28369241", "http://www.ncbi.nlm.nih.gov/pubmed/24786571", "http://www.ncbi.nlm.nih.gov/pubmed/25362808", "http://www.ncbi.nlm.nih.gov/pubmed/18619696", "http://www.ncbi.nlm.nih.gov/pubmed/28059171"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Clinical studies of oral quinolone once daily in the treatment of lower respiratory tract infections.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The efficacy and safety of oral ofloxacin, 400 mg once daily, for the treatment of patients with lower respiratory tract infections were studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 146, "offsetInEndSection": 512, "text": "The most common species recovered from the sputum specimens of these patients were Haemophilus influenzae, followed by Streptococcus pneumoniae (S. pneumoniae), Staphylococcus aureus (S. aureus), Gram positive cocci unidentified, Pseudomonas aeruginosa (P. aeruginosa), Morexella catarrhalis, Streptococcus epidermidis, and another Haemophilus species in this order.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 513, "offsetInEndSection": 619, "text": "All these bacteria were susceptible to ofloxacin except for one strain of methicillin resistant S. aureus.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 693, "offsetInEndSection": 801, "text": "It is concluded that ofloxacin, 400 mg once daily, is useful for patients with respiratory tract infections.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8007629"}, {"offsetInBeginSection": 127, "offsetInEndSection": 257, "text": "This genus can be distinguished from the genus Klebsiella, in that genus use histamine as the only source of carbon in the medium.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 415, "offsetInEndSection": 501, "text": "The reservoir of Raoultella is the gastrointestinal tract and upper respiratory tract.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 518, "offsetInEndSection": 671, "text": "are opportunistic bacteria, which usually cause infections of the biliary tract, pneumonia and bacteraemia in oncologic and with lower immunity patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 672, "offsetInEndSection": 804, "text": "Raoultella planticola and Raoultella ornithinolytica are the most frequently encountered human pathogens among the genus Raoultella.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}, {"offsetInBeginSection": 805, "offsetInEndSection": 882, "text": "In this review, the current knowledge on Raoultella infections is summarized.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28063019"}]}, {"id": "5a8aa253fcd1d6a10c00001b", "body": "Which is the specificity of deubiquitinase USP25?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28327663", "http://www.ncbi.nlm.nih.gov/pubmed/23754700", "http://www.ncbi.nlm.nih.gov/pubmed/28538147", "http://www.ncbi.nlm.nih.gov/pubmed/26305951"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 201, "text": "Ubiquitin-specific protease (USP) 25, belonging to the USP family of deubiquitinases, harbors two tandem ubiquitin-interacting motifs (UIMs), a ~20-amino-acid \u03b1-helical stretch that binds to ubiquitin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663"}, {"offsetInBeginSection": 415, "offsetInEndSection": 530, "text": "Purified USP25 exhibited higher ubiquitin isopeptidase activity to Lys48-, than to Lys63-, linked ubiquitin chains.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663"}, {"offsetInBeginSection": 750, "offsetInEndSection": 1032, "text": "Moreover, when mutations that convert the binding preference from Lys48- to Lys63-linked ubiquitin chains were introduced into the tandem UIM region, the USP25 mutants acquired elevated and reduced isopeptidase activity toward Lys63- and Lys48-linked ubiquitin chains, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28327663"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "Ubiquitin-specific protease 25 (Usp25) is a deubiquitinase that is involved in multiple biological processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147"}, {"offsetInBeginSection": 110, "offsetInEndSection": 303, "text": "The N-terminal ubiquitin-binding region (UBR) of Usp25 contains one ubiquitin-associated domain, one small ubiquitin-like modifier (SUMO)-interacting motif and two ubiquitin-interacting motifs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28538147"}, {"offsetInBeginSection": 210, "offsetInEndSection": 375, "text": "Here, we found that a viral infection-induced deubiquitinase (DUB), ubiquitin-specific protease 25 (USP25) was required for host defense against RNA and DNA viruses.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26305951"}]}, {"id": "5a70dbe599e2c3af26000004", "body": "Which two genes are implicated in Juvenile polyposis syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16152648", "http://www.ncbi.nlm.nih.gov/pubmed/9491322", "http://www.ncbi.nlm.nih.gov/pubmed/27326320", "http://www.ncbi.nlm.nih.gov/pubmed/21834858", "http://www.ncbi.nlm.nih.gov/pubmed/21465659", "http://www.ncbi.nlm.nih.gov/pubmed/25841492", "http://www.ncbi.nlm.nih.gov/pubmed/22171123", "http://www.ncbi.nlm.nih.gov/pubmed/17573831", "http://www.ncbi.nlm.nih.gov/pubmed/26837502", "http://www.ncbi.nlm.nih.gov/pubmed/26159157"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Juvenile polyposis syndrome is a hamartomatous intestinal polyposis associated with malignant changes in 20% of patients at an early age.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 138, "offsetInEndSection": 321, "text": "Germline mutations mostly involve two genes, SMAD4 and BMPR1, with no strong evidence of phenotype-genotype correlation, which could be predictive of the specific long-term evolution.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 413, "offsetInEndSection": 595, "text": "Forty-two unrelated patients affected by juvenile polyposis syndrome were analyzed for germline alterations in the BMPR1A and SMAD4 genes, and for clinical and histological features.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 1007, "offsetInEndSection": 1126, "text": "SMAD4 germline mutations are responsible for a more aggressive digestive phenotype in patients with juvenile polyposis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16152648"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Deletion 10q23.2-q23.33 in a patient with gastrointestinal juvenile polyposis and other features of a Cowden-like syndrome.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 0, "offsetInEndSection": 177, "text": "A cytogenetically visible interstitial deletion of chromosome band 10q23 was found in a 6-year-old boy with mental retardation, dysmorphic features, and juvenile polyposis coli.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 432, "offsetInEndSection": 657, "text": "This patient's deletion contains the putative locus for Cowden syndrome and a recently discovered candidate tumor suppressor gene (MMAC1 or PTEN) that has been implicated in the progression of a variety of human malignancies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 658, "offsetInEndSection": 757, "text": "Furthermore, the deletion is near and possibly overlaps a locus associated with juvenile polyposis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}, {"offsetInBeginSection": 758, "offsetInEndSection": 1070, "text": "The findings in this patient with a constitutional 10q23 deletion raise the issue of whether there are separate genes in this region that are involved in Cowden syndrome, Bannayan-Riley-Ruvalcaba syndrome, juvenile polyposis, and tumor progression, or whether all of these entities could be due to a single gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9491322"}]}, {"id": "5a86bf2efaa1ab7d2e000033", "body": "What is the mechanism of the auxin-inducible degron system?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23836714", "http://www.ncbi.nlm.nih.gov/pubmed/19915560", "http://www.ncbi.nlm.nih.gov/pubmed/24236031", "http://www.ncbi.nlm.nih.gov/pubmed/28680098", "http://www.ncbi.nlm.nih.gov/pubmed/26519318", "http://www.ncbi.nlm.nih.gov/pubmed/26081484", "http://www.ncbi.nlm.nih.gov/pubmed/27010248", "http://www.ncbi.nlm.nih.gov/pubmed/25181302"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 76, "text": "An expanded tool kit for the auxin-inducible degron system in budding yeast.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "Fusion of inducible degradation signals, so-called degrons, to cellular proteins is an elegant method of controlling protein levels in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 141, "offsetInEndSection": 259, "text": "Recently, a degron system relying on the plant hormone auxin has been described for use in yeast and vertebrate cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 430, "offsetInEndSection": 592, "text": "We have minimized the size of the degron and appended a series of additional epitope tags, allowing detection by commercial antibodies or fluorescence microscopy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 593, "offsetInEndSection": 753, "text": "The vectors are compatible with PCR-based genomic tagging strategies, allow for C- or N-terminal fusion of the degron, and provide a range of selection markers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23836714"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "An auxin-based degron system for the rapid depletion of proteins in nonplant cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "Plants have evolved a unique system in which the plant hormone auxin directly induces rapid degradation of the AUX/IAA family of transcription repressors by a specific form of the SCF E3 ubiquitin ligase.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 205, "offsetInEndSection": 439, "text": "Other eukaryotes lack the auxin response but share the SCF degradation pathway, allowing us to transplant the auxin-inducible degron (AID) system into nonplant cells and use a small molecule to conditionally control protein stability.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 440, "offsetInEndSection": 795, "text": "The AID system allowed rapid and reversible degradation of target proteins in response to auxin and enabled us to generate efficient conditional mutants of essential proteins in yeast as well as cell lines derived from chicken, mouse, hamster, monkey and human cells, thus offering a powerful tool to control protein expression and study protein function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19915560"}, {"offsetInBeginSection": 0, "offsetInEndSection": 99, "text": "2A and the auxin-based degron system facilitate control of protein levels in Plasmodium falciparum.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24236031"}]}, {"id": "5a6e3155b750ff445500003f", "body": "Which R/Bioconductor package has been developed for cancer subtype identification?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28605519", "http://www.ncbi.nlm.nih.gov/pubmed/26607490"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "CancerSubtypes: an R/Bioconductor package for molecular cancer subtype identification, validation and visualization.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 120, "offsetInEndSection": 287, "text": "We introduce CancerSubtypes, an R package for identifying cancer subtypes using multi-omics data, including gene expression, miRNA expression and DNA methylation data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 288, "offsetInEndSection": 582, "text": "CancerSubtypes integrates four main computational methods which are highly cited for cancer subtype identification and provides a standardized framework for data pre-processing, feature selection, and result follow-up analyses, including results computing, biology validation and visualization.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 724, "offsetInEndSection": 1308, "text": "The package is useful for inferring cancer subtypes from an input genomic dataset, comparing the predictions from different well-known methods and testing new subtype discovery methods, as shown with different application scenarios in the Supplementary Material.Availability and implementation: The package is implemented in R and available under GPL-2 license from the Bioconductor website (http://bioconductor.org/packages/CancerSubtypes/).Contact: thuc.le@unisa.edu.au or jiuyong.li@unisa.edu.au.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28605519"}, {"offsetInBeginSection": 0, "offsetInEndSection": 103, "text": "Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 0, "offsetInEndSection": 74, "text": "UNLABELLED: Breast cancer is one of the most frequent cancers among women.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 75, "offsetInEndSection": 288, "text": "Extensive studies into the molecular heterogeneity of breast cancer have produced a plethora of molecular subtype classification and prognosis prediction algorithms, as well as numerous gene expression signatures.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 477, "offsetInEndSection": 681, "text": "Here, we present the genefu R/Bioconductor package, a multi-tiered compendium of bioinformatics algorithms and gene signatures for molecular subtyping and prognostication in breast cancer.AVAILABILITY AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 682, "offsetInEndSection": 748, "text": "IMPLEMENTATION: The genefu package is available from Bioconductor.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}, {"offsetInBeginSection": 749, "offsetInEndSection": 886, "text": "http://www.bioconductor.org/packages/devel/bioc/html/genefu.html Source code is also available on Github https://github.com/bhklab/genefu", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26607490"}]}, {"id": "5a75fbf383b0d9ea6600000a", "body": "Name the phase 3 clinical trials for tofacitinib in colitis.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28467869", "http://www.ncbi.nlm.nih.gov/pubmed/26376350", "http://www.ncbi.nlm.nih.gov/pubmed/27177233", "http://www.ncbi.nlm.nih.gov/pubmed/22894574", "http://www.ncbi.nlm.nih.gov/pubmed/25651782", "http://www.ncbi.nlm.nih.gov/pubmed/29051788", "http://www.ncbi.nlm.nih.gov/pubmed/26669566", "http://www.ncbi.nlm.nih.gov/pubmed/28829236", "http://www.ncbi.nlm.nih.gov/pubmed/25110261", "http://www.ncbi.nlm.nih.gov/pubmed/25047498"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 72, "text": "Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 173, "text": "BACKGROUND: Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 174, "offsetInEndSection": 260, "text": "We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 260, "offsetInEndSection": 406, "text": "METHODS: We conducted three phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib therapy in adults with ulcerative colitis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 407, "offsetInEndSection": 741, "text": "In the OCTAVE Induction 1 and 2 trials, 598 and 541 patients, respectively, who had moderately to severely active ulcerative colitis despite previous conventional therapy or therapy with a tumor necrosis factor antagonist were randomly assigned to receive induction therapy with tofacitinib (10 mg twice daily) or placebo for 8 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 790, "offsetInEndSection": 1011, "text": "In the OCTAVE Sustain trial, 593 patients who had a clinical response to induction therapy were randomly assigned to receive maintenance therapy with tofacitinib (either 5 mg or 10 mg twice daily) or placebo for 52 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 1060, "offsetInEndSection": 1300, "text": "RESULTS: In the OCTAVE Induction 1 trial, remission at 8 weeks occurred in 18.5% of the patients in the tofacitinib group versus 8.2% in the placebo group (P=0.007); in the OCTAVE Induction 2 trial, remission occurred in 16.6% versus 3.6% (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 1300, "offsetInEndSection": 1462, "text": "PCONCLUSIONS: In patients with moderately to severely active ulcerative colitis, tofacitinib was more effective as induction and maintenance therapy than placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28467869"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376350"}, {"offsetInBeginSection": 13, "offsetInEndSection": 120, "text": "AIMS: Accurate biomarkers of disease activity and therapeutic response can be valuable for clinical trials.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26376350"}]}, {"id": "5a679be1b750ff4455000005", "body": "Are organisms in the genus Morexella associated with sepsis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24669633", "http://www.ncbi.nlm.nih.gov/pubmed/9587088", "http://www.ncbi.nlm.nih.gov/pubmed/24786571", "http://www.ncbi.nlm.nih.gov/pubmed/6954635", "http://www.ncbi.nlm.nih.gov/pubmed/3071072", "http://www.ncbi.nlm.nih.gov/pubmed/10403734", "http://www.ncbi.nlm.nih.gov/pubmed/18696148", "http://www.ncbi.nlm.nih.gov/pubmed/8909835"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 64, "text": "Causative bacteria and antibiotic resistance in neonatal sepsis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 0, "offsetInEndSection": 132, "text": "BACKGROUND: Neonatal sepsis is characterised by bacteraemia and clinical symptoms caused by microorganisms and their toxic products.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 133, "offsetInEndSection": 200, "text": "Gram negative bacteria are the commonest causes of neonatal Sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 408, "offsetInEndSection": 573, "text": "We have carried out this study to find out various bacteria causing neonatal sepsis and their susceptibility to antibiotics for better management of neonatal sepsis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 573, "offsetInEndSection": 687, "text": "METHODS: A total of 130 neonates with sepsis who were found to be blood culture positive were taken in this study.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 688, "offsetInEndSection": 821, "text": "Culture/sensitivity was done, isolated organisms identified and their sensitivity/resistance was noted against different antibiotics.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 880, "offsetInEndSection": 1042, "text": "RESULTS: Out of 130 culture proven cases of neonatal sepsis, gram negative bacteria were found in 71 (54.6%) cases and gram positive bacteria in 59 (45.4%) cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 1043, "offsetInEndSection": 1169, "text": "Staphylococcus aureus was the most common bacteria found in 35 (26.9%) cases followed by Escherichia coli in 30 (23.1%) cases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 1170, "offsetInEndSection": 1389, "text": "Acinetobacter species, Staphylococcus epidermidis, Klebseila, Streptococci, Enterobacter cloacae and Morexella species were found in 17 (13.1%), 17 (13.1%), 13 (10%), 7 (5.4%), 6 (4.6%), and 5 (3.8%) cases respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}, {"offsetInBeginSection": 1390, "offsetInEndSection": 1591, "text": "In most of the cases causative organisms were found to be resistant to commonly used antibiotics like ampicillin, amoxicillin, cefotaxime, and ceftriaxone (77.7%, 81.5%, 63.1%, and 66.9% respectively).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24669633"}]}, {"id": "5a70e1d999e2c3af26000007", "body": "Is Solanezumab effective for Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22288451", "http://www.ncbi.nlm.nih.gov/pubmed/25459121", "http://www.ncbi.nlm.nih.gov/pubmed/21504387", "http://www.ncbi.nlm.nih.gov/pubmed/27239538", "http://www.ncbi.nlm.nih.gov/pubmed/26238576", "http://www.ncbi.nlm.nih.gov/pubmed/27025080", "http://www.ncbi.nlm.nih.gov/pubmed/26271177", "http://www.ncbi.nlm.nih.gov/pubmed/23574434", "http://www.ncbi.nlm.nih.gov/pubmed/24450890", "http://www.ncbi.nlm.nih.gov/pubmed/22339463"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Solanezumab for the treatment of mild-to-moderate Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 192, "text": "Solanezumab (LY2062430) is a humanized monoclonal antibody that binds to the central region of \u03b2-amyloid, a peptide believed to play a key role in the pathogenesis of Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 193, "offsetInEndSection": 305, "text": "Eli Lilly & Co is developing an intravenous formulation of solanezumab for the treatment of mild-to-moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 306, "offsetInEndSection": 592, "text": "Acute and subchronic treatment with solanezumab of transgenic mice attenuated or reversed memory deficits with no effects on incidence or severity of cerebral amyloid angiopathy-associated microhemorrhages, a severe side effect associated with bapineuzumab, another monoclonal antibody.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 593, "offsetInEndSection": 726, "text": "Phase II studies in AD patients have shown a good safety profile with encouraging indications on cerebrospinal and plasma biomarkers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 789, "offsetInEndSection": 1031, "text": "While there is a strong hope that solanezumab may represent the first effective passive vaccine for AD treatment, skepticism still exists on the ability of the drug to slow the rate of deterioration in patients with fully established disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22288451"}, {"offsetInBeginSection": 0, "offsetInEndSection": 56, "text": "Amyloid beta peptide immunotherapy in Alzheimer disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 0, "offsetInEndSection": 161, "text": "Recent advances in the understanding of Alzheimer's disease pathogenesis have led to the development of numerous compounds that might modify the disease process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 162, "offsetInEndSection": 261, "text": "Amyloid \u03b2 peptide represents an important molecular target for intervention in Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}, {"offsetInBeginSection": 262, "offsetInEndSection": 366, "text": "The main purpose of this work is to review immunotherapy studies in relation to the Alzheimer's disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25459121"}]}, {"id": "5a86ecc7faa1ab7d2e000039", "body": "What is the function of the H19 (ICR) locus in the human genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24023912", "http://www.ncbi.nlm.nih.gov/pubmed/19546235", "http://www.ncbi.nlm.nih.gov/pubmed/16006531", "http://www.ncbi.nlm.nih.gov/pubmed/20427289", "http://www.ncbi.nlm.nih.gov/pubmed/21991322", "http://www.ncbi.nlm.nih.gov/pubmed/20047949", "http://www.ncbi.nlm.nih.gov/pubmed/26328763", "http://www.ncbi.nlm.nih.gov/pubmed/17948025", "http://www.ncbi.nlm.nih.gov/pubmed/21600199", "http://www.ncbi.nlm.nih.gov/pubmed/16815976"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "The chicken HS4 insulator element does not protect the H19 ICR from differential DNA methylation in yeast artificial chromosome transgenic mouse.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "Mono-allelic expression at the mouse IGF2/H19 locus is controlled by differential allelic DNA methylation of the imprinting control region (ICR).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 146, "offsetInEndSection": 529, "text": "Because a randomly integrated H19 ICR fragment, when incorporated into the genome of transgenic mice (TgM), was allele-specifically methylated in somatic, but not in germ cells, it was suggested that allele-discriminating epigenetic signature, set within or somewhere outside of the Tg H19 ICR fragment in germ cells, was later translated into a differential DNA methylation pattern.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 530, "offsetInEndSection": 820, "text": "To test if the chicken \u03b2-globin HS4 (cHS4) chromatin insulator might interfere with methylation imprinting establishment at the H19 ICR, we inserted the H19 ICR fragment, flanked by a set of floxed cHS4 core sequences, into a human \u03b2-globin locus YAC and generated TgM (insulated ICR' TgM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 821, "offsetInEndSection": 988, "text": "As controls, the cHS4 sequences were removed from one side (5'HS4-deleted ICR') or both sides (pseudo-WT ICR') of the insulated ICR' by in vivo cre-loxP recombination.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 989, "offsetInEndSection": 1218, "text": "The data show that while maternally inherited transgenic H19 ICR was not methylated in insulated ICR' TgM, it was significantly methylated upon paternal transmission, though the level was lower than in the pseudo-WT ICR' control.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 1219, "offsetInEndSection": 1442, "text": "Because this reduced level of methylation was also observed in the 5'HS4-deleted ICR' TgM, we speculate that the phenotype is due to VEZF1-dependent demethylation activity, rather than the insulator function, borne in cHS4.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 1443, "offsetInEndSection": 1678, "text": "Collectively, although we cannot rule out the possibility that cHS4 is incapable of blocking an allele-discriminating signal from outside of the transgene, the epigenetic signature appears to be marked intrinsically within the H19 ICR.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24023912"}, {"offsetInBeginSection": 0, "offsetInEndSection": 144, "text": "A randomly integrated transgenic H19 imprinting control region acquires methylation imprinting independently of its establishment in germ cells.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235"}, {"offsetInBeginSection": 0, "offsetInEndSection": 261, "text": "The imprinted expression of the mouse Igf2/H19 locus is governed by the differential methylation of the imprinting control region (ICR), which is established initially in germ cells and subsequently maintained in somatic cells, depending on its parental origin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19546235"}]}, {"id": "5a6e354fb750ff4455000042", "body": "Which R/bioconductor package has been developed to aid in epigenomic analysis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28334349", "http://www.ncbi.nlm.nih.gov/pubmed/26704973", "http://www.ncbi.nlm.nih.gov/pubmed/26415965", "http://www.ncbi.nlm.nih.gov/pubmed/26424858"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "DeepBlueR: large-scale epigenomic analysis in R.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349"}, {"offsetInBeginSection": 0, "offsetInEndSection": 170, "text": "Motivation: While large amounts of epigenomic data are publicly available, their retrieval in a form suitable for downstream analysis is a bottleneck in current research.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349"}, {"offsetInBeginSection": 171, "offsetInEndSection": 908, "text": "The DeepBlue Epigenomic Data Server provides a powerful interface and API for filtering, transforming, aggregating and downloading data from several epigenomic consortia.Results: To make public epigenomic data conveniently available for analysis in R, we developed an R/Bioconductor package that connects to the DeepBlue Epigenomic Data Server, enabling users to quickly gather and transform epigenomic data from selected experiments for analysis in the Bioconductor ecosystem.Availability and Implementation: http://deepblue.mpi-inf.mpg.de/R .Requirements: R 3.3, Bioconductor 3.4.Contact: felipe.albrecht@mpi-inf.mpg.de or markus.list@mpi-inf.mpg.de.Supplementary information: Supplementary data are available at Bioinformatics online.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28334349"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 332, "offsetInEndSection": 532, "text": "Although many important discoveries have been made by TCGA's research network, opportunities still exist to implement novel methods, thereby elucidating new biological pathways and diagnostic markers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 728, "offsetInEndSection": 957, "text": "We developed an R/Bioconductor package called TCGAbiolinks to address these challenges and offer bioinformatics solutions by using a guided workflow to allow users to query, download and perform integrative analyses of TCGA data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 958, "offsetInEndSection": 1127, "text": "We combined methods from computer science and statistics into the pipeline and incorporated methodologies developed in previous TCGA marker studies and in our own group.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26704973"}, {"offsetInBeginSection": 778, "offsetInEndSection": 916, "text": "RESULTS: To overcome the burden of integrating various data types with multiple tools, we developed two companion R/Bioconductor packages.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965"}, {"offsetInBeginSection": 2101, "offsetInEndSection": 2323, "text": "These packages are instrumental in providing biologists with minimal R skills a complete toolkit facilitating the analysis of their own data, or in accelerating the analyses performed by more experienced bioinformaticians.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26415965"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "regioneR: an R/Bioconductor package for the association analysis of genomic regions based on permutation tests.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26424858"}]}, {"id": "5a76dd749e632bc066000008", "body": "What does VBP15 do to skeletal muscle?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24014378"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Absence of dystrophin makes skeletal muscle more susceptible to injury, resulting in breaches of the plasma membrane and chronic inflammation in Duchenne muscular dystrophy (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 617, "offsetInEndSection": 744, "text": "We find VBP15 protects and promotes efficient repair of skeletal muscle cells upon laser injury, in opposition to prednisolone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}, {"offsetInBeginSection": 745, "offsetInEndSection": 930, "text": "Potent inhibition of NF-\u03baB is mediated through protein interactions of the glucocorticoid receptor, however VBP15 shows significantly reduced hormonal receptor transcriptional activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24014378"}]}, {"id": "5a6a02a3b750ff4455000021", "body": "What protein is the most common cause of hereditary  renal amyloidosis?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/29142973", "http://www.ncbi.nlm.nih.gov/pubmed/25331409", "http://www.ncbi.nlm.nih.gov/pubmed/26299174", "http://www.ncbi.nlm.nih.gov/pubmed/22540225", "http://www.ncbi.nlm.nih.gov/pubmed/22967253", "http://www.ncbi.nlm.nih.gov/pubmed/19073821", "http://www.ncbi.nlm.nih.gov/pubmed/28153807", "http://www.ncbi.nlm.nih.gov/pubmed/16468976", "http://www.ncbi.nlm.nih.gov/pubmed/8560604", "http://www.ncbi.nlm.nih.gov/pubmed/19013120"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 91, "text": "Renal Amyloidosis Associated With 5 Novel\u00a0Variants in the Fibrinogen A Alpha Chain Protein.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29142973"}, {"offsetInBeginSection": 0, "offsetInEndSection": 356, "text": "Introduction: Fibrinogen A alpha chain amyloidosis is an autosomal dominant disease associated with mutations in the fibrinogen A alpha chain (Methods: Six patients presented with proteinuria, hypertension, and/or lower limb edema and underwent detailed clinical and laboratory investigations.Results: A novel Discussion: We report 6 novel mutations in the", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29142973"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "[Hereditary fibrinogen A\u03b1-chain amyloidosis caused by the E526V mutation: a case report and literature review].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 0, "offsetInEndSection": 101, "text": "Mutations in the fibrinogen A\u03b1-chain genes are the most common cause of hereditary renal amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 102, "offsetInEndSection": 313, "text": "The renal histologic appearance in the patient is characteristic and shows striking glomerular enlargement with almost complete obliteration of the normal glomerular architecture by extensive amyloid deposition.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 314, "offsetInEndSection": 420, "text": "In contrast, the vessels and renal tubular interstitium of such patient contains almost no amyloid at all.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 421, "offsetInEndSection": 553, "text": "Here, we described a patient with hereditary fibrinogen amyloidosis, who presented with proteinuria, hypertension and renal failure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25331409"}, {"offsetInBeginSection": 0, "offsetInEndSection": 82, "text": "Hereditary apolipoprotein AI-associated renal amyloidosis: A diagnostic challenge.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "Hereditary renal amyloidosis is an autosomal dominant condition with considerable overlap with other amyloidosis types.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}, {"offsetInBeginSection": 204, "offsetInEndSection": 321, "text": "We describe a patient with nephrotic syndrome and progressive renal failure, who had a mother with renal amiloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26299174"}]}, {"id": "5a7234352dc08e987e000007", "body": "What is the most common histological diagnosis of \"butterfly glioma\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/1656290", "http://www.ncbi.nlm.nih.gov/pubmed/28361164"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 126, "text": "A 45 year-old male with a butterfly glioma received stereotactic biopsy for histologic confirmation of the clinical diagnosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 127, "offsetInEndSection": 303, "text": "Microscopically, the results were controversial since some biopsy specimens showed distinct inflammatory changes, while others displayed typical features of a malignant glioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 416, "offsetInEndSection": 686, "text": "In addition to a large butterfly glioblastoma originating from the frontal part of the corpus callosum, neuropathologic examination revealed a mycotic encephalitis with formation of numerous fungi-containing inflammatory foci in all parts of the brain and in the glioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 779, "offsetInEndSection": 997, "text": "A previous steroid medication over several weeks for treatment of increased intracranial pressure may be considered as an important factor in the origin of the pulmonary aspergillosis complicating the butterfly glioma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/1656290"}, {"offsetInBeginSection": 37, "offsetInEndSection": 101, "text": "Corpus callosum glioblastoma multiforme (GBM): butterfly glioma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}, {"offsetInBeginSection": 134, "offsetInEndSection": 281, "text": "The diagnosis of butterfly glioma (glioblastoma multiforme) was made based on imaging characteristics and was further confirmed by biopsy findings.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}, {"offsetInBeginSection": 448, "offsetInEndSection": 616, "text": "Other neoplastic and non-neoplastic conditions that may involve the corpus callosum and mimic a butterfly glioma, as well as associated imaging features, are discussed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28361164"}]}, {"id": "5a86fd5bfaa1ab7d2e00003b", "body": "Is a CpG island methylator phenotype involved in ependymomas?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24553142", "http://www.ncbi.nlm.nih.gov/pubmed/22109108", "http://www.ncbi.nlm.nih.gov/pubmed/28548123", "http://www.ncbi.nlm.nih.gov/pubmed/25182241", "http://www.ncbi.nlm.nih.gov/pubmed/23619990", "http://www.ncbi.nlm.nih.gov/pubmed/24674026", "http://www.ncbi.nlm.nih.gov/pubmed/17096326", "http://www.ncbi.nlm.nih.gov/pubmed/19136926", "http://www.ncbi.nlm.nih.gov/pubmed/10411935", "http://www.ncbi.nlm.nih.gov/pubmed/19571709"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Ependymomas are common childhood brain tumours that occur throughout the nervous system, but are most common in the paediatric hindbrain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 269, "offsetInEndSection": 443, "text": "Whole-genome and whole-exome sequencing of 47 hindbrain ependymomas reveals an extremely low mutation rate, and zero significant recurrent somatic single nucleotide variants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 444, "offsetInEndSection": 614, "text": "Although devoid of recurrent single nucleotide variants and focal copy number aberrations, poor-prognosis hindbrain ependymomas exhibit a CpG island methylator phenotype.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 615, "offsetInEndSection": 821, "text": "Transcriptional silencing driven by CpG methylation converges exclusively on targets of the Polycomb repressive complex 2 which represses expression of differentiation genes through trimethylation of H3K27.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 822, "offsetInEndSection": 988, "text": "CpG island methylator phenotype-positive hindbrain ependymomas are responsive to clinical drugs that target either DNA or H3K27 methylation both in vitro and in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24553142"}, {"offsetInBeginSection": 0, "offsetInEndSection": 183, "text": "Supratentorial and spinal pediatric ependymomas display a hypermethylated phenotype which includes the loss of tumor suppressor genes involved in the control of cell growth and death.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 211, "offsetInEndSection": 265, "text": "However little is known about DNA methylation changes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 529, "offsetInEndSection": 739, "text": "Supratentorial and spinal tumors displayed significantly more hypermethylated genes than posterior fossa tumors, similar to the 'CpG island methylator phenotype' (CIMP) identified in glioma and colon carcinoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 740, "offsetInEndSection": 910, "text": "This hypermethylated profile was associated with an increase in expression of genes encoding for proteins involved in methylating DNA, suggesting an underlying mechanism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}, {"offsetInBeginSection": 1043, "offsetInEndSection": 1197, "text": "Most notably genes involved in the control of cell growth and death and the immune system were identified, including members of the JNK pathway and PPARG.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22109108"}]}, {"id": "5a6e4814b750ff445500004a", "body": "Are loop domains preserved upon cohesin loss?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28985562"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 41, "text": "Cohesin Loss Eliminates All Loop Domains.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 142, "offsetInEndSection": 269, "text": "\"Loop domains\" form because of tethering between two loci-almost always bound by CTCF and cohesin-lying on the same chromosome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 361, "offsetInEndSection": 411, "text": "Here, we explore the effects of degrading cohesin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 412, "offsetInEndSection": 508, "text": "All loop domains are eliminated, but neither compartment domains nor histone marks are affected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 509, "offsetInEndSection": 637, "text": "Loss of loop domains does not lead to widespread ectopic gene activation but does affect a significant minority of active genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 638, "offsetInEndSection": 805, "text": "In particular, cohesin loss causes superenhancers to co-localize, forming hundreds of links within and across chromosomes and affecting the regulation of nearby genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}, {"offsetInBeginSection": 806, "offsetInEndSection": 872, "text": "We then restore cohesin and monitor the re-formation of each loop.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28985562"}]}, {"id": "5a7723b79e632bc06600000b", "body": "What are the prednisone side effects in DMD patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/12548530", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/25809413", "http://www.ncbi.nlm.nih.gov/pubmed/22655511", "http://www.ncbi.nlm.nih.gov/pubmed/19306039", "http://www.ncbi.nlm.nih.gov/pubmed/16980656", "http://www.ncbi.nlm.nih.gov/pubmed/28450193", "http://www.ncbi.nlm.nih.gov/pubmed/9128400"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 149, "offsetInEndSection": 320, "text": "As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 321, "offsetInEndSection": 498, "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 499, "offsetInEndSection": 583, "text": "The DMD-STEROID group was further subdivided into Deflazacort and prednisone groups.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 812, "offsetInEndSection": 925, "text": "Deflazacort compared with prednisone yielded 508 regulated probes, including many involved in adipose metabolism.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 926, "offsetInEndSection": 1106, "text": "These genes and pathways help explain mechanisms of efficacy and side effects of corticosteroids, and could provide new treatment targets for DMD and other neuromuscular disorders.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 58, "text": "Early prednisone treatment in Duchenne muscular dystrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}, {"offsetInBeginSection": 0, "offsetInEndSection": 270, "text": "The purpose of this long-term, open parallel-group, double-consent study of alternate-day, low-dose prednisone in 2-4-year-old patients with Duchenne muscular dystrophy (DMD) was to determine whether prednisone produces a beneficial effect when given earlier than usual.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}, {"offsetInBeginSection": 271, "offsetInEndSection": 363, "text": "Muscle function was evaluated by timed tests, and muscle strength with a hand-held myometer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12548530"}]}, {"id": "5a6e42f1b750ff4455000046", "body": "What gene is mutated in Familial Mediterranean Fever?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12387810", "http://www.ncbi.nlm.nih.gov/pubmed/20437121", "http://www.ncbi.nlm.nih.gov/pubmed/24980720", "http://www.ncbi.nlm.nih.gov/pubmed/12615073", "http://www.ncbi.nlm.nih.gov/pubmed/18347298", "http://www.ncbi.nlm.nih.gov/pubmed/10666224", "http://www.ncbi.nlm.nih.gov/pubmed/18219832", "http://www.ncbi.nlm.nih.gov/pubmed/28690860", "http://www.ncbi.nlm.nih.gov/pubmed/17431422", "http://www.ncbi.nlm.nih.gov/pubmed/20645115"], "snippets": [{"offsetInBeginSection": 462, "offsetInEndSection": 543, "text": "Familial Mediterranean fever (FMF) has been traced to mutations in the MEFV gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 544, "offsetInEndSection": 661, "text": "Mutations in the MVK gene, encoding the enzyme mevalonate kinase, cause the hyper-IgD periodic fever syndrome (HIDS).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 662, "offsetInEndSection": 896, "text": "The tumour necrosis factor(TNF)-receptor-associated periodic syndromes (TRAPS) have been linked to mutations in theTNFRSF1A gene, encoding a TNF-alpha receptor, and the CIAS1 gene is mutated in familial cold autoinflammatory syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12387810"}, {"offsetInBeginSection": 0, "offsetInEndSection": 219, "text": "We aimed to investigate the rate of MEFV, the gene mutated in familial Mediterranean fever, mutations in patients with myeloid neoplasm and to determine if known mutations of MEFV cause a tendency for myeloid neoplasms.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121"}, {"offsetInBeginSection": 370, "offsetInEndSection": 576, "text": "We identified 1 homozygous (E148Q/E148Q), 1 compound heterozygous (M694V/E148Q) and 5 heterozygous MEFV gene mutations; none had their own and/or family history compatible with familial Mediterranean fever.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20437121"}, {"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "A novel insertion mutation identified in exon 10 of the MEFV gene associated with Familial Mediterranean Fever.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 212, "text": "BACKGROUND: Familial Mediterranean Fever (FMF), characterized by recurrent fever and inflammation of serous membranes, is an autosomal recessive disease caused by mutations in the Mediterranean fever (MEFV) gene.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24980720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615073"}, {"offsetInBeginSection": 0, "offsetInEndSection": 153, "text": "Cryopyrin, a member of the Nod protein family mutated in familial cold urticaria and Muckle-Wells syndrome, has been recently implicated in inflammation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615073"}, {"offsetInBeginSection": 547, "offsetInEndSection": 725, "text": "Notably, pyrin, the product of the familial Mediterranean fever gene, inhibited cryopyrin-mediated apoptosis and NF-kappaB activation by disrupting the cryopyrin-ASC interaction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12615073"}]}, {"id": "5a7242a22dc08e987e00000e", "body": "Describe swirl sign in intracerebral hemorrhage.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23013418", "http://www.ncbi.nlm.nih.gov/pubmed/23517301"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Swirl sign in intracerebral haemorrhage: definition, prevalence, reliability and prognostic value.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "BACKGROUND: Swirl sign has previously been described in epidural hematomas as areas of low attenuation, radiolucency or irregular density.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 139, "offsetInEndSection": 336, "text": "The aims of this study were to describe swirl sign in ICH, study its prevalence, study the reliability of the subjective evaluation on computed tomography (CT), and to explore its prognostic value.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 336, "offsetInEndSection": 436, "text": "METHODS: CTs of 203 patients with ICH were retrospectively evaluated for the presence of swirl sign.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 437, "offsetInEndSection": 530, "text": "Association between swirl sign and different clinical and radiological variables was studied.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 530, "offsetInEndSection": 685, "text": "RESULTS: Inter- and intraobserver agreement with regard to the occurrence of swirl sign was substantial (\u041a 0.80) and almost perfect (\u041a 0.87), respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 686, "offsetInEndSection": 738, "text": "Swirl sign was found in 30% of the study population.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 739, "offsetInEndSection": 842, "text": "61% of patients with swirl sign were dead at one month compared with 21% of those with no swirl sign (p", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 843, "offsetInEndSection": 958, "text": "CONCLUSIONS: As swirl sign showed to be an ominous sign, we recommend identification of this sign in cases of ICHs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23013418"}, {"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Prediction of evolution toward brain death upon admission to ICU in comatose patients with spontaneous intracerebral hemorrhage using simple signs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23517301"}]}, {"id": "5a8718a261bb38fb24000007", "body": "What is the function of yeast TERRA RNAs?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19026778", "http://www.ncbi.nlm.nih.gov/pubmed/24698720", "http://www.ncbi.nlm.nih.gov/pubmed/29145644", "http://www.ncbi.nlm.nih.gov/pubmed/20376293", "http://www.ncbi.nlm.nih.gov/pubmed/21525956", "http://www.ncbi.nlm.nih.gov/pubmed/22139922", "http://www.ncbi.nlm.nih.gov/pubmed/28666128", "http://www.ncbi.nlm.nih.gov/pubmed/24550456", "http://www.ncbi.nlm.nih.gov/pubmed/24074956", "http://www.ncbi.nlm.nih.gov/pubmed/20679250"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 133, "text": "The Rat1p 5' to 3' exonuclease degrades telomeric repeat-containing RNA and promotes telomere elongation in Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Vertebrate telomeres are transcribed into telomeric repeat-containing RNA (TERRA) that associates with telomeres and may be important for telomere function.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 273, "offsetInEndSection": 376, "text": "Yeast TERRA is polyadenylated and stabilized by Pap1p and regulated by the 5' to 3' exonuclease, Rat1p.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 377, "offsetInEndSection": 503, "text": "rat1-1 mutant cells accumulate TERRA and harbor short telomeres because of defects in telomerase-mediated telomere elongation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 808, "offsetInEndSection": 891, "text": "Telomere transcription is conserved in different kingdoms of the eukaryotic domain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19026778"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "Breaking new ground: digging into TERRA function.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 0, "offsetInEndSection": 179, "text": "Despite the fact that telomeres carry chromatin marks typically associated with silent heterochromatin, they are actively transcribed into TElomeric Repeat containing RNA (TERRA).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 180, "offsetInEndSection": 349, "text": "TERRA transcription is conserved from yeast to man, initiates in the subtelomeric region and proceeds through the telomeric tract of presumably each individual telomere.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 350, "offsetInEndSection": 472, "text": "TERRA levels are increased in yeast survivors and in cancer cells employing ALT as a telomere maintenance mechanism (TMM).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}, {"offsetInBeginSection": 473, "offsetInEndSection": 558, "text": "Thus, TERRA may be a promising biomarker and potential target in anti-cancer therapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24698720"}]}, {"id": "5a6e4d22b750ff445500004d", "body": "Mutations in which gene cause Schimke immune-osseous dysplasia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28623093", "http://www.ncbi.nlm.nih.gov/pubmed/26354575", "http://www.ncbi.nlm.nih.gov/pubmed/27813696", "http://www.ncbi.nlm.nih.gov/pubmed/15523612", "http://www.ncbi.nlm.nih.gov/pubmed/24589093", "http://www.ncbi.nlm.nih.gov/pubmed/23359635", "http://www.ncbi.nlm.nih.gov/pubmed/16648978", "http://www.ncbi.nlm.nih.gov/pubmed/18520775"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 218, "text": "SMARCAL1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily A-Like 1), also known as HARP, is an ATP-dependent annealing helicase that stabilizes replication forks during DNA damage.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28623093"}, {"offsetInBeginSection": 219, "offsetInEndSection": 397, "text": "Mutations in this gene are the cause of Schimke immune-osseous dysplasia (SIOD), an autosomal recessive disorder characterized by T-cell immunodeficiency and growth dysfunctions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28623093"}, {"offsetInBeginSection": 0, "offsetInEndSection": 48, "text": "Schimke immune-osseous dysplasia: A case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 254, "text": "Schimke immune-osseous dysplasia (SIOD) is a rare autosomal recessive disorder characterized by spondylo-epiphyseal dysplasia (SED), progressive renal insufficiency beginning as steroid-resistant nephrotic syndrome (SRNS) and defective cellular immunity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575"}, {"offsetInBeginSection": 320, "offsetInEndSection": 531, "text": "A 14.5-year-old male patient presented with disproportionate short stature, SRNS (focal and segmental glomerulosclerosis), laboratory evidence of cellular immune deficiency and radiologic characteristics of SED.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575"}, {"offsetInBeginSection": 255, "offsetInEndSection": 319, "text": "This article reports a case from Egypt with a mild form of SIOD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26354575"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Chromatin changes in SMARCAL1 deficiency: A hypothesis for the gene expression alterations of Schimke immuno-osseous dysplasia.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696"}, {"offsetInBeginSection": 0, "offsetInEndSection": 326, "text": "Mutations in SMARCAL1, which encodes a DNA annealing helicase with roles in DNA replication fork restart, DNA repair, and gene expression modulation, cause Schimke immuno-osseous dysplasia (SIOD), an autosomal recessive disease characterized by skeletal dysplasia, renal disease, T-cell immunodeficiency, and arteriosclerosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696"}, {"offsetInBeginSection": 327, "offsetInEndSection": 497, "text": "The clinical features of SIOD arise from pathological changes in gene expression; however, the underlying mechanism for these gene expression alterations remains unclear.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696"}, {"offsetInBeginSection": 498, "offsetInEndSection": 574, "text": "We hypothesized that changes of the epigenome alter gene expression in SIOD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27813696"}]}, {"id": "5a7727f39e632bc06600000d", "body": "What are the side effects of deflazacort in DMD patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/11148511", "http://www.ncbi.nlm.nih.gov/pubmed/19488064", "http://www.ncbi.nlm.nih.gov/pubmed/8882570", "http://www.ncbi.nlm.nih.gov/pubmed/10951436", "http://www.ncbi.nlm.nih.gov/pubmed/22655511"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 53, "text": "Deflazacort treatment of Duchenne muscular dystrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "OBJECTIVE: We report the long-term effects on muscle strength and side effects with deflazacort in Duchenne muscular dystrophy (DMD).STUDY", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 281, "offsetInEndSection": 349, "text": "Muscle function, pulmonary function, and side effects were compared.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 349, "offsetInEndSection": 432, "text": "RESULTS: The boys not treated with deflazacort stopped walking at 9.8 +/-1.8 years.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 433, "offsetInEndSection": 499, "text": "Seven of 30 treated boys had stopped walking at 12.3+/-2.7 years (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 499, "offsetInEndSection": 633, "text": "PCONCLUSIONS: We conclude that deflazacort can preserve gross motor and pulmonary function in boys with DMD with limited side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/11148511"}, {"offsetInBeginSection": 0, "offsetInEndSection": 79, "text": "Corticosteroid effects on blood gene expression in Duchenne muscular dystrophy.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 148, "text": "Though Deflazacort and prednisone improve clinical endpoints in Duchenne muscular dystrophy (DMD) patients, Deflazacort produces fewer side effects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 149, "offsetInEndSection": 320, "text": "As mechanisms of improvement and side effect differences remain unknown, we evaluated effects of corticosteroid administration on gene expression in blood of DMD patients.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}, {"offsetInBeginSection": 321, "offsetInEndSection": 498, "text": "Whole blood was obtained from 14 children and adolescents with DMD treated with corticosteroids (DMD-STEROID) and 20 DMD children and adolescents na\u00efve to corticosteroids (DMD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19488064"}]}, {"id": "5a6e47b1b750ff4455000049", "body": "Is overproduction of transthyretin is associated with amyloidosis associated neuropathy?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12762139", "http://www.ncbi.nlm.nih.gov/pubmed/28802308", "http://www.ncbi.nlm.nih.gov/pubmed/28217248", "http://www.ncbi.nlm.nih.gov/pubmed/25819286", "http://www.ncbi.nlm.nih.gov/pubmed/8579098", "http://www.ncbi.nlm.nih.gov/pubmed/24082415", "http://www.ncbi.nlm.nih.gov/pubmed/17554795", "http://www.ncbi.nlm.nih.gov/pubmed/14987380", "http://www.ncbi.nlm.nih.gov/pubmed/10694917", "http://www.ncbi.nlm.nih.gov/pubmed/2847318"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 119, "text": "A transthyretin mutation (Tyr78Phe) associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 109, "text": "BACKGROUND: More than 80 transthyretin (TTR) mutations have been described, most associated with amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 110, "offsetInEndSection": 340, "text": "Peripheral neuropathy is the most common clinical presentation in TTR amyloidosis although the carpal tunnel syndrome (CTS) may be the first symptom and skin can be involved, as transthyretin amyloidosis is a systemic disease.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 569, "offsetInEndSection": 631, "text": "Amyloidosis was diagnosed on salivary gland and skin biopsies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 1227, "offsetInEndSection": 1354, "text": "CONCLUSION: This TTR mutation (Tyr78Phe) is associated with peripheral neuropathy, carpal tunnel syndrome and skin amyloidosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12762139"}, {"offsetInBeginSection": 0, "offsetInEndSection": 167, "text": "Vitreous amyloidosis with autonomic neuropathy of the digestive tract associated with a novel transthyretin p.Gly87Arg variant in a Bangladeshi patient: a case report.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 0, "offsetInEndSection": 165, "text": "BACKGROUND: Hereditary transthyretin amyloidosis is an autosomal dominant inherited disorder, first described in families with sensorimotor and autonomic neuropathy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 166, "offsetInEndSection": 475, "text": "Since its first description, more than 120 amyloidogenic transthyretin mutations have been reported with various geographic distributions and associated with a wide range of phenotypes involving the peripheral nerve, the heart, the gastrointestinal tract, the eyes, the central nervous system, or the kidneys.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 476, "offsetInEndSection": 577, "text": "In some cases of transthyretin amyloidosis, the first clinical manifestation is vitreous opacity.CASE", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}, {"offsetInBeginSection": 578, "offsetInEndSection": 857, "text": "PRESENTATION: A 46-year-old Bangladeshi woman presented with vitreous amyloidosis and progressive autonomic neuropathy of the digestive tract as initial clinical manifestations, with no clinical evidence of cardiac, renal, central nervous system, or peripheral nerve dysfunction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28802308"}]}, {"id": "5a7244aa2dc08e987e00000f", "body": "Which two interleukins are inhibited by Ustekinumab?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22123062", "http://www.ncbi.nlm.nih.gov/pubmed/19882785", "http://www.ncbi.nlm.nih.gov/pubmed/18486739", "http://www.ncbi.nlm.nih.gov/pubmed/19217154", "http://www.ncbi.nlm.nih.gov/pubmed/19886505", "http://www.ncbi.nlm.nih.gov/pubmed/18703004", "http://www.ncbi.nlm.nih.gov/pubmed/29042094", "http://www.ncbi.nlm.nih.gov/pubmed/21436972", "http://www.ncbi.nlm.nih.gov/pubmed/20421912", "http://www.ncbi.nlm.nih.gov/pubmed/22758911"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 139, "text": "Monoclonal antibody (mAb) therapy was first established upon the approval of a mouse antibody for treatment of human acute organ rejection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 499, "offsetInEndSection": 738, "text": "A recent example is ustekinumab, a first-in-class therapeutic human immunoglobulin G1 kappa mAb that binds to the interleukins (IL)-12 and IL-23, cytokines that modulate lymphocyte function, including T-helper (Th) 1 and Th17 cell subsets.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 739, "offsetInEndSection": 854, "text": "Ustekinumab was generated via recombinant human IL-12 immunization of human immunoglobulin (hu-Ig) transgenic mice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 855, "offsetInEndSection": 1026, "text": "Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor \u03b21 subunit of the IL-12 and IL-23 receptor complexes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 1027, "offsetInEndSection": 1175, "text": "Ustekinumab is approved for treatment of moderate-to-severe plaque psoriasis and has demonstrated efficacy in Crohn disease and psoriatic arthritis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22123062"}, {"offsetInBeginSection": 0, "offsetInEndSection": 22, "text": "Ustekinumab: new drug.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 0, "offsetInEndSection": 266, "text": "(1) For adults with plaque psoriasis, after failure of topical symptomatic treatments and PUVA therapy, several systemic immunosuppressive agents are acceptable for severe disease: methotrexate, then ciclosporin, and possible a TNF alpha antagonist (etanercept, etc.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 266, "offsetInEndSection": 390, "text": "); (2) Ustekinumab is an inhibitor of interleukins 12 and 23, which are believed to be implicated in the onset of psoriasis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 391, "offsetInEndSection": 742, "text": "It is authorized in the European Union for patients who fail to respond to conventional systemic treatments; (3) In one trial with a low level of evidence (single-blind), 2 subcutaneous injections of ustekinumab at an interval of 4 weeks appeared to be statistically more effective than twice-weekly subcutaneous injections of etanercept for 12 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}, {"offsetInBeginSection": 743, "offsetInEndSection": 912, "text": "More patients achieved a 75% reduction in the score most widely used to evaluate the extent and intensity of plaque psoriasis lesions (PASI score): about 71% versus 57%.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19882785"}]}, {"id": "5a8863948cb19eca6b000002", "body": "How can network assortativity be applied in the three-dimensional analysis of the genome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27391817", "http://www.ncbi.nlm.nih.gov/pubmed/23536826", "http://www.ncbi.nlm.nih.gov/pubmed/25121490", "http://www.ncbi.nlm.nih.gov/pubmed/26816262", "http://www.ncbi.nlm.nih.gov/pubmed/26172652", "http://www.ncbi.nlm.nih.gov/pubmed/25981854", "http://www.ncbi.nlm.nih.gov/pubmed/27967190", "http://www.ncbi.nlm.nih.gov/pubmed/25894574", "http://www.ncbi.nlm.nih.gov/pubmed/24505274", "http://www.ncbi.nlm.nih.gov/pubmed/15697429"], "snippets": [{"offsetInBeginSection": 83, "offsetInEndSection": 206, "text": "Assortativity is a network property used in social sciences to identify factors affecting how people establish social ties.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 932, "offsetInEndSection": 1073, "text": "Polycomb group proteins and associated histone marks are the features with the highest chromatin assortativity in promoter-centered networks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 1665, "offsetInEndSection": 1836, "text": "Our approach facilitates the study of multiple genome-wide epigenomic profiles, considering network topology and allowing the comparison of chromatin interaction networks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/27391817"}, {"offsetInBeginSection": 0, "offsetInEndSection": 215, "text": "The spatial conformation of a genome plays an important role in the long-range regulation of genome-wide gene expression and methylation, but has not been extensively studied due to lack of genome conformation data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 216, "offsetInEndSection": 609, "text": "The recently developed chromosome conformation capturing techniques such as the Hi-C method empowered by next generation sequencing can generate unbiased, large-scale, high-resolution chromosomal interaction (contact) data, providing an unprecedented opportunity to investigate the spatial structure of a genome and its applications in gene regulation, genomics, epigenetics, and cell biology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 610, "offsetInEndSection": 823, "text": "In this work, we conducted a comprehensive, large-scale computational analysis of this new stream of genome conformation data generated for three different human leukemia cells or cell lines by the Hi-C technique.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 1091, "offsetInEndSection": 1370, "text": "Our analysis demonstrates that Hi-C data can be effectively applied to study tissue-specific genome conformation, chromosome-chromosome interaction, chromosomal translocations, and spatial gene-gene interaction and regulation in a three-dimensional genome of primary tumor cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 1371, "offsetInEndSection": 1612, "text": "Particularly, for the first time, we constructed genome-scale spatial gene-gene interaction network, transcription factor binding site (TFBS) - TFBS interaction network, and TFBS-gene interaction network from chromosomal contact information.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23536826"}, {"offsetInBeginSection": 0, "offsetInEndSection": 93, "text": "Phenotypic robustness and the assortativity signature of human transcription factor networks.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121490"}, {"offsetInBeginSection": 314, "offsetInEndSection": 503, "text": "These nearby genes may themselves encode TFs, giving rise to a transcription factor network (TFN), wherein nodes represent TFs and directed edges denote regulatory interactions between TFs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25121490"}]}, {"id": "5a6fabfeb750ff4455000062", "body": "Are there mammalian promoters with distal enhancer functions?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28581502"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Genome-wide characterization of mammalian promoters with distal enhancer functions.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 0, "offsetInEndSection": 137, "text": "Gene expression in mammals is precisely regulated by the combination of promoters and gene-distal regulatory regions, known as enhancers.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 138, "offsetInEndSection": 219, "text": "Several studies have suggested that some promoters might have enhancer functions.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 220, "offsetInEndSection": 366, "text": "However, the extent of this type of promoters and whether they actually function to regulate the expression of distal genes have remained elusive.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 367, "offsetInEndSection": 499, "text": "Here, by exploiting a high-throughput enhancer reporter assay, we unravel a set of mammalian promoters displaying enhancer activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 500, "offsetInEndSection": 612, "text": "These promoters have distinct genomic and epigenomic features and frequently interact with other gene promoters.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 613, "offsetInEndSection": 778, "text": "Extensive CRISPR-Cas9 genomic manipulation demonstrated the involvement of these promoters in the cis regulation of expression of distal genes in their natural loci.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}, {"offsetInBeginSection": 779, "offsetInEndSection": 902, "text": "Our results have important implications for the understanding of complex gene regulation in normal development and disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28581502"}]}, {"id": "5a774431faa1ab7d2e000004", "body": "Why is the Fyn kinase considered a promising therapeutic target for Alzheimer's Disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25874001", "http://www.ncbi.nlm.nih.gov/pubmed/28709498", "http://www.ncbi.nlm.nih.gov/pubmed/24495408"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 128, "text": "INTRODUCTION: Despite significant progress, a disease-modifying therapy for Alzheimer's disease (AD) has not yet been developed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 249, "offsetInEndSection": 448, "text": "We recently described a signaling cascade whereby oligomeric amyloid beta binds to cellular prion protein on the neuronal cell surface, activating intracellular Fyn kinase to mediate synaptotoxicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 449, "offsetInEndSection": 598, "text": "Fyn kinase has been implicated in AD pathophysiology both in in vitro models and in human subjects, and is a promising new therapeutic target for AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 599, "offsetInEndSection": 801, "text": "Herein, we present a Phase Ib trial of the repurposed investigational drug AZD0530, a Src family kinase inhibitor specific for Fyn and Src kinase, for the treatment of patients with mild-to-moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 1323, "offsetInEndSection": 1714, "text": "Secondary endpoints included changes in clinical efficacy measures (Alzheimer's Disease Assessment Scale - cognitive subscale, MMSE, Alzheimer's Disease Cooperative Study - Activities of Daily Living Inventory, Neuropsychiatric Inventory, and Clinical Dementia Rating Scale - Sum of Boxes) and regional cerebral glucose metabolism measured by fluorodeoxyglucose positron emission tomography.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 2480, "offsetInEndSection": 2662, "text": "Targeting Fyn kinase may be a promising therapeutic approach in AD, and a larger Phase IIa clinical trial of AZD0530 for the treatment of patients with AD has recently launched.TRIAL", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25874001"}, {"offsetInBeginSection": 0, "offsetInEndSection": 44, "text": "Targeting Fyn Kinase in Alzheimer's Disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}, {"offsetInBeginSection": 0, "offsetInEndSection": 110, "text": "The past decade has brought tremendous progress in unraveling the pathophysiology of Alzheimer's disease (AD).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}, {"offsetInBeginSection": 111, "offsetInEndSection": 469, "text": "While increasingly sophisticated immunotherapy targeting soluble and aggregated brain amyloid-beta (A\u03b2) continues to dominate clinical research in AD, a deeper understanding of A\u03b2 physiology has led to the recognition of distinct neuronal signaling pathways linking A\u03b2 to synaptotoxicity and neurodegeneration and to new targets for therapeutic intervention.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}, {"offsetInBeginSection": 879, "offsetInEndSection": 1119, "text": "I discuss preclinical studies targeting Fyn as a therapeutic intervention in AD and our recent experience with the safety, tolerability, and cerebrospinal fluid penetration of the Src family kinase inhibitor saracatinib in patients with AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28709498"}]}, {"id": "5a6f7138b750ff445500004f", "body": "How does parathyroid hormone affect circulating levels of periostin?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/23918682", "http://www.ncbi.nlm.nih.gov/pubmed/26721738", "http://www.ncbi.nlm.nih.gov/pubmed/22927401", "http://www.ncbi.nlm.nih.gov/pubmed/20654714"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Circulating periostin levels do not differ between postmenopausal women with normal and low bone mass and are not affected by zoledronic acid treatment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Periostin is a secreted extracellular matrix protein preferentially expressed in bone by osteocytes and periosteal osteoblasts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 128, "offsetInEndSection": 284, "text": "Reduced periostin expression may affect osteoblast differentiation and collagen type I synthesis and predispose to osteoporosis and increased fracture risk.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 285, "offsetInEndSection": 497, "text": "We aimed to evaluate circulating periostin levels in postmenopausal women with low bone mass, their possible correlations with clinical and laboratory parameters, as well as the 3-month effect of zoledronic acid.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 498, "offsetInEndSection": 863, "text": "Serum samples for periostin, 25-hydroxyvitamin D, parathyroid hormone (PTH), C-terminal telopeptide of type I collagen (CTx), and total alkaline phosphatase (tALP) were obtained from 46 postmenopausal women with low bone mass at baseline and 3 months after zoledronic acid infusion and from 30 age-matched, postmenopausal controls with normal bone mass at baseline.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 864, "offsetInEndSection": 1001, "text": "There was no difference in periostin levels between women with normal and low bone mass (250\u00b115 vs. 272\u00b114\u2009ng/ml, respectively; p=0.279).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 1002, "offsetInEndSection": 1098, "text": "Periostin remained essentially unchanged after zoledronic acid infusion (262\u00b118\u2009ng/ml; p=0.130).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 1099, "offsetInEndSection": 1243, "text": "Serum periostin levels at baseline were not affected by previous bisphosphonate treatment, and were correlated only to tALP (rs=0.351; p=0.018).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 1647, "offsetInEndSection": 1713, "text": "Women with higher tALP have independently higher periostin levels.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23918682"}, {"offsetInBeginSection": 0, "offsetInEndSection": 25, "text": "Periostin action in bone.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26721738"}]}, {"id": "5a7247182dc08e987e000010", "body": "Describe mechanism of action of Ozanimod.", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28783871", "http://www.ncbi.nlm.nih.gov/pubmed/29125718", "http://www.ncbi.nlm.nih.gov/pubmed/27144850", "http://www.ncbi.nlm.nih.gov/pubmed/28398597", "http://www.ncbi.nlm.nih.gov/pubmed/26239599", "http://www.ncbi.nlm.nih.gov/pubmed/26879276", "http://www.ncbi.nlm.nih.gov/pubmed/26702336", "http://www.ncbi.nlm.nih.gov/pubmed/28812220"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 115, "text": "Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 0, "offsetInEndSection": 159, "text": "Ozanimod is a novel, selective, oral sphingosine-1-phosphate (1 and 5) receptor modulator in development for multiple sclerosis and inflammatory bowel disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 160, "offsetInEndSection": 349, "text": "This randomized, double-blind, placebo-controlled, positive-controlled, parallel-group thorough QT study characterized the effects of ozanimod on cardiac repolarization in healthy subjects.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 721, "offsetInEndSection": 869, "text": "The upper limits of the 2-sided 90% confidence intervals for \u0394\u0394QTcF for both ozanimod 1 and 2\u00a0mg were below the 10-millisecond regulatory threshold.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 957, "offsetInEndSection": 1079, "text": "There was no evidence of a positive relationship between concentrations of ozanimod and its active metabolites and \u0394\u0394QTcF.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 1080, "offsetInEndSection": 1222, "text": "Although ozanimod blunted the observed diurnal increase in heart rate, excursions below predose heart rates were no greater than with placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 1223, "offsetInEndSection": 1400, "text": "Results demonstrate that ozanimod does not prolong the QTc interval or cause clinically significant bradycardia, supporting ozanimod's evolving favorable cardiac safety profile.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28783871"}, {"offsetInBeginSection": 0, "offsetInEndSection": 123, "text": "Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}, {"offsetInBeginSection": 0, "offsetInEndSection": 198, "text": "Ozanimod (RPC1063) is an oral selective modulator of the sphingosine-1-phosphate 1 and 5 receptors under development for the treatment of relapsing multiple sclerosis and inflammatory bowel disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}, {"offsetInBeginSection": 199, "offsetInEndSection": 388, "text": "The effects of high-fat and low-fat meals on the pharmacokinetics (PK) of a single oral dose of ozanimod were evaluated in 24 healthy volunteers in a randomized, open-label crossover trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/29125718"}]}, {"id": "5a895f51fcd1d6a10c000004", "body": "What is the preferred orientation of CTCF binding sites for chromatin looping?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26527277", "http://www.ncbi.nlm.nih.gov/pubmed/28536180", "http://www.ncbi.nlm.nih.gov/pubmed/25135475", "http://www.ncbi.nlm.nih.gov/pubmed/26276636", "http://www.ncbi.nlm.nih.gov/pubmed/27569350", "http://www.ncbi.nlm.nih.gov/pubmed/28137913", "http://www.ncbi.nlm.nih.gov/pubmed/24990380", "http://www.ncbi.nlm.nih.gov/pubmed/29076501", "http://www.ncbi.nlm.nih.gov/pubmed/21282187", "http://www.ncbi.nlm.nih.gov/pubmed/23650640"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 51, "text": "CTCF Binding Polarity Determines Chromatin Looping.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 0, "offsetInEndSection": 121, "text": "CCCTC-binding factor (CTCF) is an architectural protein involved in the three-dimensional (3D) organization of chromatin.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 122, "offsetInEndSection": 248, "text": "In this study, we assayed the 3D genomic contact profiles of a large number of CTCF binding sites with high-resolution 4C-seq.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 249, "offsetInEndSection": 393, "text": "As recently reported, our data also suggest that chromatin loops preferentially form between CTCF binding sites oriented in a convergent manner.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 394, "offsetInEndSection": 552, "text": "To directly test this, we used CRISPR/Cas9 genome editing to delete core CTCF binding sites in three loci, including the CTCF site in the Sox2 super-enhancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 553, "offsetInEndSection": 697, "text": "In all instances, CTCF and cohesin recruitment were lost, and chromatin loops with distal, convergent CTCF sites were disrupted or destabilized.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 698, "offsetInEndSection": 841, "text": "Re-insertion of oppositely oriented CTCF recognition sequences restored CTCF and cohesin recruitment, but did not re-establish chromatin loops.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 842, "offsetInEndSection": 958, "text": "We conclude that CTCF binding polarity plays a functional role in the formation of higher-order chromatin structure.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26527277"}, {"offsetInBeginSection": 0, "offsetInEndSection": 94, "text": "YY1 and CTCF orchestrate a 3D chromatin looping switch during early neural lineage commitment.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "CTCF is an architectural protein with a critical role in connecting higher-order chromatin folding in pluripotent stem cells.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28536180"}]}, {"id": "5a761ac7aacfb9cd4c000003", "body": "What is the ReliableGenome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/27605105"], "snippets": []}, {"id": "5a774585faa1ab7d2e000005", "body": "What is masitinib an inhibitor of?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25961655", "http://www.ncbi.nlm.nih.gov/pubmed/19789626", "http://www.ncbi.nlm.nih.gov/pubmed/18823406", "http://www.ncbi.nlm.nih.gov/pubmed/25122671", "http://www.ncbi.nlm.nih.gov/pubmed/19614621", "http://www.ncbi.nlm.nih.gov/pubmed/19541476", "http://www.ncbi.nlm.nih.gov/pubmed/26978025", "http://www.ncbi.nlm.nih.gov/pubmed/20033487", "http://www.ncbi.nlm.nih.gov/pubmed/27400786", "http://www.ncbi.nlm.nih.gov/pubmed/21504563"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 68, "text": "Masitinib for the treatment of mild to moderate Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961655"}, {"offsetInBeginSection": 717, "offsetInEndSection": 852, "text": "Dual actions of masitinib as an inhibitor of mast cell-glia axis and a Fyn kinase blocker are discussed in the context of AD pathology.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961655"}, {"offsetInBeginSection": 853, "offsetInEndSection": 1014, "text": "Masitinib is in Phase III clinical trials for the treatment of malignant melanoma, mastocytosis, multiple myeloma, gastrointestinal cancer and pancreatic cancer.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25961655"}, {"offsetInBeginSection": 0, "offsetInEndSection": 83, "text": "Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 677, "offsetInEndSection": 823, "text": "Masitinib also potently inhibited recombinant PDGFR and the intracellular kinase Lyn, and to a lesser extent, fibroblast growth factor receptor 3.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 1426, "offsetInEndSection": 1543, "text": "Furthermore, masitinib potently inhibited human and murine KIT with activating mutations in the juxtamembrane domain.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 1671, "offsetInEndSection": 1826, "text": "CONCLUSIONS: Masitinib is a potent and selective tyrosine kinase inhibitor targeting KIT that is active, orally bioavailable in vivo, and has low toxicity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 1209, "offsetInEndSection": 1425, "text": "Molecular modelling and kinetic analysis suggest a different mode of binding than imatinib, and masitinib more strongly inhibited degranulation, cytokine production, and bone marrow mast cell migration than imatinib.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19789626"}, {"offsetInBeginSection": 0, "offsetInEndSection": 77, "text": "Masitinib is safe and effective for the treatment of canine mast cell tumors.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823406"}, {"offsetInBeginSection": 138, "offsetInEndSection": 260, "text": "OBJECTIVE: To evaluate the efficacy of masitinib, a potent and selective inhibitor of KIT, in the treatment of canine MCT.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/18823406"}]}, {"id": "5a6f7245b750ff4455000050", "body": "What is the mode of action of teriparatide?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24870841", "http://www.ncbi.nlm.nih.gov/pubmed/20872215", "http://www.ncbi.nlm.nih.gov/pubmed/15262455", "http://www.ncbi.nlm.nih.gov/pubmed/16234962", "http://www.ncbi.nlm.nih.gov/pubmed/17538470", "http://www.ncbi.nlm.nih.gov/pubmed/15940379", "http://www.ncbi.nlm.nih.gov/pubmed/22451221", "http://www.ncbi.nlm.nih.gov/pubmed/19281056", "http://www.ncbi.nlm.nih.gov/pubmed/26104116", "http://www.ncbi.nlm.nih.gov/pubmed/24086927"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 37, "text": "[Treatment of osteoporosis with PTH].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 0, "offsetInEndSection": 65, "text": "Teriparatide is an only available bone anabolic drug in practice.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 66, "offsetInEndSection": 124, "text": "It is a N-terminal fragment of parathyroid hormone (PTH) .", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 125, "offsetInEndSection": 250, "text": "Mode of actions of teriparatide is pharmacological but not physiological as it is administered to patients with osteoporosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 251, "offsetInEndSection": 362, "text": "Physicians need to understand the fact that treatment with teriparatide is not just like a hormone replacement.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 363, "offsetInEndSection": 559, "text": "They also should administer teriparatide to their patients after rigorous evaluation of its clinical superiority to other anti-osteoprosis drugs, because it is not classified as a first-line drug.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24870841"}, {"offsetInBeginSection": 0, "offsetInEndSection": 164, "text": "Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 250, "offsetInEndSection": 302, "text": "Most bone-quality data for PTH is from teriparatide.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 303, "offsetInEndSection": 499, "text": "Teriparatide results in a rapid increase in bone-formation markers, followed by increases in bone-resorption markers, opening an \"anabolic window,\" a period of time when PTH is maximally anabolic.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}, {"offsetInBeginSection": 500, "offsetInEndSection": 611, "text": "Teriparatide reverses the structural damage seen in osteoporosis and restores the structure of trabecular bone.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20872215"}]}, {"id": "5a7340962dc08e987e000017", "body": "Is Apremilast effective for Behcet\u2019s syndrome?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25875256", "http://www.ncbi.nlm.nih.gov/pubmed/26676621", "http://www.ncbi.nlm.nih.gov/pubmed/24882690", "http://www.ncbi.nlm.nih.gov/pubmed/24797159", "http://www.ncbi.nlm.nih.gov/pubmed/28823583", "http://www.ncbi.nlm.nih.gov/pubmed/27747762", "http://www.ncbi.nlm.nih.gov/pubmed/28213862", "http://www.ncbi.nlm.nih.gov/pubmed/26555450", "http://www.ncbi.nlm.nih.gov/pubmed/27486641", "http://www.ncbi.nlm.nih.gov/pubmed/26089047"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 70, "text": "Apremilast for Beh\u00e7et's syndrome--a phase 2, placebo-controlled study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "BACKGROUND: Oral ulcers, the hallmark of Beh\u00e7et's syndrome, can be resistant to conventional treatment; therefore, alternative agents are needed.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 146, "offsetInEndSection": 243, "text": "Apremilast is an oral phosphodiesterase-4 inhibitor that modulates several inflammatory pathways.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 243, "offsetInEndSection": 481, "text": "METHODS: We conducted a phase 2, multicenter, placebo-controlled study in which 111 patients with Beh\u00e7et's syndrome who had two or more oral ulcers were randomly assigned to receive 30 mg of apremilast twice daily or placebo for 12 weeks.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 650, "offsetInEndSection": 737, "text": "The patients and clinicians were unaware of the study assignments throughout the trial.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 1017, "offsetInEndSection": 1183, "text": "RESULTS: The mean (\u00b1SD) number of oral ulcers per patient at week 12 was significantly lower in the apremilast group than in the placebo group (0.5\u00b11.0 vs. 2.1\u00b12.6) (", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 1183, "offsetInEndSection": 1305, "text": "PCONCLUSIONS: Apremilast was effective in treating oral ulcers, which are the cardinal manifestation of Beh\u00e7et's syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 1306, "offsetInEndSection": 1504, "text": "This preliminary study was neither large enough nor long enough to assess long-term efficacy, the effect on other manifestations of Beh\u00e7et's syndrome, or the risk of uncommon serious adverse events.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25875256"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "OBJECTIVE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a disease with an uncertain cause and limited effective treatments.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26676621"}, {"offsetInBeginSection": 141, "offsetInEndSection": 281, "text": "Apremilast (Celgene Corporation, Summit, NJ, USA) is a selective phosphodiesterase type 4 (PDE4) inhibitor that modulates the immune system.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26676621"}]}, {"id": "5a857bfffaa1ab7d2e000030", "body": "Can the yeast protein Abf1 act as insulator?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/7663308", "http://www.ncbi.nlm.nih.gov/pubmed/10601031", "http://www.ncbi.nlm.nih.gov/pubmed/7608180", "http://www.ncbi.nlm.nih.gov/pubmed/9430660", "http://www.ncbi.nlm.nih.gov/pubmed/18996839", "http://www.ncbi.nlm.nih.gov/pubmed/8536307", "http://www.ncbi.nlm.nih.gov/pubmed/1545789", "http://www.ncbi.nlm.nih.gov/pubmed/25748434", "http://www.ncbi.nlm.nih.gov/pubmed/15456886", "http://www.ncbi.nlm.nih.gov/pubmed/2511628"], "snippets": [{"offsetInBeginSection": 976, "offsetInEndSection": 1056, "text": "The expression of ADH1 was activated synergistically by both ABF1 binding sites.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7663308"}, {"offsetInBeginSection": 0, "offsetInEndSection": 97, "text": "Yeast autonomously replicating sequence binding factor is involved in nucleotide excision repair.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031"}, {"offsetInBeginSection": 345, "offsetInEndSection": 473, "text": "Yeast ABF1 protein is encoded by an essential gene required for DNA replication, transcriptional regulation, and gene silencing.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031"}, {"offsetInBeginSection": 825, "offsetInEndSection": 911, "text": "These studies define a novel and unexpected role for ABF1 protein during NER in yeast.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10601031"}, {"offsetInBeginSection": 1051, "offsetInEndSection": 1243, "text": "Although three CKII enzymes, yeast, sea star, and recombinant human, utilize casein as a substrate with similar efficiencies, only the yeast enzyme efficiently phosphorylates the ABF1 protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/7608180"}, {"offsetInBeginSection": 0, "offsetInEndSection": 67, "text": "Saccharomyces cerevisiae Cdc6 stimulates Abf1 DNA binding activity.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660"}, {"offsetInBeginSection": 164, "offsetInEndSection": 260, "text": "We describe in this study how yeast Cdc6 protein stimulates Abf1 protein DNA binding activities.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660"}, {"offsetInBeginSection": 486, "offsetInEndSection": 675, "text": "We demonstrated that recombinant Abf1 binds to ARS1 in vitro, and its DNA binding activity can be highly stimulated by the addition of a fusion glutathione S-transferase (GST)-Cdc6 protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660"}, {"offsetInBeginSection": 676, "offsetInEndSection": 784, "text": "Deletion analysis revealed that the stimulating region is located at the amino terminus of the Cdc6 protein.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/9430660"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "Functional analysis of the ABF1-binding sites within the Ya regions of the MATa and HMRa loci of Saccharomyces cerevisiae.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/8536307"}]}, {"id": "5a8053effaa1ab7d2e00001e", "body": "Describe the Manta algorithm for detection of structural variants", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26647377"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 105, "text": "Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 0, "offsetInEndSection": 122, "text": "UNLABELLED: : We describe Manta, a method to discover structural variants and indels from next generation sequencing data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 123, "offsetInEndSection": 472, "text": "Manta is optimized for rapid germline and somatic analysis, calling structural variants, medium-sized indels and large insertions on standard compute hardware in less than a tenth of the time that comparable methods require to identify only subsets of these variant types: for example NA12878 at 50\u00d7 genomic coverage is analyzed in less than 20\u2009min.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 473, "offsetInEndSection": 688, "text": "Manta can discover and score variants based on supporting paired and split-read evidence, with scoring models optimized for germline analysis of diploid individuals and somatic analysis of tumor-normal sample pairs.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 689, "offsetInEndSection": 867, "text": "Call quality is similar to or better than comparable methods, as determined by pedigree consistency of germline calls and comparison of somatic calls to COSMIC database variants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 868, "offsetInEndSection": 1035, "text": "Manta consistently assembles a higher fraction of its calls to base-pair resolution, allowing for improved downstream annotation and analysis of clinical significance.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}, {"offsetInBeginSection": 1275, "offsetInEndSection": 1374, "text": "Source code, documentation and Linux binaries are available from https://github.com/Illumina/manta.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26647377"}]}, {"id": "5a7d4e9afaa1ab7d2e000013", "body": "How many amino acids does davunetide consist of?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/21902667", "http://www.ncbi.nlm.nih.gov/pubmed/24210139", "http://www.ncbi.nlm.nih.gov/pubmed/24533805", "http://www.ncbi.nlm.nih.gov/pubmed/22956189"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "This review focuses on the discovery of activity-dependent neuroprotective protein (ADNP) and the ensuing discovery of NAP (davunetide) toward clinical development with emphasis on microtubule protection.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 583, "offsetInEndSection": 707, "text": "NAP (davunetide), an eight amino acid peptide derived from ADNP partly ameliorated deficits associated with ADNP deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 708, "offsetInEndSection": 949, "text": "NAP (davunetide) interacted with microtubules, protected against microtubule toxicity associated with zinc, nocodazole and oxidative stress in vitro and against tau pathology and MAP6 (stable tubuleonly polypeptide - STOP) pathology in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 950, "offsetInEndSection": 1138, "text": "NAP (davunetide) provided neurotrophic functions promoting neurite outgrowth as measured by increases in MAP2 immunoreactivity and synapse formation by increasing synaptophysin expression.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 1139, "offsetInEndSection": 1306, "text": "NAP (davunetide) protection against neurodegeneration has recently been shown to extend to katanin-related microtubule disruption under conditions of tau deficiencies.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 1307, "offsetInEndSection": 1514, "text": "In conclusion, NAP (davunetide) provided potent neuroprotection in a broad range of neurodegenerative models, protecting the neuroglial cytoskeleton in vitro and inhibiting tau pathology (tauopathy) in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 1515, "offsetInEndSection": 1707, "text": "Based on these extensive preclinical results, davunetide (NAP) is now being evaluated in a Phase II/III study of the tauopathy, progressive supranuclear palsy (PSP); (Allon Therapeutics Inc.).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 205, "offsetInEndSection": 386, "text": "ADNP immunoreactivity was shown to occasionally decorate microtubules and ADNP silencing inhibited neurite outgrowth as measured by microtubule associated protein 2 (MAP2) labeling.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21902667"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24210139"}]}, {"id": "5a6f77d7b750ff4455000051", "body": "Is autosomal dominant inheritanced form of Osteogenesis imperfecta caused by mutations in the genes associated with collagen production?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/2886666", "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "http://www.ncbi.nlm.nih.gov/pubmed/23771926", "http://www.ncbi.nlm.nih.gov/pubmed/18566967", "http://www.ncbi.nlm.nih.gov/pubmed/19533842", "http://www.ncbi.nlm.nih.gov/pubmed/20839288", "http://www.ncbi.nlm.nih.gov/pubmed/27312322", "http://www.ncbi.nlm.nih.gov/pubmed/25656619", "http://www.ncbi.nlm.nih.gov/pubmed/8100856", "http://www.ncbi.nlm.nih.gov/pubmed/25007323"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 114, "text": "Prenatal prediction of osteogenesis imperfecta (OI type IV): exclusion of inheritance using a collagen gene probe.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 0, "offsetInEndSection": 116, "text": "Autosomal dominant osteogenesis imperfecta is caused by mutations in the COL1A2 and COL1A1 genes of type I collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 117, "offsetInEndSection": 308, "text": "In a family with OI type IV genetically linked to the COL1A2 gene, we attempted prenatal diagnosis in a pregnancy at risk by genotyping the DNA of the fetus for a COL1A2 gene associated RFLP.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 404, "offsetInEndSection": 512, "text": "Linkage analysis can thus be used in the prenatal diagnosis of dominantly inherited osteogenesis imperfecta.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/2886666"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 492, "offsetInEndSection": 825, "text": "Three of 10 children with lethal or severe osteogenesis imperfecta, who did not have a primary collagen defect yet had excess post-translational modification of collagen, were found to have a recessive condition resulting in CRTAP deficiency, suggesting that prolyl 3-hydroxylation of type I collagen is important for bone formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 69, "text": "New genes in bone development: what's new in osteogenesis imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926"}, {"offsetInBeginSection": 0, "offsetInEndSection": 127, "text": "Osteogenesis imperfecta (OI) is a heritable bone dysplasia characterized by bone fragility and deformity and growth deficiency.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926"}, {"offsetInBeginSection": 128, "offsetInEndSection": 256, "text": "Most cases of OI (classical types) have autosomal dominant inheritance and are caused by mutations in the type I collagen genes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23771926"}]}, {"id": "5a7346662dc08e987e00001a", "body": "What causes \"Puffy hand syndrome\"?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/19216010", "http://www.ncbi.nlm.nih.gov/pubmed/16911735", "http://www.ncbi.nlm.nih.gov/pubmed/15529083", "http://www.ncbi.nlm.nih.gov/pubmed/17072191", "http://www.ncbi.nlm.nih.gov/pubmed/27269656", "http://www.ncbi.nlm.nih.gov/pubmed/24198977", "http://www.ncbi.nlm.nih.gov/pubmed/23856549"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 22, "text": "[Puffy hand syndrome].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 0, "offsetInEndSection": 78, "text": "Puffy hand syndrome is an unrecognized complication of intravenous drug abuse.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 79, "offsetInEndSection": 158, "text": "This painless syndrome appears during or after a long period of drug addiction.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 304, "offsetInEndSection": 508, "text": "Physiopathological mechanisms of the puffy hand syndrome are unclear and include venous and lymphatic insufficiencies, infectious complications and direct toxicity of injected drugs and their adulterants.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 509, "offsetInEndSection": 634, "text": "Low-stretch bandage and elastic garment, usually used in lymphedema treatment, are proposed to treat the puffy hand syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19216010"}, {"offsetInBeginSection": 0, "offsetInEndSection": 84, "text": "Puffy hand syndrome due to drug addiction: a case-control study of the pathogenesis.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 0, "offsetInEndSection": 80, "text": "AIM: We studied the pathogenesis of puffy hand syndrome of intravenous drug use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 1013, "offsetInEndSection": 1212, "text": "In 69.7% of the cases and 59.4% of the controls, respectively, there was a high-dose sublingual buprenorphine misuse, although it appeared not to be a significant risk factor for puffy hand syndrome.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16911735"}, {"offsetInBeginSection": 0, "offsetInEndSection": 49, "text": "[Puffy hand in long-term intravenous drug users].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083"}, {"offsetInBeginSection": 162, "offsetInEndSection": 245, "text": "The puffy hand sign is a more uncommon complication of hard-core injection addicts.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/15529083"}]}, {"id": "5a86e66dfaa1ab7d2e000035", "body": "Does the association of PARP1 and CTCF follow a circadian rhythm?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26321255"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 125, "text": "PARP1- and CTCF-Mediated Interactions between Active and Repressed Chromatin at the Lamina Promote Oscillating Transcription.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 153, "offsetInEndSection": 306, "text": "However, here we uncovered an inter-chromosomal network connecting active loci enriched in circadian genes to repressed lamina-associated domains (LADs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 307, "offsetInEndSection": 368, "text": "The interactome is regulated by PARP1 and its co-factor CTCF.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 369, "offsetInEndSection": 486, "text": "They not only mediate chromatin fiber interactions but also promote the recruitment of circadian genes to the lamina.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 487, "offsetInEndSection": 760, "text": "Synchronization of the circadian rhythm by serum shock induces oscillations in PARP1-CTCF interactions, which is accompanied by oscillating recruitment of circadian loci to the lamina, followed by the acquisition of repressive H3K9me2 marks and transcriptional attenuation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 761, "offsetInEndSection": 958, "text": "Furthermore, depletion of H3K9me2/3, inhibition of PARP activity by olaparib, or downregulation of PARP1 or CTCF expression counteracts both recruitment to the envelope and circadian transcription.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 959, "offsetInEndSection": 1127, "text": "PARP1- and CTCF-regulated contacts between circadian loci and the repressive chromatin environment at the lamina therefore mediate circadian transcriptional plasticity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}, {"offsetInBeginSection": 0, "offsetInEndSection": 152, "text": "Transcriptionally active and inactive chromatin domains tend to segregate into separate sub-nuclear compartments to maintain stable expression patterns.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26321255"}]}, {"id": "5a805974faa1ab7d2e000020", "body": "What is the Strelka workflow?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/22581179"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 89, "text": "Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 464, "offsetInEndSection": 651, "text": "The method uses a novel Bayesian approach which represents continuous allele frequencies for both tumor and normal samples, while leveraging the expected genotype structure of the normal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 984, "offsetInEndSection": 1175, "text": "We demonstrate that the method has superior accuracy and sensitivity on impure samples compared with approaches based on either diploid genotype likelihoods or general allele-frequency tests.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 1175, "offsetInEndSection": 1270, "text": "AVAILABILITY: The Strelka workflow source code is available at ftp://strelka@ftp.illumina.com/.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}, {"offsetInBeginSection": 1270, "offsetInEndSection": 1301, "text": "CONTACT: csaunders@illumina.com", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/22581179"}]}, {"id": "5a7d535ffaa1ab7d2e000018", "body": "What does the human IVIG treatment for Alzheimer's disease contain?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/24760109", "http://www.ncbi.nlm.nih.gov/pubmed/28381506", "http://www.ncbi.nlm.nih.gov/pubmed/24760112", "http://www.ncbi.nlm.nih.gov/pubmed/23861639", "http://www.ncbi.nlm.nih.gov/pubmed/18294736", "http://www.ncbi.nlm.nih.gov/pubmed/20329802", "http://www.ncbi.nlm.nih.gov/pubmed/25115546", "http://www.ncbi.nlm.nih.gov/pubmed/18956886", "http://www.ncbi.nlm.nih.gov/pubmed/21138577", "http://www.ncbi.nlm.nih.gov/pubmed/23735288"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 138, "text": "Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 0, "offsetInEndSection": 271, "text": "Intravenous immunoglobulin (IVIG) has shown limited promise so far in human clinical studies on Alzheimer's disease (AD), yet overwhelmingly positive preclinical work in animals and human brain cultures support the notion that the therapy remains potentially efficacious.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 272, "offsetInEndSection": 472, "text": "Here, we elaborate on IVIG neuropreservation by demonstrating that IVIG protects human primary neurons against oxidative stress in vitro and that IVIG preserves antioxidant defense mechanisms in vivo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 473, "offsetInEndSection": 747, "text": "Based on these results, we propose the following translational impact: If the dosage and treatment conditions are adequately optimized, then IVIG treatment could play a significant role in preventing and/or delaying the progression of neurodegenerative diseases, such as AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/24760109"}, {"offsetInBeginSection": 0, "offsetInEndSection": 59, "text": "A phase 3 trial of IV immunoglobulin for Alzheimer disease.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 0, "offsetInEndSection": 145, "text": "OBJECTIVE: We tested biweekly infusions of IV immunoglobulin (IVIg) as a possible treatment for mild to moderate Alzheimer disease (AD) dementia.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 435, "offsetInEndSection": 715, "text": "The primary cognitive outcome was change from baseline to 18 months on the 11-item cognitive subscale of the Alzheimer's Disease Assessment Scale; the primary functional outcome was 18-month change on the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 1250, "offsetInEndSection": 1390, "text": "IVIg-treated participants had more systemic reactions (chills, rashes) but fewer respiratory infections than participants receiving placebo.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 1390, "offsetInEndSection": 1642, "text": "CONCLUSIONS: Participants with mild to moderate AD showed good tolerability of treatment with low-dose human IVIg for 18 months but did not show beneficial effects on cognition or function relative to participants who received placebo.CLINICALTRIALSGOV", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}, {"offsetInBeginSection": 1685, "offsetInEndSection": 1864, "text": "EVIDENCE: This study provides Class II evidence that IVIg infusions performed every 2 weeks do not improve cognition or function at 18 months in patients with mild to moderate AD.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/28381506"}]}, {"id": "5a70ce4ab750ff4455000064", "body": "List the 6 genes associated with the autosomal recessive form of Osteogenesis imperfecta", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/12110407", "http://www.ncbi.nlm.nih.gov/pubmed/17192541", "http://www.ncbi.nlm.nih.gov/pubmed/25565926", "http://www.ncbi.nlm.nih.gov/pubmed/25656619", "http://www.ncbi.nlm.nih.gov/pubmed/8100856", "http://www.ncbi.nlm.nih.gov/pubmed/23613367", "http://www.ncbi.nlm.nih.gov/pubmed/23054245", "http://www.ncbi.nlm.nih.gov/pubmed/12110406", "http://www.ncbi.nlm.nih.gov/pubmed/23301918", "http://www.ncbi.nlm.nih.gov/pubmed/21670757"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 71, "text": "Osteogenesis imperfecta type VII maps to the short arm of chromosome 3.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407"}, {"offsetInBeginSection": 0, "offsetInEndSection": 140, "text": "We have identified a novel form of autosomal recessive osteogenesis imperfecta (OI) in a small First Nations community from northern Quebec.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407"}, {"offsetInBeginSection": 141, "offsetInEndSection": 275, "text": "Mutation screening of the COL1A1/COL1A2 genes revealed no detectable mutations, and type I collagen protein analyses were also normal.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407"}, {"offsetInBeginSection": 276, "offsetInEndSection": 398, "text": "By linkage analysis, we mapped this unique autosomal recessive variant of osteogenesis imperfecta to chromosome 3p22-24.1.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/12110407"}, {"offsetInBeginSection": 0, "offsetInEndSection": 87, "text": "Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 169, "text": "Classic osteogenesis imperfecta, an autosomal dominant disorder associated with osteoporosis and bone fragility, is caused by mutations in the genes for type I collagen.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 170, "offsetInEndSection": 227, "text": "A recessive form of the disorder has long been suspected.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 492, "offsetInEndSection": 825, "text": "Three of 10 children with lethal or severe osteogenesis imperfecta, who did not have a primary collagen defect yet had excess post-translational modification of collagen, were found to have a recessive condition resulting in CRTAP deficiency, suggesting that prolyl 3-hydroxylation of type I collagen is important for bone formation.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/17192541"}, {"offsetInBeginSection": 0, "offsetInEndSection": 112, "text": "Novel Deletion of SERPINF1 Causes Autosomal Recessive Osteogenesis Imperfecta Type VI in Two Brazilian Families.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25565926"}, {"offsetInBeginSection": 0, "offsetInEndSection": 258, "text": "Autosomal recessive osteogenesis imperfecta (OI) accounts for 10% of all OI cases, and, currently, mutations in 10 genes (CRTAP, LEPRE1, PPIB, SERPINH1, FKBP10, SERPINF1, SP7, BMP1, TMEM38B, and WNT1) are known to be responsible for this form of the disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25565926"}]}, {"id": "5a737e233b9d13c70800000d", "body": "Does Enzastaurin improve survival of glioblastoma patients?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/20124186", "http://www.ncbi.nlm.nih.gov/pubmed/23911595", "http://www.ncbi.nlm.nih.gov/pubmed/28259301", "http://www.ncbi.nlm.nih.gov/pubmed/26643807", "http://www.ncbi.nlm.nih.gov/pubmed/20150385", "http://www.ncbi.nlm.nih.gov/pubmed/25398844", "http://www.ncbi.nlm.nih.gov/pubmed/19098118", "http://www.ncbi.nlm.nih.gov/pubmed/21896554", "http://www.ncbi.nlm.nih.gov/pubmed/22917813"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 111, "text": "Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 0, "offsetInEndSection": 172, "text": "PURPOSE: This phase III open-label study compared the efficacy and safety of enzastaurin versus lomustine in patients with recurrent glioblastoma (WHO grade 4).PATIENTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 173, "offsetInEndSection": 339, "text": "METHODS: Patients were randomly assigned 2:1 to receive 6-week cycles of enzastaurin 500 mg/d (1,125-mg loading dose, day 1) or lomustine (100 to 130 mg/m(2), day 1).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 516, "offsetInEndSection": 655, "text": "RESULTS: Enrollment was terminated at 266 patients (enzastaurin, n = 174; lomustine, n = 92) after a planned interim analysis for futility.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 966, "offsetInEndSection": 1096, "text": "Stable disease occurred in 38.5% and 35.9% of patients and objective response occurred in 2.9% and 4.3% of patients, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1220, "offsetInEndSection": 1312, "text": "Four patients discontinued enzastaurin because of drug-related serious adverse events (AEs).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1313, "offsetInEndSection": 1412, "text": "Eleven patients treated with enzastaurin died on study (four because of AEs; one was drug-related).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1413, "offsetInEndSection": 1496, "text": "All four deaths that occurred in patients receiving lomustine were disease-related.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1497, "offsetInEndSection": 1621, "text": "Grade 3 to 4 hematologic toxicities were significantly higher with lomustine (46 events) than with enzastaurin (one event; P", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}, {"offsetInBeginSection": 1622, "offsetInEndSection": 1810, "text": "CONCLUSION: Enzastaurin was well tolerated and had a better hematologic toxicity profile but did not have superior efficacy compared with lomustine in patients with recurrent glioblastoma.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/20124186"}]}, {"id": "5a8965f6fcd1d6a10c000005", "body": "Are splicing speckles associated with transcription?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16467386", "http://www.ncbi.nlm.nih.gov/pubmed/10444064", "http://www.ncbi.nlm.nih.gov/pubmed/26496460", "http://www.ncbi.nlm.nih.gov/pubmed/10366587", "http://www.ncbi.nlm.nih.gov/pubmed/21984414", "http://www.ncbi.nlm.nih.gov/pubmed/15093744", "http://www.ncbi.nlm.nih.gov/pubmed/26441864", "http://www.ncbi.nlm.nih.gov/pubmed/9135155", "http://www.ncbi.nlm.nih.gov/pubmed/22871813", "http://www.ncbi.nlm.nih.gov/pubmed/12473687"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 149, "text": "Splicing speckles are not reservoirs of RNA polymerase II, but contain an inactive form, phosphorylated on serine2 residues of the C-terminal domain.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 0, "offsetInEndSection": 108, "text": "\"Splicing speckles\" are major nuclear domains rich in components of the splicing machinery and polyA(+) RNA.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 321, "offsetInEndSection": 476, "text": "RNA polymerase II transcribes mRNAs and is required for splicing, with some reports suggesting that the inactive complexes are stored in splicing speckles.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16467386"}, {"offsetInBeginSection": 0, "offsetInEndSection": 120, "text": "Three-dimensional visualization of transcription sites and their association with splicing factor-rich nuclear speckles.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 0, "offsetInEndSection": 162, "text": "Transcription sites are detected by labeling nascent transcripts with BrUTP in permeabilized 3T3 mouse fibroblasts followed by laser scanning confocal microscopy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 163, "offsetInEndSection": 384, "text": "Inhibition and enzyme digestion studies confirm that the labeled sites are from RNA transcripts and that RNA polymerase I (RP I) and II (RP II) are responsible for nucleolar and extranucleolar transcription, respectively.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 562, "offsetInEndSection": 683, "text": "The number of transcription sites, their three-dimensional organization and arrangement into functional zones (Wei et al.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 752, "offsetInEndSection": 984, "text": "Significant levels of total RP II mediated transcription sites (45%) were associated with splicing factor-rich nuclear speckles even though the speckles occupied 90%) had moderate to high levels of associated transcription activity.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 985, "offsetInEndSection": 1078, "text": "Transcription sites were found along the periphery as well as inside the speckles themselves.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}, {"offsetInBeginSection": 1217, "offsetInEndSection": 1526, "text": "Our results demonstrate that nuclear speckles and their surrounding regions are major sites of RP II-mediated transcription in the cell nucleus, and support the view that both speckle- and nonspeckle-associated regions of the nucleus contain sites for the coordination of transcription and splicing processes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/10444064"}]}, {"id": "5a80a63ffaa1ab7d2e000023", "body": "What is the HPG pore?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/26921234", "http://www.ncbi.nlm.nih.gov/pubmed/26148840"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 75, "text": "HPG pore: an efficient and scalable framework for nanopore sequencing data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 670, "offsetInEndSection": 768, "text": "RESULTS: Here we present HPG Pore, a toolkit for exploring and analysing nanopore sequencing data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 769, "offsetInEndSection": 1006, "text": "HPG Pore can run on both individual computers and in the Hadoop distributed computing framework, which allows easy scale-up to manage the large amounts of data expected to result from extensive use of nanopore technologies in the future.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 1006, "offsetInEndSection": 1156, "text": "CONCLUSIONS: HPG Pore allows for virtually unlimited sequencing data scalability, thus guaranteeing its continued management in near future scenarios.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 1157, "offsetInEndSection": 1226, "text": "HPG Pore is available in GitHub at http://github.com/opencb/hpg-pore.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26921234"}, {"offsetInBeginSection": 0, "offsetInEndSection": 204, "text": "A microporous hydrogel scaffold was developed from hyperbranched poly(glycidol) (HPG) and poly(ethylene oxide) (PEO) using electron beam (e-beam) induced cross-linking for tissue engineering applications.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 205, "offsetInEndSection": 386, "text": "In this study, HPG was synthesized from glycidol using trimethylol propane as a core initiator and cross-linked hydrogels were made using 0, 10, 20, and 30% HPG with respect to PEO.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 387, "offsetInEndSection": 568, "text": "The effects of %-HPG on the swelling ratio, cross-linking density, mechanical properties, morphology, degradation, and cytotoxicity of the hydrogel scaffolds were then investigated.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 734, "offsetInEndSection": 819, "text": "In contrast, the presence of HPG decreased the cross-linking density of the hydrogel.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}, {"offsetInBeginSection": 921, "offsetInEndSection": 1037, "text": "The pore size of hydrogel scaffolds could be easily tailored by controlling the content of HPG in the polymer blend.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/26148840"}]}, {"id": "5a70ce82b750ff4455000065", "body": "What is the mode of action of the drug Prolia?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/25052047", "http://www.ncbi.nlm.nih.gov/pubmed/19836866", "http://www.ncbi.nlm.nih.gov/pubmed/25509894", "http://www.ncbi.nlm.nih.gov/pubmed/22023901"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 147, "text": "Development and evaluation of an algorithm to identify users of Prolia(\u00ae) during the early postmarketing period using health insurance claims data.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 0, "offsetInEndSection": 142, "text": "PURPOSE: The goal of this study is to develop and validate an algorithm to identify Prolia(\u00ae) users within a health insurance claims database.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 142, "offsetInEndSection": 496, "text": "METHODS: Patients with a denosumab-specific or nonspecific administration claim during the early period of Prolia availability in the USA (June 1, 2010 to March 31, 2012) were classified as definite, probable, possible, and nonusers of Prolia using an algorithm consisting of nine different components based on claims patterns consistent with Prolia use.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 713, "offsetInEndSection": 1037, "text": "Requiring claims for a bone or cartilage disorder or osteoporotic fracture after excluding claims for cancer prior to a denosumab-specific administration code gave the highest PPV (95.8%), followed by requiring a Prolia National Drug Code on the same claim as a denosumab-specific or nonspecific administration code (88.2%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 1038, "offsetInEndSection": 1174, "text": "Among the 87 confirmed Prolia users, osteoporosis diagnoses were seen more frequently in the medical record than in claims (83% vs 62%).", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 1174, "offsetInEndSection": 1368, "text": "CONCLUSIONS: Prolia users are most accurately identified with administration code claims in conjunction with claims for Prolia National Drug Code and bone disorder treatment and diagnosis codes.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 1369, "offsetInEndSection": 1429, "text": "Osteoporosis diagnoses may be under-recorded in claims data.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25052047"}, {"offsetInBeginSection": 231, "offsetInEndSection": 465, "text": "Recently anti-RANKL agents (receptor activator of nuclear factor-kappaB ligand) such as denosumab (Prolia, Amgen Inc., California, USA) that have a similar mode of action to bisphosphonates have been introduced to treat such diseases.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/19836866"}, {"offsetInBeginSection": 0, "offsetInEndSection": 151, "text": "[Preliminary results of an open-label observational study evaluating the efficacy and safety of Prolia used in women with postmenopausal osteoporosis].", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894"}, {"offsetInBeginSection": 0, "offsetInEndSection": 264, "text": "AIM: To evaluate the efficacy and safety of Denosumab (Prolia), a first-line osteoporosis (OP) medication that is a fully human monoclonal antibody to the receptor activator of nuclear factor xB ligand (RANKL), within an open-label observational study.SUBJECTS AND", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/25509894"}]}, {"id": "5a75df9483b0d9ea66000001", "body": "What is the mechanism of action of Tisagenlecleucel?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/28887358", "http://www.ncbi.nlm.nih.gov/pubmed/28751490"], "snippets": []}, {"id": "5a74e6eb0384be9551000009", "body": "What is Morgellons disease?", "documents": ["http://www.ncbi.nlm.nih.gov/pubmed/16489838", "http://www.ncbi.nlm.nih.gov/pubmed/21390982", "http://www.ncbi.nlm.nih.gov/pubmed/23326202", "http://www.ncbi.nlm.nih.gov/pubmed/19681520", "http://www.ncbi.nlm.nih.gov/pubmed/20489569", "http://www.ncbi.nlm.nih.gov/pubmed/21437061", "http://www.ncbi.nlm.nih.gov/pubmed/21110523", "http://www.ncbi.nlm.nih.gov/pubmed/19830222", "http://www.ncbi.nlm.nih.gov/pubmed/25192328", "http://www.ncbi.nlm.nih.gov/pubmed/21749875"], "snippets": [{"offsetInBeginSection": 0, "offsetInEndSection": 57, "text": "The mystery of Morgellons disease: infection or delusion?", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 0, "offsetInEndSection": 98, "text": "Morgellons disease is a mysterious skin disorder that was first described more than 300 years ago.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 246, "offsetInEndSection": 340, "text": "In this respect, Morgellons disease resembles and may be confused with delusional parasitosis.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 341, "offsetInEndSection": 507, "text": "The association with Lyme disease and the apparent response to antibacterial therapy suggest that Morgellons disease may be linked to an undefined infectious process.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 508, "offsetInEndSection": 602, "text": "Further clinical and molecular research is needed to unlock the mystery of Morgellons disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/16489838"}, {"offsetInBeginSection": 0, "offsetInEndSection": 62, "text": "Hypnosis in the treatment of Morgellons disease: a case study.", "beginSection": "title", "endSection": "title", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 245, "text": "Morgellons Disease is a condition involving painful skin lesions, fibrous growths protruding from the skin, and subcutaneous stinging and burning sensations, along with symptoms of anxiety, depression, fatigue, and memory and attention deficits.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 378, "offsetInEndSection": 447, "text": "There are currently no established treatments for Morgellons Disease.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 448, "offsetInEndSection": 547, "text": "The following case example depicts treatment of a woman with Morgellons Disease using hypnotherapy.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/21390982"}, {"offsetInBeginSection": 0, "offsetInEndSection": 156, "text": "Morgellons disease is an emerging skin disease characterized by formation of dermal filaments associated with multisystemic symptoms and tick-borne illness.", "beginSection": "abstract", "endSection": "abstract", "document": "http://www.ncbi.nlm.nih.gov/pubmed/23326202"}]}]}